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Abstract 
Numerous studies have documented the cognitive-enhancing effects of 
standardized Ginkgo biloba leaf extracts (Gingko) both in humans and in rodents. In 
addition to its antioxidant and platelet-activating factor inhibiting properties, Ginkgo has 
been shown to protect cellular membrane fluidity, to enhance cerebral blood flow and 
microcirculation, and to modulate cholinergic system functioning, properties that have 
been suggested to underlie its cognitive-enhancing effects. However, the possible 
neurogenic-enhancing effects of Ginkgo on adult hippocampal neurogenesis as a possible 
mechanism underlying its nootropic effects have not been evaluated. The experiments 
discussed in the present thesis assessed such a possibility. 
Chapter 1 reviews studies that have evaluated the nootropic effects of Ginkgo in 
humans and in rodents. The anti-stress properties of Ginkgo as well as several molecular 
mechanisms proposed to account for its beneficial effects on central nervous system 
functioning are also discussed. Experiments presented in Chapter 2 used c-Fos 
immunoreactivity to characterize functional activity in selected brain regions following 
acute oral (150 mg/kg) and intraperitoneal (2.5-25 mg/kg, i.p.) administration of Ginkgo. 
Both routes of administration increased c-Fos immunoreactivity in the insular cortex and 
amygdala. However, some additional regions including the nucleus accumbens and 
dentate gyrus showed increased c-Fos immunoreactivity only in response to parenteral 
administration. 
Experiments presented in Chapter 3 evaluated the possible neurogenic properties 
of Ginkgo. The anxiolytic effects of the extract using the elevated plus maze, light/dark 
emergence and social interaction tests were also assessed. Acute administration of 
i i i 
Ginkgo (2.5-25 mg/kg, i.p.) had neither stimulating nor depressive effects on cell 
proliferation in the adult dentate gyrus. Survival of newborn neurons in the dentate gyrus 
of adult male rats was also not affected by chronic Ginkgo administration. Furthermore, 
the results showed that chronic administration of Ginkgo treatment had neither anxiolytic 
nor anxiogenic properties; however acute administration of a high and moderate dose of 
Ginkgo induced anxiety in some measures. 
Experiments described in Chapter 4 investigated whether suppressed neurogenesis 
induced by corticosterone (CORT) treatment could be restored by Ginkgo co-treatment. 
The results revealed that survival of newborn cells was inhibited in the dorsal dentate 
gyrus of rats chronically treated with CORT; however, Ginkgo co-treatment did not 
buffer this effect. 
Finally, experiments described in Chapter 5 evaluated the cognitive-enhancing 
effects of Ginkgo on young adult male rats using a food-reinforced two-component 
double Y-maze task. Results showed that Ginkgo-tieated rats reached the training criteria 
faster, and made fewer errors. Rats treated with Ginkgo during the learning phase made 
fewer working memory errors. However, neither acute nor chronic post-training 
treatment with Ginkgo enhanced spatial working memory. 
Taken together, the results of the present dissertation showed that Ginkgo 
increased c-Fos immunoreactivity in several brain structures involved in learning and 
memory. Moreover, Ginkgo enhanced acquisition and performance of a double-Y maze 
task, but did not offer any continued benefits in an already-learned working memory task. 
Interestingly, a dose of Ginkgo (13.75 mg/kg) that was found to improve cognitive 
function failed to promote either cell proliferation or cell survival in the adult dentate 
iv 
gyrus. It also failed to restore the suppressive effects of CORT on dentate gyrus cell 
survival. It is concluded that Ginkgo pre-treatment subtly enhances learning, but this 
effect is likely not related to a modulatory effect on adult hippocampal neurogenesis. 
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Chapter 1: Introduction 
Chapter 1 2 
Ginkgo biloba {Ginkgo) is an ancient tree native to eastern Asia. It has survived 
over millions of years and as such is referred to as a 'living fossil' (Bombardelli, Cristoni, 
& Morazzoni, 2000; Jacobs & Browner, 2000; Major, 1967). Ginkgo is a dioecious tree, 
meaning that the male and female blossoms are formed separately on two individual 
trees. It grows to a height of 30 to 40 m and to a diameter of 1 to 4 m and can live for 
hundreds of years (Del Tredici, 2000; Melzheimer & Lichius, 2000). Ginkgo trees are 
highly resistant to pests, bacteria, fungi, viruses, and air pollution, and are considered 
ideal ornamental trees in large cities (Laurain, 2000; Major, 1967). It is noteworthy that 
Ginkgo trees were the only trees reported to sprout one year after their destruction by the 
Hiroshima atomic bomb (Jacobs & Browner, 2000; Laurain, 2000) 
The unusual fan-shaped Ginkgo leaves are dark green in colour during the 
summer, and turn bright yellow in autumn (Laurain, 2000). Ginkgo fruits resemble small 
apricots and contain an almond-shaped nut. Ginkgo leaves and seeds have long been used 
in traditional Chinese medicine to treat various kidney and bladder disorders, as well as 
lung-related illnesses such as asthma and bronchitis (Del Tredici, 2000). However, 
pharmaceutical use of the extract of the Ginkgo biloba leaf originated in Germany in 
1965. The first commercially available and standardized Ginkgo biloba leaf extract, EGb 
761, was registered in 1974 in France (Del Tredici, 2000). 
The Ginkgo biloba leaf extract EGb 761 
Ginkgo extract EGb 761 is a water-acetone extract of dried green leaves of 
Ginkgo biloba. It is prepared with a defined 27-step extraction procedure that yields 1 
pound of the extract from 50 pounds of dried leaves. During the extraction process, EGb 
761 is standardized to contain 24% flavonoid glycosides (including quercetin, 
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kaempferol, isorhamnetin and myricetin), 6% terpenoids (containing 3.1 % ginkgolides 
A, B, C, and J and 2.9% bilobalide), and less than 9% proanthocyanidins and organic 
acids (Chan, Xia, & Fu, 2007; DeFeudis & Drieu, 2000; Maclennan, Darlington, & 
Smith, 2002; Ponto & Schultz, 2003; Zimmermann, Colciaghi, Cattabeni, & Di Luca, 
2002). Each EGb 761 constituent has a unique pharmacology; however, its overall 
therapeutic properties are believed to be the result of agonistic, antagonistic and 
synergistic effects of these active components (DeFeudis & Drieu, 2000; Nathan, 2000; 
Yoshikawa, Naito, & Kondo, 1999). 
Dr. Willmar Schwabe Pharmaceuticals (Karlsruhe, Germany) and Beaufor-Ipsen 
Pharma (Paris, France) are two well-recognized manufacturers of EGb 761. Today, EGb 
761 marketed under the trade names of Rokan, Tanakan, Tebonin and Ginkgold, is one of 
the best-selling herbal medicines in Europe and the United States (Chan et al., 2007). In 
fact, retail sales of Ginkgo biloba products in the United States alone reached $150 
million in 1998, ranking first among 13 most purchased herbal medicines in the 
mainstream market (Blumenthal, 1999). In addition, the annual worldwide sales of 
Ginkgo biloba products have been estimated at half a billion US dollars (Warrier & 
Corzine, 2000). 
Ginkgo biloba extracts are commonly prescribed in Germany and in France for 
the treatment of "cerebral insufficiency", age-related disorders, cardiovascular disease, 
vertigo (dizziness), tinnitus (ringing in ears) of vascular origin, and intermittent 
claudication characterized by cramping and pain in the lower limbs during walking or 
running due to insufficient oxygen. However, Ginkgo is also purchased as an over-the-
counter supplement as a nootropic, or cognitive enhancer (Darlington, Smith, & 
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Maclennan, 2000; Gold, Cahill, & Wenk, 2002; Yoshikawa et al., 1999). The present 
summary is centered on the effects of a Ginkgo biloba leaf extract on cognition, stress 
and anxiety. The possible mechanisms of actions of the extract are then discussed. 
Cognitive-enhancing effects of Ginkgo biloba leaf extracts 
Standardized Ginkgo extracts, such as EGb 761, appear to enhance cognitive 
functioning both in humans and in rodents (Kennedy, Haskell, Mauri, & Scholey, 2007; 
Kennedy, Jackson, Haskell, & Scholey, 2007; Kennedy, Scholey, & Wesnes, 2000, 2002; 
Le Bars et al., 1997; Mix & Crews, 2000, 2002; Stackman et al., 2003; Stoll, Scheuer, 
Pohl, & Muller, 1996; Stough, Clarke, Lloyd, & Nathan, 2001; Y. Wang, Wang, Wu, & 
Cai, 2006; E. Winter, 1991; J. C. Winter, 1998; Wirth, Stemmelin, Will, Christen, & Di 
Scala, 2000). However there are also contradictory results, particularly in the human 
clinical data, regarding its putative cognitive-enhancing efficacy. 
For example, a randomized double blind placebo-controlled study (Le Bars et al., 
1997) reported significant improvements in cognitive performance and social functioning 
of demented patients who were treated with EGb 761 (120 mg/day for 6 to 12 months). 
However, another study (van Dongen, van Rossum, Kessels, Sielhorst, & Knipschild, 
2000) reported no significant improvements in either cognitive or social functioning of a 
similar population, but after only 6 months of treatment with EGb 761 (160 and 240 
mg/day). A meta-analysis of four randomized, placebo-controlled double blind studies 
with the total sample size of 212 in each Ginkgo and placebo groups reported a modest 
effect on objective measurements of cognitive abilities on elderly patients with dementia. 
The effect was evident after three to six months of treatment with 120 and 240 mg daily 
dose (Oken, Storzbach, & Kaye, 1998). Nevertheless, a more recent meta-analysis, which 
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included 35 randomized, double blind studies with a total of 4247 participants, concluded 
that the evidence for beneficial effects of Ginkgo on cognitive abilities of patients with 
dementia or cognitive impairment was 'inconsistent and unconvincing' (Birks & Grimley 
Evans, 2007). In fact, results of a recent longitudinal double-blind, placebo-controlled 
study following participants for a median of 6.1 years, have shown that EGb 761 (120 
mg, twice daily) failed to prevent cognitive decline in aged (75 years and older) 
volunteers with mild cognitive impairments (DeKosky et al., 2008). 
The influence of the extract on the cognitive abilities of healthy older adults has 
also been investigated. For example, Mix and Crews (2000; 2002) using a double-blind, 
placebo-controlled design, reported that EGb 761 (180 mg/day for 6 weeks) enhanced 
certain aspects of cognitive performance in healthy elderly volunteers. In contrast, 
Solomon et al. (2002) reported lack of effectiveness of a similar Ginkgo extract 
(Ginkoba, 120 mg/day for 6 weeks) in a similar population (i.e. healthy elderly). 
In regards to young healthy individuals, acute administration of a Ginkgo extract 
(GK-501,120 mg, 240 mg and 360 mg) has been reported to dose-dependently (240 and 
360 mg) improve performance on the 'speed of attention', measured by combining the 
reaction times of three different attentional tasks. Albeit, the lowest dose (120 mg) tested 
in that study negatively affected 'speed of attention', but it enhanced 'quality of memory' 
at 1 and 4 h following the treatment (Kennedy et al., 2000). In a different study the same 
group of researchers investigated the effects of acute administration of similar doses of 
Ginkgo extract on performance of more demanding cognitive tasks in young healthy 
volunteers and reported a significant dose-dependent enhancement in speed of responding 
during one of the tasks, namely the serial three subtraction test (Kennedy et al., 2002). 
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Recently, acute administration of a lower dose of Ginkgo extract (120 mg) complexed 
with soy-phospholipid (phosphatidylserine), which enhances bioavailability of active 
components of the extract, has been reported to significantly enhance performance and 
accuracy of memory tasks as well as speed of memory task performance measured 1 to 6 
h following administration in young healthy adults. Such observed effects were not 
evident after administration of the extract alone (120 mg) or complexed with 
phosphatidylcholine (Kennedy, Haskell et al., 2007). Moreover, chronic administration of 
EGb 761 (120 mg/day for 30 days), in young healthy volunteers, has been shown to 
facilitate speed of information processing, executive processing, and working memory 
(Stough et al., 2001). Nonetheless, results of a recent meta-analysis of 15 randomized 
clinical trials examining the cognitive enhancing effects of the extract in young healthy 
individuals were less than compelling (Canter & Ernst, 2007). Seven of the studies 
included in the meta-analysis were acute studies with sample sizes ranging from 8 to 70, 
leading to a total sample size of 202. Doses of the extract administered ranged from 120 
to 600 mg. Eight other studies included in the above meta-analysis were longer-term 
studies with sample sizes ranging from 8 to 104 making a total sample size of 349. Doses 
of the extract used ranged from 40 to 300 mg per day and the treatment duration ranged 
from 2 to 91 days. The meta-analysis results showed no favourable effects of the extracts 
on any aspects of cognitive performance in young healthy adults after either acute or 
chronic administrations (Canter & Ernst, 2007). Following the aforementioned meta-
analysis study Kennedy et al. (2007) reanalyzed data from three placebo-controlled, 
double blind studies, which were identical in their methodologies, with a total sample 
size of 78. The results revealed that thel20 mg dose of the extract acutely administered to 
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young healthy volunteers significantly improved accuracy of memory task performance, 
but significantly slowed 'speed of attention' measured by combining the reaction times of 
three different attentional tasks. These effects were not due to a 'trade off between speed 
and accuracy as the authors found no direct effect on the speed of memory task 
performance and accuracy of attention task performance. Taken together, data from 
clinical studies in regards to the cognitive enhancing effects of Ginkgo are inconclusive. 
The effects of Ginkgo on cognitive functioning of young and aged rodents has 
also been investigated (Stackman et al., 2003; Stoll et al., 1996; Y. Wang et al., 2006; E. 
Winter, 1991; J. C. Winter, 1998; Wirth et al , 2000). For example, chronic pre-treatment 
with EGb 761 has been shown to enhance acquisition and performance of an appetitive 
operant conditioning task. After 4 or 8 weeks of EGb 761 (100 mg/kg) treatment, young 
healthy mice (9 or 13 weeks old) were trained in a two-lever operant response sequence 
for food reward for 30 days. The number of correct responses as well as the speed of 
acquisition was enhanced in EGb 761-treated groups. EGb 761 treatment was maintained 
until the retention test 10 weeks later, and an improvement of retention of the learned 
response was evident in EGb 761-treated mice (E. Winter, 1991). 
Chronic daily pre-session treatment of Ginkgo (50 mg/kg) has also been shown to 
facilitate learning an eight-arm radial maze in rats. The radial maze task was designed to 
measure both working memory, measured by re-entries into the already visited arms, and 
reference memory, measured by entries into the arms that have never been baited. 
Interestingly, the life span of the Gmfcgotreated rats was significantly increased (J. C. 
Winter, 1998). Moreover, in a follow up experiment it was shown that chronic pre-
session Ginkgo (100 and 200 mg/kg) treatment enhanced learning in a delayed non-
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matching to position task, in which a 30-min delay was imposed between the two 
sessions, in 20-months-old rats (J. C. Winter, 1998). 
In another study, young (3 months old), middle-aged (12 months old) and aged 
(22 to 24 months old) mice were treated with EGb 761 (100 mg/kg for 3 weeks) prior to 
learning a passive avoidance task. Short-term memory measured by avoidance latency 60 
s after shock was significantly improved in aged mice, but no effect was found in long-
term memory measured by avoidance latency 24 h after the shock. No improvement was 
evident in the younger groups (Stoll et al., 1996). However, the facilitative effects of 
acute injection of Ginkgo (60 and 120 mg/kg, i.p.) on an olfactory short-term recognition 
test in both young and aged rats have been demonstrated (Wirth et al., 2000). 
Moreover, spatial memory deficits in aged rats (Y. Wang et al., 2006) and in 
transgenic mice model of Alzheimer's disease (Tg 2576) were prevented by chronic 
Ginkgo treatment (Stackman et al., 2003)— effects that have been shown and attributed to 
enhancement of hippocampal long-term potentiation by Ginkgo (Y. Wang et al., 2006). 
After chronic treatment with EGb 761 (30 and 60 mg/kg, 30 days), aged rats were 
anesthetized and underwent electrophysiological recordings. Field excitatory postsynaptic 
potentials were recorded from the CA1 region of the hippocampus in response to 
ipsilateral high-frequency stimulation of the Schaffer collateral/commissural pathway, 
and a significant enhancement in long-term potentiation induced by high frequency 
stimulation was observed in Gm%o-treated rats. The authors concluded that Ginkgo 
might ameliorate spatial learning and memory deficits associated with aging by 
increasing hippocampal long-term potentiation (Y. Wang et al., 2006). In support of this, 
an earlier study found that acute exposure to EGb 761 to brain slices taken from aged 
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mice significantly increased neuronal excitability by decreasing the population spike 
threshold, and increased the early phase of long-term potentiation. In addition, the 
population spike threshold and long-term potentiation in slices of aged mice fed 
chronically with EGb 761 (300 mg/kg for 30 days) was significantly increased (Williams, 
Watanabe, Schultz, Rimbach, & Krucker, 2004). 
However, one study reported lack of improvements in both acquisition or 
retention of memory in the water maze task in aged mice chronically treated with EGb 
761 (100 mg/kg) for 28 and 70 days. In this latter study, there was a significant difference 
in baseline anxiety levels measured using the elevated plus maze prior to water maze 
training. Thus, in a subsequent experiment, to reduce pre-existing differences in anxiety 
levels, a matched-pair design was applied and EGb 761 was found to significantly reduce 
stress induced by cold water exposure. The authors suggested that Ginkgo might act as an 
"anti-stress buffer" rather than a cognitive enhancer (Ward et al., 2002). Indeed, 
anxiolytic properties of EGb 761 have been recognized (e.g., see DeFeudis & Drieu, 
2004) and are discussed in the following section. 
It is noteworthy that most animal studies that have evaluated the putative 
cognitive enhancing effects of Ginkgo treatment have focused on its effects on the 
acquisition of information (i.e., learning), rather than the post-training effects in a 
working memory task. To the author's knowledge, only one study has examined the 
post-training effects of Ginkgo treatment in young adult rats. This study reported no 
significant effects in a Morris water maze task, or in radial arm maze tasks designed to 
assess short-term working and long-term reference memory (Shif et al., 2006). 
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Anti-stress and anxiolytic effects of Ginkgo biloba leaf extracts 
Ginkgo extracts possess "stress-alleviating" and "vigilance-enhancing" properties 
(DeFeudis & Drieu, 2004). For example, chronic treatment with a standardized Ginkgo 
extract (LI 1370, 120 mg per day for 4, 6 and 10 months) has been found to improve 
mood in healthy geriatric volunteers who reported being better able to cope with the 
stressful demands of daily living (Trick, Boyle, & Hindmarch, 2004). A recent double-
blind, placebo-controlled study also reported that EGb 761 (480 and 240 mg/kg for 4 
weeks) alleviated symptoms of anxiety in a dose-dependent manner in younger patients 
who were either diagnosed with generalized anxiety disorder or adjustment disorder with 
anxious mood. For example, a four-week exposure to EGb 761 led to considerably 
reduced reports of somatic symptoms by patients. In addition, significant improvements 
were seen in the clinician's rating scores using Hamilton Rating Scale for Anxiety test, a 
standard measure of the severity of anxiety (Woelk, Arnoldt, Kieser, & Hoerr, 2007). A 
single dose of EGb 761 (120 mg) was also found to significantly reduce stress-induced 
rises in systolic arid diastolic blood pressure, without influencing the heart rate, in young 
healthy volunteers in a double blind placebo-controlled study. The stress used in this 
study involved a combination of static exercise (handgrip) and mental load (memory 
test). In addition, male participants showed an increase in salivary Cortisol levels 
measured in the afternoon that was effectively reduced by single EGb 761 treatment 
(Jezova, Duncko, Lassanova, Kriska, & Moncek, 2002). 
The anti-stress effects of Ginkgo in rodents using various behavioural models of 
stress have also been documented. For example, rats pre-treated chronically with EGb 
761 (50 and 100 mg/kg for 5 days) prior to inescapable shocks in the learned helplessness 
Chapter 1 11 
paradigm showed fewer escape failures in subsequent tests (Porsolt, Martin, Lenegre, 
Fromage, & Drieu, 1990). Mice pre-treated chronically with the extract (50 and 100 
mg/kg for 5 days) also showed significantly reduced stress in the emotional hypophagia 
test evident by increased novel food consumption in a novel environment (Porsolt et al., 
1990). Chronic EGb 761 (100 mg/kg for 15 days) treatment was also found to prevent 
development of stress-induced polydipsia resulting from stress-induced handling and 
intubation feeding under light ether anesthesia (Rodriguez de Turco, Droy-Lefaix, & 
Bazan, 1993). Additionally, chronic Ginkgo pre-treatment considerably decreased stress 
induced by cold water exposure (Ward et al., 2002), stress-induced learning deficits in a 
discrimination task (Rapin, Lamproglou, Drieu, & DeFeudis, 1994) and stress-induced 
memory deficits in a passive avoidance task (Walesiuk, Trofimiuk, & Braszko, 2005). 
Moreover, mice treated with Ginkgo (125 mg/kg for one week) spent significantly more 
time on the open arms of the elevated plus maze compared to vehicle-treated mice, 
suggesting an anxiolytic-like effect of the extract (Kuribara, Weintraub, Yoshihama, & 
Maruyama, 2003). Additionally, zingicomb, a preparation of Ginkgo and ginger extract, 
has been reported to have anxiolytic properties in the elevated plus maze (Hasenohrl et 
al., 1996). 
Chermat and colleagues (1997) investigated the interaction of Ginkgo, diazepam 
(an anxiolytic agent and full agonist at the GAB AA/benzodiazepine/Cl" channel complex) 
and ethyl p-carboline-3-carboxylate ((3-CCE; an anxiogenic agent and partial inverse 
agonist at the GAB AA receptor complex) using the social interaction test of anxiety. 
Interactions of pairs of unfamiliar rats from similar treatment groups were assessed in a 
novel and brightly illuminated environment for 10 minutes. Both acute injection (8 and 
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16 mg/kg, 30 min prior to testing) and chronic oral pre-treatment (48 and 96 mg/kg for 8 
days) of EGb 761 reduced social interaction. Acute diazepam administration however 
increased social interaction, an effect that was potentiated by concurrent EGb 761 
administration. Conversely, acute P-CCE administration reduced social interaction, but 
concurrent Ginkgo treatment significantly reversed that effect to a level similar to that of 
vehicle-treated rats (Chermat et al., 1997). The apparent anxiogenic activity of Ginkgo 
administered on its own in this latter study, evident by reduced social contact, is 
surprising; however, the authors (Chermat et al., 1997) suggested that Ginkgo possibly 
increased arousal or vigilance of the animals. It has also been suggested that the existing 
state of the animal may govern the effects of EGb 761 such that EGb 761 potentiated the 
anxiolytic effects of diazepam, but neutralized the anxiogenic effects of (3-CCE 
(DeFeudis & Drieu, 2004) 
More recently, it was reported that Ginkgo produced antidepressant effects 
measured by a significant decrease in immobility duration in the forced swimming test in 
rats chronically pre-treated with Ginkgo extract (Ginkgolon-24, 10 and 50 mg/kg for 14 
days). An acute intraperitoneal Ginkgo injection (50 and 100 mg/kg) was also found to 
decrease immobility duration in the tail suspension test in mice (Sakakibara et al., 2006). 
However, chronic or acute EGb 761 treatment has been ineffective in some other 
behavioural models of stress and anxiety including shock-suppressed licking (Vogal 
conflict test) in rats, and shock-suppressed exploration and spontaneous exploration in 
mice, leading to the suggestion that the underlying mechanisms of anxiolytic or anti-
stress properties of Ginkgo may differ from that of classical antidepressants such as 
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impiramine, or anxiolytics such as diazepam, which have been shown to be effective in 
the above tests (Porsolt et al., 1990). 
Mechanisms of actions of Ginkgo biloba leaf extracts 
Various pharmacological effects of Ginkgo may be the result of agonistic, 
antagonistic and synergistic effects of its active constituents (DeFeudis & Drieu, 2000; 
Nathan, 2000; Yoshikawa et al., 1999). Here, several molecular mechanisms proposed to 
account for the beneficial effects of Ginkgo and its active components including its 
neuroprotective, nootropic and anxiolytic effects are summarized. 
Antioxidant and free radical scavenging 
Ginkgo has been suggested to serve as a useful therapy in the treatment and 
prevention of disorders and conditions that are associated with oxidative stress such as 
ischemia and neurodegenerative diseases, as well as the aging process (Drieu & 
DeFeudis, 2000). Reactive oxygen species (ROS) such as nitric oxide (NO), superoxide 
(02«-) and hydroxyl radicals (»OH) are potent free radicals. They are by-products of 
normal cellular functions such as mitochondrial respiration, fatty acid metabolism, or 
microphage function. Under normal biological conditions, enzymatic antioxidants such as 
superoxide dismutase, catalase, and glutathione peroxidase, and non-enzymatic 
antioxidants such as vitamin C and E, scavenge or prevent the formation of ROS. 
However, under some pathological conditions as well as aging, there may be an 
imbalance between the production of ROS and antioxidant defence mechanisms. This 
state of imbalance is called oxidative stress (Beckman & Ames, 1998). The abnormal 
production of ROS can damage lipids in cell membranes by peroxidation, can cause 
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protein fragmentation by oxidating amino acid chains, and can lead to breakdown of 
DNA by reacting with thymine in nuclear and mitochondrial DNA (Farber, Kyle, & 
Coleman, 1990). 
Using cell-free biochemical techniques, superoxide scavenging effects and 
superoxide dismutase activity of Ginkgo have been demonstrated (Pincemail et al., 1989). 
Using flow cytometric analysis it has also been shown that pre-treatment of cortical 
neurons with Ginkgo protected them from oxidative stress or apoptosis induced by 
hydrogen peroxide (Ni, Zhao, Hou, & Xin, 1996; Oyama, Chikahisa, Ueha, Kanemaru, & 
Noda, 1996). Pre-treatment of macrophage cells (Kobuchi, Droy-Lefaix, Christen, & 
Packer, 1997), endothelial cells (Cheung, Siow, Chen, & O, 1999) and hippocampal 
neurons (Bastianetto, Zheng, & Quirion, 2000) with Ginkgo has also been shown to 
protect them from nitric oxide-induced toxicity. Chronic EGb 761 treatment (100 mg/kg 
for 14 days) in rats has also been found to significantly reduce lipid peroxidation in the 
hippocampus, while increasing the activity of the antioxidant enzymes superoxide 
dismutase and catalase in the hippocampus, substantia nigra and striatum (Bridi, 
Crossetti, Steffen, & Henriques, 2001). These studies suggest that the neuroprotective 
effects of Ginkgo may, in part, be the result of its antioxidant and free radical scavenging 
properties. 
Inhibition of platelet-activating factor 
Platelet-activating factor (PAF) is a name commonly used for a large number of 
structurally related, biologically potent, phospholipids that are produced by various cell 
types (Stafforini, Mclntyre, Zimmerman, & Prescott, 2003) including neurons (Yue, 
Lysko, & Feuerstein, 1990). They mediate diverse physiological effects by interacting 
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with specific PAF surface receptors that are expressed on a wide range of cell types. 
However, up-regulation of PAF, which may be the result of either excessive synthesis or 
impaired degradation of PAF, is associated with many pathological conditions that are 
usually accompanied by inflammation and thrombosis (Stafforini et al., 2003). 
Neuropathology of the brain following hypoxia and ischemia has been shown to be 
related to the up-regulation of PAF (for a review, see Yue & Feuerstein, 1994). For 
example, physiological levels of PAF have been shown to increase significantly in the 
hippocampus, cortex, and thalamus in response to ischemia at early stages of reperfusion 
leading to neuronal death and damage (Nishida & Markey, 1996). 
Neuroprotective effects of Ginkgo have been attributed to its PAF antagonistic 
activity. For example, the Ginkgo constituents ginkgolides A and B are potent PAF 
receptor antagonists, and it has been demonstrated that acute pre- and post-treatment (25 
mg/kg, once pre and once post ischemia) with ginkgolides A and B significantly 
decreased ischemia-induced neuronal death in the occipital and parietal cerebral cortex, 
as well as in CA1 and CA3 hippocampal subfields in rats (Prehn & Krieglstein, 1993). 
Pre-treatment with EGb 761 (25, 50 and 100 mg/kg for 7 days) and bilobalide (3 and 6 
mg/kg for 7 days) has also been shown to protect CA1 neurons against neuronal damage 
induced by ischemia in rats (Chandrasekaran et al., 2002). EGb 761 also reduces infarct 
volume after permanent and transient focal cerebral ischemia. Additionally, rats treated 
with EGb 761 showed significant improvement in neurobehavioural testing 3 to 7 days 
following transient focal cerebral artery occlusion (Lee et al., 2002). Bilobalide 
administered one hour before or immediately after ischemia has also been found to 
significantly and dose-dependently decrease the infarct volume in mouse brain 
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(Krieglstein et al., 1995). In addition, EGb 761, bilobalide, ginkgolide A and B have been 
found to dose-dependently protect primary neuronal cultures against glutamate-induced 
excitotoxicity (Chandrasekaran et al., 2002; Prehn & Krieglstein, 1993). In vitro studies 
have also shown that EGb 761 suppressed the formation of amyloid beta fibril, which is 
one of the characteristics of Alzheimer's disease. Furthermore, EGb 761 inhibited 
activation of the apoptotic enzyme caspase-3 (Luo et al., 2002). Neurotoxicity induced by 
beta-amyloid was also found to be significantly and dose-dependently reduced in 
hippocampal cultured neurons incubated with EGb 761 or the flavonoid fraction of the 
extract, but not with the terpenoid fraction (Bastianetto, Ramassamy et al., 2000), 
suggesting that neuroprotective effects of the extract may also be attributed to antioxidant 
and free radical scavenging activities of its flavonoid fraction. 
Down-regulation of glucocorticoids 
It has been suggested that EGb 761 facilitates behavioural adaptation under 
stressful conditions by reducing glucocorticoid synthesis (Amri, Ogwuegbu, Boujrad, 
Drieu, & Papadopoulos, 1996). Repeated treatment with EGb 761 (50 and 100 mg/kg for 
8 days) and ginkgolide A and B (2 mg/kg for 8 days), but not with bilobalide (4 mg/kg 
for 8 days), has been demonstrated to dose-dependently down-regulate glucocorticoid 
synthesis by reducing levels of messenger RNA protein and drug binding of 
adrenocortical mitochondrial peripheral-type benzodiazepine receptors in rats (Amri et 
al., 1996). Accordingly, Ginkgo pre-treatment has been reported to normalize elevated 
levels of circulating corticosterone induced by restraint stress in rats (Rai, Bhatia, Sen, & 
Palit, 2003; Shah, Sharma, & Vohora, 2003). Repeated treatment with EGb 761 (50 and 
100 mg/kg for 20 days) was also found to significantly and dose-dependently reduce the 
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auditory stress-induced elevation of circulating levels of epinephrine, norepinephrine and 
corticosterone in both young and aged rats (Rapin et al., 1994). It has been suggested that 
the ability of Ginkgo to down-regulate glucocorticoid synthesis may contribute to its anti-
stress activity, which in turn increases vigilance and awareness leading to improved 
cognition (Drieu & DeFeudis, 2000). 
Improving blood flow and membrane fluidity 
It has also been proposed that the cognitive enhancing effects of Ginkgo may be 
related to positive effects on cerebral blood flow and microcirculation (Drieu & 
DeFeudis, 2000). Under normal conditions Ginkgo treatment is associated with 
vasodilatation and improved blood flow in the whole body, including the brain 
(Ahlemeyer & Krieglstein, 2003; Iliff & Auer, 1983). Intravenous injection of Ginkgo 
(0.3 mg/kg/min for 30 min) in cats has been shown to significantly enhance dilation of 
pial arteries, which led to an increase in cerebral blood flow and microcirculation (Iliff & 
Auer, 1983). Acute intravenous Ginkgo (130 mg/kg) injection has also been shown to 
enhance cerebral blood flow and microcirculation in rats by 50 to 100% in 39 brain 
structures analyzed including the dentate gyrus of the hippocampus (Krieglstein, Beck, & 
Seibert, 1986). It appears that the enhancement effects of Ginkgo on cerebral blood flow 
and microcirculation is related to its terpenoid fraction (Ahlemeyer & Krieglstein, 2003). 
Under pathological conditions Ginkgo treatment is also associated with 
enhancement of blood flow. For example immediately after ischemia, cerebral blood flow 
increases and then decreases to 40 to 60% of pre-ischemia for several hours. Treating rats 
with EGb 761 5 and 45 min following global cerebral ischemial increased cerebral blood 
flow to relatively normal levels (Krieglstein et al., 1995). Treatment with EGb 761 (100 
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and 200 mg/kg) 2 h post transient middle cerebral artery occlusion has also been shown 
to significantly increase local cortical blood flow 24 h after such reperfusion injury (Lee 
et al., 2002). 
Ginkgo treatment has also been shown to enhance in vitro proliferation of 
endothelial progenitor cells in a dose-dependent manner. Migration, adhesion and in vitro 
vasculogenesis capacity of endothelial cells was also improved by Ginkgo treatment 
(Chen et al., 2004). Endothelial progenitor cells are derived from bone marrow and 
contribute to endothelial cells in newly formed neovascularization (Murayama et al., 
2002). 
In addition, Ginkgo appears to enhance cell membrane fluidity, which is reduced 
by aging or by agents such as excessive ascorbic acid or ferrous ions. In one study 
synaptosomes obtained by homogenization followed by centrifugation of brain cortices of 
young mice were incubated with or without ascorbic acid and varying doses of EGb 761 
(2-16 ug/ml) for 60 min. The reduction of membrane fluidity induced by ascorbic acid 
was significantly reduced by EGb 761 treatment in a dose-dependent manner 
(Ramassamy, Girbe, Christen, & Costentin, 1993). Furthermore, in vivo treatment of aged 
mice (22-24 months old) with EGb 761 (100 mg/kg) for 21 days was found to 
significantly protect neuronal membrane fluidity, which is considerably reduced by 
ageing (Stoll et al., 1996). 
Neurotransmitter and receptor modulation 
The effects of Ginkgo on neurotransmitters and receptors have also been 
investigated. Aging is associated with reduced density of serotonin 5-hydroxytryptamine 
(5-HT) type 1A receptors in the cerebral cortex of rats, and chronic EGb 761 treatment 
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was found to reverse this effect by 33% (Huguet, Drieu, & Piriou, 1994). Synaptosomes, 
prepared from the cerebral cortex of mice, incubated with EGb 761 and CP 202 (EGb 761 
devoid of terpenoid fraction) but not with BN 52063 (EGb 761 devoid of flavonoid 
fraction) displayed increased uptake of 5-HT. However, concurrent treatment of 
synaptosomes with clomipramine, a 5-HT uptake antagonist, diminished this effect 
(Ramassamy, Christen, Clostre, & Costentin, 1992). Chronic Ginkgo (5 mg/kg for 21 
days) treatment has also been shown to reverse the age-related decrease in the number of 
0C2 -adrenoceptors in the hippocampus (Huguet & Tarrade, 1992). Moreover, oral 
administration of a single dose of Ginkgo (50, 100 and 200 mg/kg) attenuated working 
memory deficits in rats induced by the (X2 -adrenoceptors antagonist yohimbine (Zhang & 
Cai, 2005). Chronic Ginkgo treatment has also been shown to reduce whole brain levels 
of dopamine, norepinephrine and serotonin induced by restraint stress (Shah et al., 2003). 
Of particular interest is the modulatory effect of Ginkgo on the cholinergic system 
(Chopin & Briley, 1992; Das et al., 2002; Kristofikova, Benesova, & Tejkalova, 1992; 
Taylor, 1986; Yamamoto, Adachi, Fujii, & Kamei, 2007). For example, long-term 
Ginkgo (100 mg/kg for 28 days) treatment has been shown to increase hippocampal 
cholinergic muscarinic receptor numbers (Taylor, 1986). Chronic Ginkgo (50 mg/kg for 
30 days) treatment has also been shown to enhance the release of acetylcholine by 
increasing sodium-dependent high-affinity choline uptake into hippocampal 
synaptosomes (Kristofikova et al., 1992). In vitro dose-dependent inhibitory effects of 
Ginkgo on acetylcholinesterase activity have also been reported (Das et al., 2002), and it 
has been shown that Ginkgo reversed amnesia induced by the cholinergic muscarinic 
receptor antagonist scopolamine in passive avoidance (Chopin & Briley, 1992; Das et al., 
Chapter 1 20 
2002), and radial arm maze tasks (Yamamoto et al., 2007). In addition, doses of Ginkgo 
(30 and 60 mg/kg) that reversed scopolamine-induced amnesia were found to inhibit 
acetylcholinesterase activity ex vivo, but these inhibitory effects on acetylcholinesterase 
activity were not evident ex vivo when a lower dose of the extract (15 mg/kg) was 
administered. Furthermore, this lower dose failed to reverse scopolamine-induced 
amnesia. Thus, it has been suggested that the ability of Ginkgo to enhance activity of the 
cholinergic system may contribute to its cognitive enhancing properties (Das et al., 
2002). Of particular relevance to the present dissertation are recent findings suggesting a 
role for the cholinergic system in regulating adult hippocampal neurogenesis (Cooper-
Kuhn, Winkler, & Kuhn, 2004; Kaneko, Okano, & Sawamoto, 2006; Kotani, Yamauchi, 
Teramoto, & Ogura, 2006, 2008). For example, adult hippocampal neurogenesis has been 
found to be suppressed in rats by immunotoxic lesioning of neurons of the cholinergic 
basal forebrain that project to the dentate gyrus (Cooper-Kuhn et al., 2004). 
It is also noteworthy that the cognitive enhancing effects of Ginkgo are often 
associated with long-term use (Muller & Chatterjee, 2003). This corresponds well with 
the hypothesis that Ginkgo enhances adult hippocampal neurogenesis, since newborn 
neurons require at least a few weeks to become fully functional and to integrate into the 
existing neuronal circuitry (van Praag et al., 2002). As one of the aims of the present 
dissertation was to investigate such a hypothesis, the following section provides an 
overview of adult hippocampal neurogenesis. 
Adult hippocampal neurogenesis 
Adult neurogenesis is the process of birth and growth of functionally integrated 
neurons in the postnatal brain (H. Song et al., 2005). This phenomenon has only been 
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recently confirmed in the adult mammalian brain. Lack of methodological advances to 
distinguish between multiplying glial cells from mitotic neurons led Santiago Roman y 
Cajal, the founder of modern neuroscience, to conclude that neurogenesis was only 
limited to prenatal brains (Gross, 2000). In the late 1950s, [H3]-thymidine 
autoradiography, which allowed labeling replicating DNA, was developed. By taking 
advantage of this new technique, Altaian and Das (1965) challenged the dogma that "new 
neurons are not added to the adult mammalian brain" (Gross, 2000) and provided 
evidence for neurogenesis in specific regions of adult rat brain including the dentate 
gyrus of the hippocampus (Altaian & Das, 1965), olfactory bulb (Altaian, 1969) and 
neocortex (Altman & Das, 1966). 
Towards the early 1990s, a new method was developed for labeling dividing cells 
using bromodeoxyuridine (BrdU), which is incorporated into replicating DNA and can be 
detected by immunohistochemistry. Before the end of the twentieth century, using this 
technique in combination with cell-specific markers for immunohistochemical 
identification of newly generated cells and stereological quantification, the presence of 
two neurogenic regions in the central nervous system of all mammals examined including 
humans was confirmed (Eriksson et al., 1998). Neurogenesis in the adult mammalian 
brain is believed to be limited to the subventricular zone (SVZ) of the lateral ventricle, 
and the subgranular zone (SGZ) of the dentate gyrus in the hippocampus. Adult 
neurogenesis outside these two regions has been suggested, but at present remains 
controversial (Gould, 2007; Rakic, 2002). 
Adult neuronal stem cells reside in the neurogenic niche of the SGZ of the dentate 
gyrus (Seri, Garcia-Verdugo, McEwen, & Alvarez-Buylla, 2001) and give rise to 
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transient amplifying progenitor cells (Kempermann, Jessberger, Steiner, & Kronenberg, 
2004; Ming & Song, 2005). The niche has a special microenvironment that not only 
maintains neuronal stem and progenitor cells, but also promotes their proliferation and 
fate determination. Resident astrocytes and vasculatures are two integrative components 
of the neurogenic niche. Clusters of proliferating cells in the granule cell layers have been 
shown to reside in close proximity to fine capillaries. It appears that astrocytes and blood 
factors released from vasculature may play important roles in proliferation and fate 
specification of neuronal stem cells (Palmer, Willhoite, & Gage, 2000; H. J. Song, 
Stevens, & Gage, 2002). 
Transient amplifying progenitors have limited potential for self-renewal. Some 
will die, while others divide symmetrically and rapidly give rise to a pool of progenitors 
that in turn differentiate into immature neurons expressing doublecortin (DCX) and the 
polysiallylated form of the neural cell adhesion molecule (PSA-NCAM). The immature 
neurons migrate locally and move into the granule cell layer (Ming & Song, 2005; van 
Praag et al., 2002). As they migrate, immature neurons undergo unique morphological 
(Zhao, Teng, Summers, Ming, & Gage, 2006) and physiological (Ge et al., 2006; 
Schmidt-Hieber, Jonas, & Bischofberger, 2004; S. Wang, Scott, & Wojtowicz, 2000) 
changes. 
Neurite outgrowth initiates soon after newborn neurons exit the progenitor cell 
cycle. In a few days, dendritic and axonal growth starts. Newly generated axons interact 
initially with hilar mossy cells and interneurons located in the hilus (Zhao et al., 2006). 
At this stage, immature neurons have a higher intracellular concentration of chloride ions, 
and unlike mature neurons depolarize in response to GAB A (Ge et al., 2006). 
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Approximately 8 to 10 days later, axons of immature neurons reach CA3 pyramidal 
neurons and begin synaptic interactions with them. At about 16 days after birth, dendritic 
spines of immature neurons begin to grow (Zhao et al., 2006). Interestingly, the immature 
neurons have a much lower threshold for long-term potentiation compared to the existing 
older granule neurons (Schmidt-Hieber et al., 2004). The excitatory action of GABA on 
newborn neurons changes to inhibitory at approximately 2 to 4 weeks after birth. 
Glutamatergic synapses develop once the dendritic branches of newborn neurons cross 
the molecular cell layer of the dentate gyrus (Ambrogini et al., 2004). The density and 
complexity of spines, however, continue to increase for several months (Zhao et al., 
2006). The inhibitory GABAergic inputs probably precede excitatory glutamatergic 
inputs to allow integration of newborn neurons into the existing circuit without the risk of 
excitation-induced neurotoxicity (Lledo, Alonso, & Grubb, 2006). 
It has been estimated that about 9000 new BrdU-labeled cells are generated in the 
adult rat dentate gyrus every day (Cameron & McKay, 2001). However, half of the 
newborn neurons die within the first 3 weeks after birth. If they survive this critical 
period, they can survive for at least 11 more months in the dentate gyrus of the rodents 
(Kempermann, Gast, Kronenberg, Yamaguchi, & Gage, 2003) and for at least 2 more 
years in the human dentate gyrus (Eriksson et al., 1998). At 4 weeks of age, newborn 
neurons start expressing neuron-specific nuclear protein (NeuN), a marker of mature 
neurons (Ming & Song, 2005). Newborn granular neurons integrate functionally into the 
existing neuronal circuit in the dentate gyrus, receiving inputs from the perforant path and 
sending the outputs to CA3 pyramidal cells (van Praag et al., 2002). At 4 months of age, 
they morphologically (Zhao, Deng, & Gage, 2008) resemble existing mature neurons in 
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the granular cell layer, suggesting that newly generated neurons might be involved in 
hippocampal activity. In fact, recent studies that have relied on activity-dependent 
immediate-early gene expression have provided the most convincing support for the 
involvement of newborn dentate gyrus neurons in cognitive processes and their relevance 
to hippocampal activities (Kee, Teixeira, Wang, & Frankland, 2007; Ramirez-Amaya, 
Marrone, Gage, Worley, & Barnes, 2006). 
Adult hippocampal neurogenesis and cognition 
Several studies suggest that the number of newborn neurons in the adult dentate 
gyrus correlates with learning abilities (e.g., see Kempermann, Kuhn, & Gage, 1997b; 
van Praag, Christie, Sejnowski, & Gage, 1999). Factors that have been shown to affect 
adult hippocampal neurogenesis have also been found to influence learning and memory. 
For example, survival of newborn granule neurons has been shown to increase 
considerably in adult mice that lived in an enriched environment (Kempermann, Kuhn, & 
Gage, 1997a). Cell proliferation in the dentate gyrus of adult mice is also significantly 
enhanced by voluntary wheel running (van Praag, Kempermann, & Gage, 1999). Both 
enriched environment (Kempermann et al., 1997a) and voluntary exercise (van Praag, 
Christie et al., 1999) have been shown to enhance spatial navigation in the Morris water 
maze, a hippocampal-dependent task. On the other hand, stress (Tanapat, Hastings, 
Rydel, Galea, & Gould, 2001), high levels of glucocorticoids (Cameron & Gould, 1994), 
and aging (McDonald & Wojtowicz, 2005)—all associated with a reduction of adult 
hippocampal neurogenesis—are also associated with impairments in hippocampal-
dependent learning tasks (Bodnoff et al., 1995; Conrad, Galea, Kuroda, & McEwen, 
1996; Drapeau et al., 2003). However, learning ability in the hidden platform version of 
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the water maze was reported not to be predictable by the number of newborn cells in the 
dentate gyrus of aged male Long-Evans (Bizon & Gallagher, 2003; Bizon, Lee, & 
Gallagher, 2004) and aged female Fischer 344 rats (Merrill, Karim, Darraq, Chiba, & 
Tuszynski, 2003). That is, although aging significantly reduced the rate of neurogenesis, 
there was no correlation between the number of newborn cells and spatial learning 
performance. 
As described earlier in this chapter, Ginkgo treatment has been shown to improve 
cognitive abilities in rodents. For example, chronic Ginkgo pre-treatment has been shown 
to enhance acquisition and performance of a two-lever response sequence task as well as 
retention of a learned response (E. Winter, 1991), improve learning in an eight-arm radial 
maze task, enhance learning in a delayed non-matching to position task (J. C. Winter, 
1998) and promote learning in a passive avoidance task (Stoll et al., 1996). Moreover, 
chronic Ginkgo treatment has been shown to prevent spatial memory deficits in aged rats 
(Y. Wang et al., 2006) and in a transgenic mouse model (Tg 2576) of Alzheimer's 
disease (Stackman et al., 2003). The exact mechanism by which Ginkgo enhances 
cognitive abilities is not fully understood, but if the number of newborn neurons in the 
adult dentate gyrus correlates positively with learning abilities, then Ginkgo treatment 
might also lead to an enhancement of adult hippocampal neurogenesis. 
Related to this point, it is noteworthy that pharmacological manipulation of the 
cholinergic system—which no doubt plays an important role in cognitive function—has 
also been found to modify adult hippocampal neurogenesis. For example, it has been 
shown that chronic (4-week) exposure to the selective acetylcholinesterase inhibitor 
treatment donepezil significantly increased neurogenesis, while scopolamine 
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administration significantly decreased this effect. The effects were specific to survival of 
newborn neurons in the dentate gyrus as neither donepezil nor scopolamine treatment 
influenced cell proliferation in the dentate gyrus (Kaneko et al., 2006; Kotani et al., 2006, 
2008). Thus, it is possible that Ginkgo may promote adult hippocampal neurogenesis by 
modulating cholinergic system activity, which in turn improves cognitive function. In 
fact, in utero exposure to Ginkgo has been shown to enhance neuronal survival and 
growth of the developing hippocampus. During gestational days 12 to 16, pregnant dams 
were injected with EGb 761 (100 or 300 mg/kg). The hippocampi of the fetuses were 
dissected and cultured at embryonic day 17. After 8 days, neuronal cells obtained from 
the EGb-treated group were more viable and had more branches compared to controls. 
Using a gene microarray assay it was also demonstrated that prenatal exposure to EGb 
761 (25, 50 or 100 mg/kg for 5 days) modified expression of a number of specific genes 
that are mainly involved in the development, maturation and repair of neuronal cells (Li 
et al., 2003). 
Furthermore, transcription of a gene that encodes for transthyretin has been found 
to increase more than three-fold in the hippocampus of adult mice fed a diet 
supplemented with EGb 761 for 4 weeks (Watanabe et al., 2001). Transthyretin protein is 
of particular interest given its involvement in the transport of the thyroid hormone 
thyroxine to cerebrospinal fluid and serum (Kuchler-Bopp, Dietrich, Zaepfel, & 
Delaunoy, 2000). Thyroid hormones have also been shown to play roles in the regulation 
of adult hippocampal neurogenesis (Ambrogini et al., 2005). Taken together, these 
studies suggest that Ginkgo may have a proliferative- and survival-promoting effect on 
hippocampal neurons. However, whether or not Ginkgo enhances survival as well as 
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proliferation of newborn granular cells-which are continuously generated in the dentate 
gyrus of adult brain—remains a matter of investigation. 
The purpose of the present dissertation 
The purpose of the present dissertation was twofold. Firstly, it aimed to identify 
neural sites involved in the cognitive enhancing effects of Ginkgo, and explore its 
possible neurogenic-enhancing properties on adult hippocampal neurogenesis. Secondly, 
the present dissertation aimed to examine separately the putative cognitive enhancing 
effects of Ginkgo on learning and on memory of a working memory task using a double 
Y-maze. 
Using c-Fos immunohistochemistry, the experiments described in Chapter 2 
characterized the neural effects of Ginkgo by quantifying functional activity in several 
brain regions known to be involved in learning and memory in rats. Furthermore, as 
described above, several lines of evidence strongly suggest that Ginkgo may enhance 
adult hippocampal neurogenesis. First, Ginkgo positively modulates activity of the 
cholinergic system (Chopin & Briley, 1992; Das et al., 2002; Kristofikova et al., 1992; 
Taylor, 1986; Yamamoto et al., 2007), which is involved in the regulation of adult 
hippocampal neurogenesis (Cooper-Kuhn et al., 2004; Kaneko et al., 2006; Kotani et al., 
2006, 2008). Second, the ability of Ginkgo to enhance microcirculation (Krieglstein et al., 
1986) and proliferation of endothelial progenitor cells (Chen et al., 2004) may suggest its 
neurogenic potential. Newborn cells in the granule cell layers reside in close proximity 
to fine capillaries and in fact, 37% of all dividing cells have been shown to be 
immunoreacive for endothelial markers (Palmer et al., 2000). Third, in utero exposure to 
Ginkgo enhances neuronal survival and growth in the developing hippocampus and 
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modifies expression of specific genes that are involved in development, maturation and 
repair of neuronal cells (Li et al., 2003). Fourth, long-term rather than short-term Ginkgo 
treatment is often associated with improved learning. This corresponds to the hypothesis 
that Ginkgo enhances neurogenesis, as newborn neurons require several weeks before 
they integrate into the neuronal circuitry and become fully functional (van Praag et al., 
2002). Thus the experiments presented in Chapter 3 evaluated the possible neurogenic 
properties of Ginkgo. Because Ginkgo treatment has been shown to reduce basal and 
stress-induced anxiety, the experiments described in Chapter 3 were supplemented with 
behavioural tests of anxiety. A battery of behavioural measures including the light/dark 
emergence, elevated plus maze and social interaction tests were employed to assess the 
acute and chronic effects of Ginkgo on anxiety. 
As previously reviewed, Ginkgo treatment counteracts the effects of 
glucocorticoids by reducing levels of messenger RNA protein and drug binding of 
adrenocortical mitochondrial peripheral-type benzodiazepine receptors (Amri et al., 
1996). For example, it normalizes elevated levels of circulating corticosterone induced by 
stress (Rai et al., 2003; Rapin et al., 1994; Shah et al, 2003). In addition, it has recently 
been shown that chronic Ginkgo treatment enhances cell proliferation in young and aged 
transgenic mice believed to be a model of Alzheimer's disease, as well as in aged wild 
type control mice (Tchantchou, Xu, Wu, Christen, & Luo, 2007). These studies raise the 
possibility that Ginkgo may have different effects in the normal healthy nervous system, 
compared to in dysfunctional nervous systems where the constitutive level of 
neurogenesis has been down-regulated. To examine this possibility, experiments in 
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Chapter 4 investigated whether corticosterone-induced suppression of hippocampal 
neurogenesis could be restored by Ginkgo co-administration. 
Several well-designed studies evaluating the cognitive-enhancing abilities of 
Ginkgo on rodents were summarized above. In most of those studies, Ginkgo treatment 
normally began weeks or months prior to the training sessions. Thus, it is not clear 
whether Ginkgo is effective in improving acquisition or memory of a task without prior 
chronic treatment. It is not also clear whether ongoing Ginkgo treatment offers any 
continued beneficial effects in an already-learned working memory task. Thus, the first 
experiment described in Chapter 5 sought to evaluate the effectiveness of Ginkgo on 
acquisition and performance of a double Y-maze task in young adult rats. Moreover, the 
effect of Ginkgo on memory, per se, is not clear since in most previous studies Ginkgo 
treatment was initiated prior to and/or during the acquisition phase. Thus, the second 
experiment in Chapter 5 aimed to examine the acute and chronic effects of Ginkgo 
directly on working memory function by administrating Ginkgo in the interval between 
acquisition and testing. 
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Foreword to Chapter 2 
The following chapter is based on a manuscript submitted to the journal Phytomedicine in 
April 2008. The manuscript was accepted for publication in August 2008 and is now 
published (Apr 2009, vol 16, pg 361-368). Dr. Paul E. Mallet and his students Clinton A. 
Moore and Melissa T. Collie are co-authors. Brains were collected from animals treated 
at the University of New England, Australia, and the immunohistochemical processing 
was conducted by Melissa Collie and Clinton Moore. The author of the present 
dissertation conducted the microscopic quantification of labelled nuclei, and conducted 
preliminary data analyses. The first draft of the manuscript was written by Dr. Mallet. 
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Chapter 2: Regional distribution of Ginkgo biloba-'mduced c-Fos immunoreactivity 
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Abstract 
A growing literature supports the notion that Gingko biloba has cognitive enhancing and 
anxiolytic properties; however, its effects on neuronal populations have yet to be 
characterized. The present study used c-Fos immunoreactivity (Fos-IR) to characterize 
neuronal activity in selected brain regions following administration of a standardized 
Ginkgo biloba extract. Because Ginkgo is typically consumed orally, Experiment 1 
sought to identify patterns of neural activity induced by oral administration. To ensure 
that the alterations in functional neural activity observed in Experiment 1 were not simply 
due to novel gustatory experience, Experiment 2 characterized patterns of Fos-IR 
following intraperitoneal administration of Ginkgo. Rats were habituated to handling and 
experimental conditions. In Experiment 1, rats self-administered 150 mg/kg Ginkgo or 
vehicle alone (strawberry jam) orally. In Experiment 2, rats were injected with Ginkgo 
(2.5 or 25 mg/kg, i.p.) or vehicle (0.3% gum Arabic). Animals were anaesthetized and 
perfused transcardially. Brains were sectioned; immunostained using a c-Fos antibody, 
then the number of labeled cells was quantified microscopically in selected brain regions. 
In both experiments Ginkgo increased Fos-IR in numerous brain regions including the 
insular cortex and amygdala. Intraperitoneal administration induced Fos-IR in some 
additional regions including the nucleus accumbens and dentate gyrus. Results provide 
important preliminary data serving to identify several candidate neural sites involved in 
the cognitive enhancing and anxiolytic effects of Ginkgo biloba. 
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EGb 761 is a water-acetone extract of dried Ginkgo biloba leaves, standardized to 
contain 24% flavonoid glycosides, 6% terpenoids, and less than 9% proanthocyanidins 
and organic acids (DeFeudis & Drieu, 2000; Maclennan et al., 2002). Extracts of Gingko 
biloba, such as EGb 761, are commonly used to increase blood circulation peripherally 
and centrally, and to protect the lipid portion of cellular membranes against damage 
induced by free radicals (reviewed by Ahlemeyer & Krieglstein, 2003). A growing 
literature supports the notion that Gingko biloba has cognitive enhancing properties. For 
example, studies using rats have shown that Gingko biloba facilitates olfactory 
recognition (Wirth et al., 2000), enhances performance in a radial maze (J. C. Winter, 
1998), and facilitates learning in a water maze (Y. Wang et al., 2006). In humans, 
extracts of Gingko biloba have been found to improve cognitive function in young 
healthy individuals (Stough et al., 2001), in the elderly (Winther, Randlov, Rein, & 
Mehlsen, 1998), and in patients with Alzheimer's disease (Maurer, Dil, Dierks, & Frolich, 
1997; Oken et al., 1998). Studies also generally support the notion that extracts of Ginkgo 
biloba reduce basal (Kuribara et al., 2003) or stress-induced anxiety (Ward et al., 2002), 
and attenuate the cognitive impairments induced by exposure to stress (Walesiuk & 
Braszko, 2009; Walesiuk et al., 2005; Walesiuk, Trofimiuk, & Braszko, 2006). 
The neural mechanisms responsible for the cognitive and behavioural effects of 
Ginkgo biloba extracts are poorly understood; however, several candidate modes of 
action have so far been identified. Administration of Ginkgo biloba dose-dependently 
inhibits acetylcholinesterase in vitro (Das et al., 2002), and increases cortical blood flow 
in vivo (Krieglstein et al., 1986). In aged rats, oral administration of an extract of Ginkgo 
biloba increases the density of hippocampal muscarinic receptors (Taylor, 1986). Other 
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neurotransmitter systems may also be affected by exposure to Ginkgo biloba including 
adrenergic, dopaminergic, serotonergic, glutamatergic and GABAergic systems 
(reviewed by Ahlemeyer & Krieglstein, 2003). Hippocampal electrophysiological 
alterations have also been noted. For example, EGb 761 was found to reduce the 
population spike threshold and increase the early phase of long-term potentiation in aged 
mouse hippocampal slices (Williams et al., 2004). Furthermore, administration of EGb 
761 to aged rats increased the magnitude of inducible long-term potentiation in the CA1 
region (Y. Wang et al., 2006). 
The aim of this study was to further characterize the neural effects of an extract of 
Ginkgo biloba by using c-Fos immunoreactivity (Fos-ER.) in rats to quantify functional 
activity in several brain regions known to be involved in learning and memory. 
Expression of the immediate early gene c-fos is largely dependent on synaptic stimulation 
(reviewed by Kaczmarek & Chaudhuri, 1997). The immunohistochemical localization of 
c-Fos can therefore serve as a useful neurobiological tool to map functional activity. 
Because Ginkgo biloba is typically consumed orally, the first experiment sought to 
identify patterns of neural activity induced by orally self-administered Ginkgo. To 
control for the influence and novel gustatory experience on c-fos expression following 
oral administration, a second experiment served to characterize patterns of Fos-ER. 
following parenteral Ginkgo administration. 
Methods 
Animals were treated in accordance with the National Health and Medical 
Research Council's "Australian code of practice for the care and use of animals for 
scientific purposes" (7th edition, 2004) and the "Principles of laboratory animal care" 
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(National Research Council, 1996). Approval for this research was obtained from the 
University of New England Animal Ethics Committee. 
Subjects. Forty male albino Wistar rats (16 for Experiment 1 and 24 for 
Experiment 2, mean weight 320 g), bred at the University of New England, were group-
housed in a temperature-controlled room (21 °C) maintained on a 12:12 h reversed light: 
dark cycle (lights on at 1900 hours). Experiments were conducted during the dark cycle. 
Animals had free access to lab chow (Barastoc, Ridley AgriProducts, Australia) and tap 
water throughout the study. Rats were handled for 7 days prior to the commencement of 
the experiment. 
Ginkgo 761 Preparation and Administration. An injectable solution was prepared 
by mixing the Ginkgo biloba extract EGb 761 (Ginkgoselect, Indena S.p.A, Milan, Italy) 
in 0.3% Gum Arabic (Sigma-Aldrich, Castle Hill, NSW). The solution was stored at 4 °C 
until needed. Ginkgoselect is composed of EGb 761-standardized to contain 24% 
ginkgoflavonglucosides, 6% ginkgolides and bilobalide, and less than 5 ppm ginkgolic 
acids—complexed with soy phospholipids at a ratio of 1:2 (w/w) to increase 
bioavailability. Injections were administered intraperitoneally in a volume of 2 ml/kg 
body weight at doses of 2.5 and 25 mg/kg body weight. Doses are expressed to reflect 
the EGb 761 content of the phospholipid complex. The i.p. administration of a similar 
dose of Ginkgoselect was found to enhance acquisition of a double Y-maze task (Satvat 
& Mallet, 2009). 
A Ginkgo biloba suspension was also prepared for oral consumption using 
commercial water-soluble EGb 761 tablets (AIM Ginkgo 3000™, AIM International, 
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Somerton Victoria, Australia). Tablets were crushed into a fine powder and mixed with 
strawberry jam (Savings brand, Coles Myer Ltd., Tooronga, Victoria, Australia) such that 
each g of jam contained 30 mg EGb 761. Rats were fed 5 g jam per kg body weight per 
dose, yielding an EGb 761 dose of 150 mg/kg. 
Procedure. 
EXPERIMENT 1: ORAL ADMINISTRATION 
To reduce flavor neophobia, a glass dish containing 30 g strawberry jam without 
Ginkgo was placed in each group home cage containing six rats on each of 2 consecutive 
days. 
The next phase of the experiment, lasting 21 days, served to reduce c-fos 
expression in response to novelty, handling, and experimental procedures. Each day 
animals were weighed and placed individually in 40 x 30 x 25 cm seclusion cages for 3 
h, in a dimly lit (two 40 W incandescent red lamps) quiet room with soft pink noise 
(noise generator model K2135, Altronics, Perth, WA, Australia). Seclusion cages 
contained a dish with 5 g/kg strawberry jam, which later served as the vehicle for Ginkgo. 
Placement in the seclusion cages was staggered to habituate the animals to the 
experimenter entering the room at 10 min intervals, which was required for the precise 
timing of the perfusions later in the experiment. 
On the next day the experiment was conducted as usual, except that the 
strawberry jam was replaced with the Ginkgo jam mixture for half the rats (n=8). At the 
end of the 3-h seclusion session, rats were deeply anesthetized with sodium pentobarbital 
(120 mg/kg, i.p.), and then perfused transcardially first with 100 ml phosphate-buffered 
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saline (0.9%, pH 7.2), then with 150 ml phosphate-buffered paraformaldehyde (4%, pH 
7.2). To ensure group differences in c-fos expression were not related to circadian 
rhythms, odd-numbered rats in the sequence were assigned to the vehicle group, and 
even-numbered rats in the sequence were assigned to the Ginkgo group. 
EXPERIMENT 2: INTRAPERITONEAL ADMINISTRATION 
On each of 4 consecutive days, animals were weighed, injected with 0.3% gum 
Arabic (i.p.), then placed individually in 40 x 30 x 25 cm seclusion cages in a dimly-lit 
quiet room (details above) for 2 h. On the following day, the experiment was conducted 
as usual, except that rats were injected with the gum Arabic vehicle (n=8), 2.5 mg/kg 
Ginkgo (n=8), or 25 mg/kg Ginkgo (n=8) prior to the 2-h seclusion session. Rats were 
then anesthetized and perfused as described above. To ensure that group differences in 
Fos-IR were not related to circadian rhythms, the order of treatments was 
counterbalanced such that one rat from each group was perfused every 45 minutes (i.e., 
one perfusion was performed every 15 min). 
Immunochemistry. Immunohistochemical staining was performed in a manner 
similar to that described earlier (Singh, McGregor, & Mallet, 2005, 2006). Following 
perfusions, brains were extracted and post-fixed in 4% phosphate-buffered 
paraformaldehyde (pH 7.2) for 48 h at 4 °C, then placed in 15% w/v phosphate-buffered 
sucrose (pH 7.2) for 24 h at 4 °C, and then finally transferred into 30% w/v phosphate-
buffered sucrose for 48-72 h at 4 °C. Brains were sectioned coronally at 40 um using a 
cryostat (Leica CM 1850), and the sections were collected in phosphate buffer (PB, pH 
7.2). 
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Free-floating sections were washed in 0.9% hydrogen peroxide for 30 min to 
inhibit endogenous peroxidase, and then were bathed for 30 min in 3% phosphate-
buffered goat serum. Sections then were incubated for 72 h at 4 °C in the primary c-Fos 
antibody (s52, Santa Cruz Biotechnology, Santa Cruz, CA; rabbit polyclonal, specific for 
the amino acid terminus of c-Fos p62, non cross-reactive with FosB, Fra-1 or Fra-2) 
diluted 1:2000 in phosphate buffered goat serum (PBG, 0.1% bovine serum albumin, 
0.2% Triton X-100, 2% normal goat serum in PB). Sections were washed for 30 min in 
PB, then were placed in biotinylated anti-rabbit IgG (Vector Laboratories, Burlingame, 
CA) diluted 1:500 in PBG for 60 min at room temperature. Next, the tissue was washed 
in PB for 30 min, and subsequently incubated for 60 min in extrAvidin-horseradish 
peroxidase (Sigma-Aldrich, Castle Hill, NSW) diluted 1:1000 in PBG. After three 
additional 30-min washes in PB, horseradish peroxidase activity was visualized using the 
nickel diaminobenzidine and glucose oxidase reaction with nickel enhancement, as 
described by Shu et al. (1988). The reaction was terminated 10 min later by washing in 
PB. Sections were mounted onto gelatine-coated slides, dehydrated in ethanol, cleared 
with dipentene (Histolene, Fronine Laboratory Supplies Pty Ltd, Riverstone, NSW, 
Australia), and coverslipped. 
Microscopy. Each microscope slide was coded to ensure "blind" counting. A total 
of 20 brain regions were examined using a Leica DMR upright light microscope at 
approximately 200x magnification. The atlas of Paxinos and Watson (1997) was used to 
identify the brain regions shown in Figure 1. A 10 x 10 square graticule was positioned 
over a standardized region of each structure and the number of labeled nuclei within the 
graticule, which covered a 500 x 500 um area, was counted manually. Only round and 
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Figure 1. Schematic diagrams of coronal sections of the rat brain (adapted from Paxinos 
& Watson, 1997). The number of c-Fos immunoreactive nuclei was quantified within the 
areas numbered and shaded in gray (shown to scale). Labels correspond to the brain 
regions listed in Table 1. 
Figure 1 
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oval nuclei that were completely black were counted. Structures examined included the 
caudate-putamen (CPu): central, dorsal, dorsomedial, and ventrolateral regions; cortex: 
cingulate, insular and piriform regions; nucleus accumbens (nAcc): core and shell 
regions; lateral septal nucleus, ventral part (LSV); bed nucleus of the stria terminalis, 
lateral division, dorsal region (BNST); thalamus: paraventricular nucleus (PV) and 
dorsomedial; amygdala: basolateral nucleus (BNA), central nucleus (CEA), and medial 
nucleus (MNA); hippocampal formation: dentate gyrus, CA1 and CA3 regions; and the 
premammillary nucleus. 
Statistical Analysis. In Experiment 1 (oral administration), the number of c-Fos 
immunoreactive cells was compared between groups using unpaired ?-tests. In 
Experiment 2 (i.p. administration), the number of labeled cells was compared between 
groups using one-way analyses of variance. (ANOVA). When a significant ANOVA was 
found, groups were further compared using post hoc Tukey tests. Because the 
homogeneity of variance and normality assumptions were frequently violated, 
independent groups randomization tests were also conducted using the program NPFact 
(May, Hunter, & Gabriel, 1993) to confirm the outcome of the parametric tests. 
Results 
The numbers of c-Fos immunoreactive cells for each brain region examined are 
shown in Table 1. In addition, representative photomicrographs of c-Fos immunoreactive 
nuclei are presented in Figure 2. In all cases but one, the randomization tests yielded the 
same outcome as the parametric tests, so for ease of interpretation only the outcome of 
the randomization tests are shown. In one case the ANOVA was marginally significant, 
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Figure 2. Photomicrographs showing c-Fos immunoreactive cells in the central nucleus 
of the amygdala from representative animals treated with vehicle, 2.5 mg/kg or 25 mg/kg 
Ginkgo from Experiment 2. Scale bar is 100 urn. 
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but the randomization test was not. Because the ANOVA homogeneity of variance 
assumption was violated, the non-significant outcome of the randomization test was 
adopted. 
Oral administration of Ginkgo (Experiment 1) increased Fos-IR moderately, but 
significantly, in the insular cortex (ti3=2.67, P<0.05) and amygdala (basolateral and 
central nuclei; t\4=5.56, P<0.001 and ?i4=5.56, P<0.05, respectively). The i.p. 
administration of Ginkgo (Experiment 2) also significantly increased Fos-IR in several 
brain regions including the prelimbic (^2,21=8.18, P<0.01) and insular cortices 
(F2,2i=4.38, P<0.05), nAcc shell (F2,2i=4.01, P<0.05), LSV (F2,2i=4.71, P<0.05), BNST 
(F2,2i=5.29, P<0.05), PV (F2,2i=7.62, P<0.01), CEA (F2,2i=7.09, P<0.01), and dentate 
gyrus (F2,2i=2.62, P<0.05). Outcomes of the post hoc pairwise comparisons are 
presented in Table 1 
Discussion 
Results revealed that both oral and parenteral administration of Ginkgo increased 
c-fos expression in selected limbic and related structures, suggesting that Ginkgo 
increases neural activity in a region-specific manner. Ginkgo significantly increased Fos-
IR in the insular cortex and CEA using both routes of administration. However, for some 
brain regions the pattern of neural activation differed depending on the route of 
administration. For example, Fos-IR was significantly increased in the PV, nAcc shell, 
and dentate gyrus following i.p. administration, but not following oral administration of 
Ginkgo. Conversely, Fos-IR was increased significantly in the BNA by oral, but not i.p. 
administration of Ginkgo. This should not be taken as evidence that different routes of 
administration produce unique neural (and consequently behavioural) effects. Indeed a 
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direct comparison of these two routes of administration is not possible given differing 
pharmacodynamics and the necessary procedural differences required to vary the route of 
administration (e.g., dose, injection, exposure to jam). Rather, Experiment 1 served to 
characterize neural activity induced by oral administration given that this is the most 
commonly employed route of administration, while Experiment 2 served to demonstrate 
that many of the observed changes in Fos-IR found in Experiment 1 cannot be simply 
explained by novel gustatory experience (i.e., a noticeable change in jam flavour by the 
addition of Ginkgo). 
Growing evidence suggests a critical role for the CEA and insular cortex in 
learning and memory. For example, the insular cortex has been shown to be involved in 
incentive memory (Balleine & Dickinson, 2000), the consolidation of object memory 
(Bermudez-Rattoni, Okuda, Roozendaal, & McGaugh, 2005), the acquisition and 
consolidation of inhibitory avoidance (Mello e Souza et al., 2001; Miranda & McGaugh, 
2004), and the consolidation of conditioned taste aversion (Miranda & McGaugh, 2004). 
The CEA plays a critical role in the acquisition, consolidation, and expression of 
Pavlovian fear conditioning (Wilensky, Schafe, Kristensen, & LeDoux, 2006). Thus, the 
finding that acute administration of Ginkgo increased neural activity in the insular cortex, 
CEA, and dentate gyrus indicates that limbic structures may have potentially important 
roles in the long-term neurocognitive effects of Ginkgo. 
The significant increase in Fos-IR found in the dentate gyrus is particularly 
interesting given the important role of the hippocampal formation in learning and 
memory (Squire, Stark, & Clark, 2004). It is not, however, clear why the increase in Fos-
IR was specific to the i.p. route of administration, but this may have been related to the 
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different time courses and doses of Ginkgo used in the two experiments. That is, the time 
between administration of Ginkgo and perfusion was 1 h longer in the experiment using 
oral administration to allow for the slower rate of absorption using this route of 
administration. It is worth noting that although the regional activity in the dentate gyrus 
was not significantly increased by oral administration of Ginkgo, a non-significant trend 
(p=0.088) was observed. Furthermore, different doses were used in each experiment. In 
Experiment 1, the dose used was 150 mg/kg because pilot studies revealed that this dose 
approached the maximum concentration in the jam vehicle tolerated by rats. That is, 
higher concentrations were not well consumed, presumably because of an undesirable 
taste. In Experiment 2, doses were 2.5 and 25 mg/kg. The higher dose approached the 
maximum quantity of Ginkgo that could be suspended in vehicle using an injection 
volume of 2 ml/kg. Further studies comparing plasma and brain concentrations of Ginkgo 
constituents following both routes of administration and time courses would be useful to 
clarify this point. 
The increase in Fos-IR in the PV and prelimbic cortex are noteworthy given the 
role of midline intralaminar nuclei in attention. Thus, PV efferents project to the 
amygdala, nucleus accumbens, and ventral aspects of the medial prefrontal cortex 
(reviewed by Huang, Ghosh, & van den Pol, 2006), all of which are limbic regions 
involved in motivation and attention. Fos-IR in the PV and prelimbic cortex was 
significantly increased by i.p. Ginkgo, but the increase following oral administration fell 
short of statistical significance in both cases. The diminished drug effect following oral 
administration despite a longer habituation period may be dose, route, or time course 
related, but is more likely due to the high baseline level of Fos-IR observed in the vehicle 
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group (oral consumption of jam), which may have been a consequence of consuming a 
highly palatable food. Support for this notion comes from the finding that PV c-fos 
expression is increased by anticipatory feeding (Nakahara, Fukui, & Murakami, 2004). It 
is therefore possible that at least some of the cognitive enhancing effects of Ginkgo may 
be attributed to enhanced cortical arousal and attention. 
It is not possible to determine conclusively from the present results alone whether 
the increase in Fos-IR found in the BNA following oral consumption of Ginkgo was the 
result of a central pharmacological effect of Ginkgo, or was simply caused by the 
subjective experience of the novel taste of Ginkgo. However, the finding that Fos-IR was 
not increased significantly in this brain region by parenteral administration of Ginkgo 
suggests that taste novelty cannot be discounted. In support of this notion, it has been 
shown that amygdalar c-fos expression is increased by exposure to a novel saccharin 
solution in mice (Montag-Sallaz, Welzl, Kuhl, Montag, & Schachner, 1999) and rats 
(Koh, Wilkins, & Bernstein, 2003). 
The nature of the neuroplastic changes responsible for the cognitive enhancing 
effects of chronic administration of Ginkgo have yet to be characterized. Nonetheless, 
results from the present study provide novel evidence that acute administration of Ginkgo 
induces neural activity in a region-specific manner. Given that the beneficial cognitive 
effects of Ginkgo are typically more pronounced following chronic dosing (reviewed by 
Muller & Chatterjee, 2003), it remains the goal of future research to determine whether 
chronic alterations in regional activity by Ginkgo induces longer-term neural plasticity 
responsible for cognitive improvements. 
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Chapter 3: Effects of Ginkgo biloba leaf extract on proliferation and survival of newborn 
cells in the dentate gyrus of the hippocampus in young adult male rats 
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Abstract 
The present study aimed to explore the possible neurogenic-enhancing effects of a 
Ginkgo biloba leaf extract {Ginkgo) on adult hippocampal neurogenesis as a means to 
explain its cognitive-enhancing properties. The acute and chronic effects of Ginkgo on 
anxiety were also assessed using a battery of behavioural measures including the 
light/dark emergence, elevated plus maze and social interaction tests. In Experiment 1, to 
evaluate the acute effects of Ginkgo on anxiety, rats (n=12) were injected with Ginkgo (0, 
2.5, 13.75, or 25 mg/kg), 30 min prior to behavioural testing. Two weeks later, to 
evaluate the acute effects of Ginkgo on hippocampal cell proliferation, half of the rats 
(n=6) in each group received a single Ginkgo (0, 2.5, 13.75, or 25 mg/kg) injection, 
followed by a single 5-bromo-2'-deoxyuridine (BrdU, 75 mg/kg) injection 30 min later. 
Animals were perfused 24 hours later. Administration of 13.75 and 25 mg/kg doses 
appeared to induce anxiety in the light/dark emergence test as indicated by increased 
duration of time spent in the hide box and longer exit latency. Locomotor activity was not 
significantly influenced by Ginkgo. Furthermore, cell proliferation in both the dorsal and 
ventral dentate gyrus was unaffected by acute Ginkgo injection. In Experiment 2, to 
evaluate the effects of Ginkgo on cell survival, rats (n=10) received 3 days of BrdU (50 
mg/kg twice daily) injection. Twenty-four hours later, rats received daily injections of 
Ginkgo (0, 2.5, 13.75, or 25 mg/kg) for 21 days. On day 22, anxiety was assessed and rats 
were perfused the next day. Ginkgo had no significant effects in all behavioural tests. In 
addition, chronic Ginkgo treatment did not influence cell survival in either the dorsal or 
the ventral dentate gyrus. In sum, results revealed that both acute and chronic 
administration of varying doses of Ginkgo had no effect on hippocampal cell proliferation 
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or survival. Ginkgo may exert its nootropic effects in young rats via mechanisms other 
than enhancement of adult hippocampal neurogenesis. 
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The Ginkgo extract EGb 761 contains 24% flavonoid glycosides, 6% terpenoids, 
and less than 9% proanthocyanidins and organic acids (Chan et al., 2007; DeFeudis & 
Drieu, 2000; Maclennan et al., 2002; Ponto & Schultz, 2003; Zimmermann et al., 2002). 
Each of these active components has its own unique pharmacology, making it difficult to 
identify a specific mechanism that may contribute to its beneficial effects on cognitive 
function. In fact, the favorable effects of the extract on cognition are believed to be the 
result of agonistic, antagonistic and synergistic effects of its various constituents 
(DeFeudis & Drieu, 2000). 
The flavonoid and proanthocyanidins components possess antioxidant and free 
radical scavenging properties (DeFeudis & Drieu, 2000), and the ginkgolide components 
antagonize the effects of platelet activating factor and improve cerebral metabolism 
(Braquet & Hosford, 1991). The bilobalide fraction of Ginkgo has neuroprotective 
properties and has been shown to protect neuronal damage induced by ischemia 
(Krieglstein et al., 1995). In addition, Ginkgo has been shown to protect cellular 
membrane fluidity (Stoll et al., 1996), and to enhance cerebral blood flow and 
microcirculation (Krieglstein et al., 1986), properties that have been suggested to underlie 
its cognitive-enhancing effects (Drieu & DeFeudis, 2000). 
The involvement of Ginkgo on promoting adult hippocampal neurogenesis, as an 
additional mechanism of action responsible for its pro-mnemonic effects, has not been 
evaluated. Given that the number of newborn dentate gyrus neurons has been shown to 
correlate with learning abilities (e.g., see Kempermann et al., 1997b; van Praag, Christie 
et al., 1999), and that newborn neurons are involved in cognitive functioning (Kee et al., 
2007; Ramirez-Amaya et al., 2006), it was hypothesized that the beneficial effects of 
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Ginkgo on learning may, at least to some extent, be attributed to its neurogenic potential; 
that is, Ginkgo may enhance learning by positively affecting proliferation and/or survival 
of newborn neurons in the dentate gyrus of the adult hippocampus. Several lines of 
evidence support this hypothesis. First, Ginkgo positively modulates activity of the 
cholinergic system (Chopin & Briley, 1992; Das et al., 2002; Kristofikova et al., 1992; 
Taylor, 1986; Yamamoto et al., 2007), which is involved in the regulation of adult 
hippocampal neurogenesis (Cooper-Kuhn et al., 2004; Kaneko et al., 2006; Kotani et al., 
2006, 2008). Second, the ability of Ginkgo to enhance microcirculation (Krieglstein et al., 
1986) and proliferation of endothelial progenitor cells (Chen et al., 2004) may suggest its 
neurogenic potential. Newborn cells in the granule cell layers are in close proximity to 
fine capillaries and in fact, 37% of all dividing cells have been shown to be 
immunoreacive for endothelial markers (Palmer et al., 2000). Third, in utero exposure to 
Ginkgo enhances neuronal survival and growth in the developing hippocampus and 
modifies expression of specific genes that are involved in development, maturation and 
repair of neuronal cells (Li et al., 2003). Fourth, results from the previous chapter also 
provided evidence that administration of Ginkgo induced neural activity in the dentate 
gyrus. Fifth, long-term rather than short-term Ginkgo treatment is often associated with 
improved learning. This corresponds to the hypothesis that Ginkgo enhances 
neurogenesis, as newborn neurons require several weeks before they integrate into the 
neuronal circuitry and become fully functional (van Praag et al., 2002). Sixth, 
transcription of a gene that encodes for transthyretin has been found to increase more 
than three-fold in the hippocampus of adult mice fed a Ginkgo supplemented diet for 4 
weeks (Watanabe et al., 2001). Transthyretin is involved in the transport of the thyroid 
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hormone thyroxine to cerebrospinal fluid and serum (Kuchler-Bopp et al., 2000). Thyroid 
hormones have also been shown to play roles in the regulation of adult hippocampal 
neurogenesis (Ambrogini et al., 2005). Thus, Experiment 1 examined the acute effects of 
Ginkgo on cell proliferation in the dentate gyrus of adult rats, and Experiment 2 
investigated whether chronic Ginkgo administration influences adult hippocampal cell 
survival. 
Antidepressants such as selective serotonin reuptake inhibitors (SSRI) have potent 
neurogenic properties and have been shown to enhance both proliferation (Malberg, 
Eisch, Nestler, & Duman, 2000) and survival (Nakagawa et al., 2002) of the dentate 
gyrus newborn neurons. Thus, the influence of fluoxetine, a SSRI antidepressant, on 
hippocampal cell survival was also examined as a positive control to verify the 
immunohistochemical and cell quantification methods employed in the present study. 
There is evidence that Ginkgo treatment reduces basal and stress-induced anxiety 
(for a review, see Chapter 1). For example, chronic Ginkgo pre-treatment has been shown 
to significantly decrease stress induced by cold water exposure (Ward et al., 2002), 
stress-induced learning deficits in a discrimination task (Rapin et al., 1994) and stress-
induced memory deficits in a passive avoidance task (Walesiuk et al., 2005). Mice treated 
with Ginkgo (125 mg/kg for one week) have also been shown to spend significantly more 
time on the open arms of the elevated plus maze compared to vehicle-treated mice, 
suggesting an anxiolytic-like effect of the extract (Kuribara et al., 2003). Thus, 
Experiments 1 and 2 were supplemented with behavioural tests of anxiety. A battery of 
behavioural measures including the light/dark emergence, elevated plus maze and social 
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interaction tests were employed to assess the acute and chronic effects of Ginkgo on 
anxiety. 
Experiment 1: Acute effects of Ginkgo on hippocampal cell proliferation 
Method 
Subject. Forty-eight male Sprague-Dawley rats (Charles River, Canada), weighing 
between 210 and 250 g upon arrival to the facility were used. Rats were pair-housed in 
standard plastic shoebox cages (45 x 25 x 20 cm) maintained at 21-22°C in a colony 
room on a 12 hour reversed light-dark cycle (lights off at 0700 h). Testing was conducted 
exclusively during the dark cycle. Experimental procedures for this and the next 
experiment followed Canadian Council on Animal Care guidelines, and were approved 
by the Wilfrid Laurier University Animal Care Committee. 
Drugs. Ginkgoselect (Indena S.p.A., Milan, Italy) was dissolved in 10% w/v 2-
hydroxypropyl-P-cyclodextrin (2-H(3C; OnBio Inc.). Ginkgoselect is composed of EGb 
761 complexed with soy phospholipids at a ratio of 1:2 (w/w) to increase bioavailability. 
Doses are expressed to reflect the EGb 761 content of the phospholipid complex. Half of 
the rats in each group (n=6) also received a single injection of 5-bromo-2'-deoxyuridine 
(BrdU, Sigma-Aldrich) administered at a dose of 75 mg/kg. BrdU was dissolved in 15% 
w/v 2-HPC at 37 °C. The drugs were administered intraperitoneally (i.p.) at a volume of 2 
ml/kg of body weight. 
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Apparatus. 
LIGHT/DARK EMERGENCE 
The light/dark emergence apparatus consists of two chambers, one of which is 
relatively smaller and dimly illuminated, while the other one is larger with brighter 
illumination. The test involves a conflict between the desire to explore a novel 
environment and the natural desire to avoid an open and typically brighter space (Lister, 
1990). Anxiolytic drugs have been found to increase exploration in the light compartment 
(i.e. increase the number of light/dark transitions or hide box exits), at doses that do not 
influence locomotor activity. Conversely, anxiogenic drugs have been found to reduce 
light/dark transitions or reduce exploratory behaviours in the light compartment (Crawley 
& Goodwin, 1980; Hascoet & Bourin, 1998; Lister, 1990). In a different version of the 
test the light and dark compartments are of the same size (Belzung, Misslin, Vogel, 
Dodd, & Chapouthier, 1987). The other version of the test, employed in the present 
study, consists of a small black-coloured hide box, which is placed inside a large arena 
maintained under red light or low level illumination (McGregor et al., 2003). 
The light/dark emergence apparatus used in the present experiments consisted of a 
white square open field (120 x 120), and a black wooden hide box (40 x 24 x 15 cm) that 
was placed inside the open field. The walls of the open field were 45 cm in height, and 
were made out of white melamine. The floor was constructed of black ABS plastic. The 
hide box was placed 2 cm away from the back wall of the open field in a location 
equidistant from the left and right corners of the arena. The open field was illuminated 
with red light (5 lux at the floor level). The distance traveled was tracked and measured 
by the ANY-maze video tracking system (version 4.3; Stoelting Co.). 
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On test days, rats were placed inside the hide box and their behaviours were 
recorded for 5 min. The percent duration of time spent in the hide box (time in the hide 
box -r total duration of the test x 100), exit latency (s) and distance traveled (m) were all 
measured. The apparatus was cleaned between test sessions with a detergent (Coverage 
256, Steris Corp) diluted 1:1000 in water, and then thoroughly dried. 
ELEVATED PLUS MAZE 
The elevated plus-maze apparatus consisted of two open and two enclosed arms, 
arranged such that the two open and enclosed arms were opposite to each other. The plus 
maze was elevated 50 cm above the floor to take advantage of the reluctance of animals 
to explore the elevated open arms. The test has been shown to be sensitive to the effects 
of both anxiolytic and anxiogenic drugs (Lister, 1990). 
The apparatus used in the present experiments consisted of two open arms (10 x 
50 cm) and two enclosed arms (10 x 50 cm) with walls 40 cm in height. A central square 
(10 x 10 cm) connected the four arms. The walls of the maze were made out of black 
plastic (UHMW polyethylene) and the floors were made out of black ABS plastic. The 
testing room was illuminated with a red light (5 lux at the maze floor). The amount of 
time spent in each arm as well as the number of entries into each arm and locomotor 
activity were measured using the ANY-maze video tracking system (version 4.3; 
Stoelting Co.). On the test day, rats were placed in the centre of the maze, facing one of 
the open arms, and were tested for 5 min. The apparatus was cleaned between each test 
session with a detergent (Coverage 256, Steris Corp) diluted 1:1000 in warm water and 
then thoroughly dried. 
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SOCIAL INTERACTION 
The social interaction test measures levels of anxiety that rats display when 
confronted by an unfamiliar conspecific (File, 1980). The model has been validated for 
demonstration of both anxiogenic and anxiolytic effects of different types of drugs (File, 
1980, 1985; File & Seth, 2003). Whereas anxiolytic drugs increase social interaction, 
anxiogenic drugs reduce social interaction without significantly influencing locomotor 
activity (Guy & Gardner, 1985). Two testing conditions, including lighting level and 
familiarity of the rats to the test environment, have been shown to influence social 
interactions. Unfamiliarity with the testing arena and high levels of illumination both 
decrease social interaction, whereas familiarity to the test environment and low levels of 
illumination both increase social interaction (File, 1980). In the present experiment, 
social interaction was measured in a familiar arena under low light illumination. 
The apparatus was a rectangular enclosure (40 x 60 x 25 cm), placed on a table 90 
cm above the floor. The top and three side walls were made out of aluminum, and the 
front wall was constructed of clear acrylic. The floor was made out of black ABS plastic. 
The testing room was illuminated with dim white light (65 lux at the enclosure floor). A 
Panasonic colour CCTV camera, mounted on a tripod next to the social interaction box, 
was connected to a monitor as well as a video recorder in an adjacent room. The video 
recorded the interactions of the animal. Each interaction was coded with a random 
number so that the experimenter could subsequently "blindly" score social interaction 
behaviours. The ODLog software package (Macropod Software, ODLog for Mac OS X 
version 2.3; www.macropodsoftware.com) was used to manually score behaviours of 
interest. 
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Rats were habituated to the social interaction apparatus one day before testing. 
During the habituation, each rat was placed in the social interaction enclosure for two 
non-consecutive 5 min periods. On the test day, immediately after plus maze or light/dark 
emergence tests, rats were placed in the social interaction apparatus for a 10 min period. 
Each pair of rats was approximately the same weight, and was in the same drug 
condition. Duration of behaviours including sniffing, following, grooming, crawling 
under and over the other rat were scored and considered as active social interactions 
(File, 1980). Duration of rearing, defined as when the rat lifted itself upright on its hind 
limbs, was also scored and used as an index of locomotor activity in the social interaction 
apparatus. The apparatus was cleaned with a detergent (Coverage 256, Steris Corp) 
diluted 1:1000 in warm water and thoroughly dried between test sessions. 
Procedure. An overview of the design of Experiment 1 is shown in Figure 3 (A). 
Rats were handled and acclimatized to the colony for one week. On the test day, pairs of 
unfamiliar rats were injected with vehicle or Ginkgo (2.5, 13.75, or 25 mg/kg). Thirty 
min following the injection pairs of unfamiliar rats from each group were tested so that 
one of the rats was tested in the light/dark emergence apparatus while the other one was 
tested in the elevated plus maze. 
Rats were placed in the plus maze facing the open arm and were placed inside the 
hide box of the light/dark emergence apparatus. The animals' activities in both the 
elevated plus maze and light/dark emergence apparatuses were tracked and recorded 
using the ANY-maze video tracking system for 5 min. The rats were then placed back 
into their home cages for 5 min, during which time both apparatuses were cleaned then 
thoroughly dried. The rats were brought back to the testing room and were placed into the 
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Figure 3. Timeline of Experiment 1 (A) and Experiment 2 (B) in Chapter 3. 
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untested apparatuses for 5 min. Immediately afterwards, both rats were placed in the 
social interaction enclosure, where they met for the first time for a 10 min period. This 
procedure allowed for unfamiliar rats to visit in the social interaction box after the same 
amount of time had elapsed after the injection. 
After a two week wash-out period, during which time the rats were weighed daily, 
the acute effects of Ginkgo on cell proliferation was investigated in half of the rats in 
each drug treatment group (n=6). The rats received a single injection of either vehicle or 
Ginkgo (2.5, 13.75, or 25 mg/kg), followed 30 min later by an injection of BrdU (75 
mg/kg). To detect the effect of acute Ginkgo injection on cell proliferation, rats were 
perfused 24 hours after BrdU injection. 
Perfusion. Rats were anaesthetized with a lethal dose of sodium pentobarbital 
(120 mg/kg, i.p.). Once non-reflexive, rats were transcardially perfused with 150 ml 0.1 
M phosphate buffer saline (PBS, pH 7.2) followed by 150 ml 4% paraformaldehyde 
(Mallinckrodt Baker, Inc) in 0.1 M PBS (pH= 7.2). Brains were extracted and fixed for 
48 hours in 4% paraformaldehyde in PBS solution at 4 °C. Brains were cryoprotected 
first in 15% w/v phosphate-buffered sucrose at 4 °C for 24 h, and then in 30% w/v 
phosphate-buffered sucrose at 4°C until they sank. 
Sectioning. Brains were sectioned coronally at 40 urn using a cryostat (Model CM 
3050 S; Leica Microsystems Nussloch GmbH) set at a temperature of -16 °C. Brain 
sections were collected in five PBS-filled vials so that each vial contained each fifth 
section (i.e. each vial contained sections 200 (am apart). To protect tissue antigenicity, 
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brain sections were transferred into polyglycerine anti-freeze solution and stored at -20 
°C until immunohistochemical processing. 
Immunohistochemistry. Only one fifth of the brains were removed from the 
freezer for immunohistochemistry. Prior to BrdU processing, all sections were washed 
three times in PBS and were stained with 0.5% cresyl violet (Sigma-Aldrich). To 
denature DNA, free-floating sections were incubated with 2N HC1 at 37°C for 30 min, 
followed by two 20-min washes in borate buffer (pH 8.5), and a 20-min wash in PBS. 
Sections were blocked in 3% normal goat serum in PBS for 30 min, and were incubated 
overnight at 4° C in primary antibody raised against BrdU (mouse monoclonal IgG, Santa 
Cruz Biotechnology, sc-20045) at 1:300 dilution in phosphate buffered goat serum (PBG) 
containing bovine serum albumin (CALLBIOCHEM), normal goat serum (PAA 
Laboratories Inc.), Triton-X 100 (ICN Biomedicals Inc) and PBS. The next day after one 
PBS wash, endogenous tissue peroxidase activity was blocked by washing the sections in 
0.9% hydrogen peroxide for 30 min. This was followed by three 20-min washes in PBS. 
Sections were then incubated at room temperature for 60 min in biotinylated secondary 
antibody (goat anti-mouse IgG-B, Santa Cruz Biotechnology, sc-2039) at 1:500 dilution 
in PBG. After a 20-min PBS wash, sections were incubated in ExtrAvidin-Peroxidase 
(Sigma-Aldrich) at 1:1000 dilution in PBG at room temperature. After three 20-min 
washes in PBS, sections were incubated in 0.05% 3,3'-diaminobenzidine-
tetrahydrochloride hydrate (DAB, Sigma-Aldrich) 0.015% H202 in PBS for 10 min to 
stain BrdU-positive cells. Sections were washed twice in PBS and were stored at 4°C 
until mounted on gelatin-coated microscope slides. For unbiased counting, the slides 
were coded. The mounted slides were submerged in 75%, 90% and 100% ethanol baths 
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for 5 min each and cleared with Harleco (clarification Neo-Clear, EMD™) for 20 min. 
The slides were then cover slipped using Permount Mounting Medium (Fisher Scientific) 
solution and allowed to dry for 3 days. 
Data quantification and analysis. The number of BrdU-labeled cells was 
quantified with a Leica DMR upright light microscope at approximately 400 x 
magnification on a series of every fifth section at 200 urn intervals. All the circular 
encapsulated BrdU-labeled cells along the granular cell layers of the dentate gyrus were 
counted separately in the dorsal (bregma -2.56 to -4.52 mm, Figure 4) and ventral 
(bregma -5.80 to -6.72 mm, Figure 5) hippocampus (Paxinos & Watson, 1997). BrdU-
labeled cells that had blood cell phenotypes were not counted. Images of the dentate 
gyrus were captured using a Leica DC camera and Leica Image Manager 50 (version 
1.10) program under approximately 50x and 12.5x magnification for the dorsal and 
ventral dentate gyrus, respectively. The outline of the dentate gyrus was traced manually 
on each photomicrograph using an Intuos3 (PTZ-930, WACOM Co. Ltd.) graphic tablet 
system. The area of each tracing was then calculated using ImageJ (Wayne Rasband, 
National Institutes of Health, version 1.37). The area of dorsal and ventral dentate gyrus 
were summed separately and multiplied by the tissue thickness (40 urn) and by 5 (to 
account for 4/5 of the sections that were not processed) to estimate the volume of the 
dorsal and ventral dentate gyrus (Gundersen & Jensen, 1987). To estimate the total 
number of BrdU-labeled cells in the dorsal and ventral dentate gyrus, the BrdU-labeled 
cell counts were multiplied by 5 to account for the samples that were not processed and 
by 8 (40 um tissue thickness/5 um depth of microscope focus) to account for the 
microscope depth of focus. BrdU-labeled cell densities in the dorsal and ventral dentate 
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Figure 4. Schematic illustration of coronal sections of the rat brain used for quantifying 
BrdU-labeled cells in the dorsal dentate gyrus. The dentate gyrus is coloured in red; 
bregma -2.56 to -4.52 mm (Paxinos & Watson, 1997). 
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Figure 5. Schematic illustration of coronal sections of the rat brain used for quantifying 
BrdU-labeled cells in the ventral dentate gyrus. The dentate gyrus is coloured in red; 
bregma -5.80 to -6.72 mm (Paxinos & Watson, 1997). 
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gyrus were calculated by dividing the estimated total number of BrdU-labeled cells in the 
dorsal and ventral dentate gyrus by their estimated volumes. There were a few missing 
sections. The number of BrdU-labeled cells and the area of the missing sections were 
estimated by taking the average of the number of labeled cells and area from the sections 
prior to and after the sections. 
Data analysis. Data from the anxiety tests were analyzed separately using one-
way analysis of variance (ANOVA). The number of BrdU-labeled cells, dentate gyrus 
volume and BrdU-labeled cell density were analyzed separately for the dorsal and ventral 
hippocampus using one-way ANOVAs. Significant effects were followed by Tukey 
post-hoc tests. 
Results 
Light/dark emergence test. The mean (+SEM) percentage of time spent in the hide 
box, mean (+SEM) exit latency, and mean (+SEM) distance traveled in the light/dark 
emergence apparatus are shown in Figure 6 (A, B, and C, respectively). The data 
obtained for percentage duration of time spent in the hide box, exit latency, and distance 
traveled were analyzed separately by one-way ANOVAs. The ANOVA found an overall 
significant effect of treatment on percentage duration of time spent in the hide box, F(3, 
44)=8.43, p<0.001, exit latency F(3,43)=4.17, /?<0.05, and distance traveled, F(3, 
44)=11.52, p<0.001. Post-hoc analysis showed that the 13.75 and 25 mg/kg Ginkgo-
treated groups spent significantly more time in the hide box (Figure 6, A), had 
significantly longer exit latencies (Figure 6, B) and traveled significantly shorter 
distances (Figure 6, C) compared to both vehicle- and 2.5 mg/kg Ginkgo-tveated animals 
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Figure 6. Mean (+SEM) percentage of time spent in the hide box (A), mean (+SEM) exit 
latency (B) and mean (+SEM) distance traveled (C) in the light/dark emergence 
apparatus. Mean (+SEM) percentage of time spent in the enclosed arms (D), mean 
(+SEM) number of open arms entries (E) and mean (+SEM) distance traveled (F) in the 
elevated plus maze. Mean (+SEM) duration of time unfamiliar rats spent interacting with 
each other (G), and mean (+SEM) duration of time rearing (H) in the social interaction 
test in Experiment 1. Rats received a single injection of 0, 2.5,13.75 or 25 mg/kg Ginkgo 
30 min prior to testing. *p<0.05, significantly different from vehicle and 2.5 mg/kg 
Ginkgo. 
Figure 6 
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(p<0.05). Because half the rats were first tested in the elevated plus maze, and the other 
half in the emergence test, two-way ANOVAs (order x treatment) were performed to also 
investigate the effect of test order on percentage duration of time spent in the hide box, 
exit latency and distance traveled. No significant effects of order were observed (data not 
shown). 
Elevated plus maze test. The percentage of time spent in the enclosed arm was 
calculated according to the formula: time spent in the enclosed arms -=- total duration of 
the test x 100. Separate one-way ANOVAs for the percentage duration of time spent in 
the enclosed arms (Figure 6, D), number of entries to the open arms (Figure 6, E), and 
distance traveled (Figure 6, D) revealed no overall significant effect of treatment. 
Furthermore, two-way ANOVAs revealed no significant order effect (data not shown). 
Social interaction test. Figure 6 (G) shows the total duration of active social 
interaction calculated by adding the duration of sniffing, following, and grooming of the 
social partner (File, 1980). Duration of rearing, defined as the rat lifting itself upright on 
its hind paws, was used as an index of locomotor activity and is shown in Figure 6 (H). 
The two separate one-way ANOVAs for the total duration of social interaction and 
rearing duration found no significant treatment effects, although as evident in Figure 6 
(H) there was a dose-dependent trend toward suppression of rearing. 
Acute effects of Ginkgo on hippocampal cell proliferation. None of the doses of 
Ginkgo tested acutely had any effect on the number of BrdU-labeled cells, volume or cell 
density in the dorsal or ventral dentate gyrus as shown in Figure 7. The number of BrdU-
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Figure 7. Mean (+SEM) number of BrdU-labeled cells (A), mean (+SEM) volume of the 
dentate gyrus (B) and mean (+SEM) BrdU-labeled cell density (C) in the dorsal region of 
the dentate gyrus. Mean (+SEM) number of BrdU-labeled cells (D), mean (+SEM) 
volume of the dentate gyrus (E) and mean (+SEM) BrdU-labeled cell density (F) in the 
ventral region. Rats were injected with a single dose of BrdU (75 mg/kg) followed by a 
single injection of 0, 2.5, 13.75 or 25 mg/kg Ginkgo 30 min later. Rats were perfused 24 
h after the BrdU injection. 
Figure 7 
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labeled cells, volume and BrdU-labeled cell density were analyzed separately for the 
dorsal and ventral hippocampus using one-way ANOVAs. None of the ANOVAs 
revealed significant treatment effects, suggesting that acute Ginkgo treatment had no 
effect on hippocampal cell proliferation either in the dorsal or in the ventral dentate 
gyrus. Representative photomicrographs of BrdU-labeled cells in the dentate gyrus of 
four groups of rats are shown in Figure 8. 
Experiment 2: Chronic effects of Ginkgo and fluoxetine on hippocampal cell survival 
This experiment was designed to investigate whether chronic Ginkgo 
administration influences hippocampal cell survival and anxiety using light/dark 
emergence, elevated plus maze and social interaction tests. Fluoxetine has been shown to 
enhance both proliferation and survival of newborn neurons (Malberg et al., 2000; 
Nakagawa et al., 2002); thus, an additional 10 rats were used as a positive control group 
for the immunohistochemistry procedures. 
Method 
Subject. Forty male Sprague-Dawley rats (Charles River, Canada), weighing 
between 230 and 270 g upon arrival to the colony were used. As in the first experiment, 
rats were pair-housed in standard plastic shoebox cages (45 x 25 x 20 cm) maintained at 
21-22°C in a colony room on a 12 hour reversed light-dark cycle (lights off at 0700 h). 
Testing was conducted exclusively during the dark cycle. 
Drugs. Ginkgoselect (Indena S.p.A., Milan, Italy) was dissolved in 10% w/v 2-
HpC. BrdU was dissolved in 10% w/v 2-HpC in a 37 ° C water bath. The drugs were 
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Figure 8. Photomicrographs (at approximately 400x magnification) of BrdU-labeled cells 
in the dentate gyrus of 0 (A), 2.5 (B), 13.75 (C) and 25 (D) mg/kg Ginkgo-treated rats in 
Experiment 1. 
Figure 8 
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administered i.p. in a volume of 2 ml/kg of body weight. Fluoxetine hydrochloride 
(Spectrum Chemical, MFG. CORP. New Brunswick) was dissolved in 10% w/v 2-H0C 
and was administered i.p. at a dose of 5 mg/kg in a volume of 2 ml/kg body weight daily 
for 21 days. 
Procedures. An overview of the design of Experiment 2 is shown in Figure 3 (B). 
After a one week handling period, all animals were injected with 50 mg/kg BrdU twice 
daily at 1100 and 1500 h for three consecutive days. This BrdU injection protocol served 
to label a relatively large number of dividing cells. To examine the effects of chronic 
Ginkgo administration on anxiety and cell survival, rats were injected with either a daily 
dose of vehicle or Ginkgo (2.5, 13.75, or 25 mg/kg) for the next 21 days. The fluoxetine 
positive control group received 5 mg/kg fluoxetine daily for 21 days. 
On the last day of drug injections, all rats were habituated to the social interaction 
apparatus. They were individually placed in the enclosure for 5 min, twice non-
consecutively. On day 22, the chronic effects of Ginkgo on anxiety were assessed using 
light/dark emergence, elevated plus maze, and social interaction tests of anxiety as 
described in the first experiment. Rats did not receive drug treatments on this day. On day 
23, the rats were perfused transcardially 24 hours after the anxiety tests. Although the 
fluoxetine group was used as a positive control to verify the immunohistochemical 
procedures employed, animals in that group underwent similar behavioural testing. The 
behavioural data were not analyzed for the fluoxetine-treated group. All procedures for 
the perfusion, brain sectioning, immunohistochemistry, quantification of BrdU-labeled 
cells and data analysis were similar to those described in the first experiment. The 
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number of BrdU-labeled cells, dentate gyrus volume and BrdU-labeled cell density were 
compared separately for the dorsal and ventral hippocampus for fluoxetine- and vehicle-
treated rats using independent samples r-tests. 
Results 
Light/dark emergence test. Chronic administration of Ginkgo for 21 days 
appeared to be neither anxiogenic nor anxiolytic as all the groups spent similar amounts 
of time in the hide box and had similar exit latencies as shown in Figure 9 (A and B, 
respectively). Hence, separate one-way ANOVAs performed for percentage duration of 
time spent in the hide box and exit latency revealed no significant effect of treatment. In 
addition, the one-way ANOVA for distance traveled also revealed no treatment effect 
(Figure 9, C). Two-way ANOVAs (order x treatment) were also performed to investigate 
whether the order of the test influenced exit latency, percentage duration of time spent in 
the hide box, and distance traveled. The results revealed a significant order effect for 
distance traveled, F(l, 32)=6.51, /?=0.016 and for the percentage duration of time spent in 
the hide box, F(l, 32)=7.22, p=0.011 (see Appendix A for additional details). 
Elevated plus maze. Figure 9 (D and E) shows that measures of anxiety in the 
elevated plus maze, namely duration of time in the enclosed arms and open arms entries, 
were not affected by chronic treatment with any dose of Ginkgo. No overall significant 
effects of treatment were revealed by one-way ANOVAs for the percentage duration of 
time spent in the enclosed arms, number of entries to the open arms, or distance traveled 
(Figure 9 D-F). To investigate the order effect on measures of anxiety in the plus maze, 
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Figure 9. Mean (+SEM) percentage of time spent in the hide box (A), mean (+SEM) exit 
latency (B) and mean (+SEM) distance traveled (C) in the light/dark emergence test. 
Mean (+SEM) percentage of time spent in the enclosed arms (D), mean (+SEM) number 
of open arms entries (E) and mean (+SEM) distance traveled (F) in the elevated plus 
maze. Mean (+SEM) duration of time unfamiliar rats spent interacting with each other 
(G), and mean (+SEM) duration of time rearing (H) in the social interaction test in 
Experiment 2. Rats were injected with 0, 2.5, 13.75, and 25 mg/kg Ginkgo for 21 days 
prior to testing. 
Figure 9 
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two-way ANOVAs (order x treatment) were also performed, but no significant effect was 
found (data now shown). 
Social interaction test. Figure 9 (G) shows the duration of active social interaction 
in the four Gm%o-treated groups. It seems that there was a slight increase in the active 
social interaction in the rats treated chronically with 2.5 mg/kg Ginkgo compared to the 
other groups, but the one-way ANOVA conducted for total duration of social interaction 
found no significant treatment effect. The one-way ANOVA for rearing duration, 
however, was significant, F(3, 36)=2.90, /?=0.048, but post-hoc multiple comparison 
failed to find any significant differences between treatments (Figure 9, H), 
Chronic effects of Ginkgo on hippocampal cell survival. As can be seen in Figure 
10, the number of BrdU-labeled cells, volume and BrdU-labeled cell density were similar 
across groups for both the dorsal and the ventral dentate gyrus. Consequently, none of the 
ANOVAs performed separately for the number of BrdU-labeled cells, volume and cell 
density in the dorsal and ventral dentate gyrus found any significant treatment effects. 
See Figure 11 for representative photomicrographs showing BrdU-labeled cells in the 
dentate gyrus of rats receiving various doses of Ginkgo. 
Chronic effects of fluoxetine on hippocampal cell survival. Figure 12 (A-C) shows 
the number of BrdU-labeled cells, volume and BrdU-labeled cell density of fluoxetine-
and vehicle-treated rats. There was no difference between the vehicle- and fluoxetine-
treated rats in the number of BrdU-labeled cells and for BrdU-labeled cell density. Figure 
13 shows photomicrographs of BrdU-labeled cells in the dorsal dentate gyrus of vehicle-
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Figure 10. Mean (+SEM) number of BrdU-labeled cells (A), mean (+SEM) volume of 
the dentate gyrus (B) and mean (+SEM) BrdU-labeled cell density (C) in the dorsal 
region used for quantifying BrdU-labeled cells. Mean (+SEM) number of BrdU-labeled 
cells (D), mean (+SEM) volume of the dentate gyrus (E) and mean (+SEM) BrdU-labeled 
cell density (F) in the ventral region. Rats received 50 mg/kg BrdU injections twice daily 
for 3 days followed by 21 days of 0, 2.5,13.75, or 25 mg/kg Ginkgo. Rats were perfused 
48 hours after the last drug injection. 
Figure 10 
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Figure 11. Photomicrographs (at approximately 400x magnification) of BrdU-labeled 
cells in the dentate gyrus of 0 (A), 2.5 (B), 13.75 (C) and 25 (D) mg/kg Ginkgo-treated 
rats in Experiment 2. 
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Figure 12. Mean (+SEM) number of BrdU-labeled cells (A), mean (+SEM) volume of 
the dentate gyrus (B) and mean (+SEM) BrdU-labeled cell density (C) in the dorsal and 
ventral dentate gyrus in rats that received 50 mg/kg BrdU injections twice daily for 3 
days followed by 21 days of vehicle or fluoxetine (5 mg/kg). */?<0.01, significantly 
different from vehicle. 
Figure 12 
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Figure 13. Photomicrographs (at approximately 400x magnification) of BrdU-labeled 
cells in the dentate gyrus of vehicle- (A) and 5 mg/kg fluoxetine- (D) treated rats. 
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and fluoxetine-treated rats. Two separate independent samples Mests for the number of 
BrdU-labeled cells and cell density were not significant. However, as shown in Figure 12 
(B), the volume of the ventral dentate gyrus appeared larger in fluoxetine-treated rats 
compared to that of the vehicle-treated rats. Accordingly, an independent samples Mest 
comparing these groups was significant, t(18) = 2.91, p<0.0l. 
Discussion 
The results of the present study revealed that Ginkgo had no influence on adult 
hippocampal neurogenesis. Firstly, cell proliferation was not affected by acute injection 
of Ginkgo either in the dorsal (Figure 7, A & C) or in the ventral dentate gyrus (Figure 7, 
D & F). Secondly, the survival of newborn cells in either the dorsal (Figure 10, A & C) or 
the ventral (Figure 10, D & F) dentate gyrus was not affected by chronic administration 
of Ginkgo. It has been suggested that adult neurogenesis in the dorsal dentate gyrus has a 
distinct role from that of the ventral dentate gyrus (Sahay & Hen, 2007). There is 
differential neuronal connectivity along the dorsal-ventral axis of the hippocampus. The 
dorsal and ventral hippocampus receive inputs from different layers of the entorhinal 
cortex and project their outputs to different structures. It appears, specifically from lesion 
studies, that the dorsal hippocampus is involved in learning behaviours and the ventral 
hippocampus is involved in response to stress and anxiety (for review, see Bannerman et 
al., 2004). For this reason, in the present study, the number of BrdU+ cells was counted 
separately in the dorsal and ventral hippocampus in order to examine whether or not 
Ginkgo and fluoxetine differentially influence dorsal and ventral hippocampal 
neurogenesis. 
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Unexpectedly, in the present study, 21 days of daily fluoxetine during the post-
BrdU survival period failed to reveal any changes in cell survival in either the dorsal or 
ventral dentate gyrus (Figure 12, A & C). However, the volume of the ventral dentate 
gyrus was found to be larger in the fluoxetine treated rats (Figure 12, B). It has been 
reported that 3 (J. W. Wang, David, Monckton, Battaglia, & Hen, 2008) and 4 
(Nakagawa et al., 2002) weeks of fluoxetine treatment significantly increased the number 
of BrdU-labeled cells in the dentate gyrus. However, 2 weeks of fluoxetine treatment 
followed by 2 weeks of no treatment had no effect on the number of BrdU-labeled cells 
(Malberg et al., 2000). In parallel with present results, a recent study also reported no 
enhancement of cell survival or cell proliferation in either the dorsal or ventral dentate 
gyrus of rats treated chronically for 25 days with 5 mg/kg fluoxetine (Cowen, Takase, 
Fornal, & Jacobs, 2008). 
While the present study was in progress, another group reported that chronic 
Ginkgo treatment enhanced cell proliferation in young and aged transgenic mice 
(TgAPP/PSl) believed to be a model of Alzheimer's disease (Tchantchou et al., 2007). In 
that study age-matched wild type mice were also used as controls. Consistent with our 
results, Ginkgo treatment had no effect on cell proliferation in young healthy mice (6 
months). This study did not investigate the effects of Ginkgo on cell survival. However, 
a critical finding of the study was that Ginkgo treatment significantly enhanced neuronal 
proliferation in aged (22 months) wild type mice. Results of the present study, together 
with the study by Tchantchou et al. (2007), raise the possibility that Ginkgo may have 
different effects in the normal healthy nervous system, compared to in dysfunctional 
nervous systems where the constitutive level of neurogenesis has been down-regulated. 
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Thus future studies should characterize the neurogenic potential of Ginkgo on 
hippocampal cells under abnormal conditions. 
The present results also revealed an apparent anxiogenic effect induced by the 
high (25 mg/kg) and moderate (13.75 mg/kg) doses of Ginkgo, when administered 
acutely and only in the light/dark emergence test as indicated by increased duration of 
time spent in the hide box and longer exit latency (Figure 6, A & B). Rats treated acutely 
with the high and moderate doses of Ginkgo also traveled significantly shorter distances 
in the light/dark emergence box compared to the other groups (Figure 6, C). This effect 
was not likely the result of a general suppressive effect of Ginkgo on locomotor activities 
because other measures of locomotion, namely distance traveled in the plus maze (Figure 
6, F) and rearing duration in the social interaction test (Figure 6, H) were unaffected by 
the same doses of Ginkgo. Nevertheless, suppression of motor activity by a single oral 
dose of Ginkgo biloba extract (500 and 1000 mg/kg but not 250 mg/kg) have been 
reported (Kuribara et al., 2003). 
When Ginkgo was administered chronically for 21 days, it induced neither 
anxiogenic nor anxiolytic effects in the light/dark emergence test (Figure 9, A & B) at all 
doses tested. In addition, acute and chronic administration of all doses of Ginkgo tested 
failed to alter the duration of time spent in the enclosed arms, number of entries into the 
open arms of the elevated plus maze (Figure 9, D & E), and duration of active social 
interactions (Figure 9, G). 
It seems surprising that administration of the acute high and moderate doses of 
Ginkgo induced anxiety only in the light/dark emergence test, and not in the other two 
anxiety tests. This suggests that the nature of the anxiety evoked by the light/dark 
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emergence, elevated plus maze, and social interaction tests are dissimilar. Both the 
light/dark emergence and the elevated plus maze are based on exploratory behaviours, 
and anxiety is generated by stimuli that are ethologically relevant to the rats. That is, the 
open space in the emergence apparatus, and the height and openness of the open arms of 
the plus maze generate behavioural and physiological changes (File, 1992). In contrast, 
unfamiliarity of a conspecific in the social interaction test generates behavioural changes 
that are used as measures of anxiety-like behaviour (File, 1980). Chronic Ginkgo 
treatment did not alter measures of anxiety in any of these ethologically based tests of 
anxiety. Thus, results of the present study do not support previous reports suggesting that 
Ginkgo can reduce anxiety (Hasenohrl et al., 1996; Kuribara et al., 2003; Porsolt et al., 
1990; Rodriguez de Turco et al., 1993; Walesiuk et al., 2005; Ward et al., 2002). Reasons 
for these inconsistencies are unclear, but may stem from different routes of 
administration, dosages or the specific behavioural tests of anxiety used in this study. 
The results of the social interaction test in the present study differed from that of 
Chermat and colleagues (1997) who found a reduction of social interaction in pairs of 
unfamiliar rats treated either acutely or chronically with Ginkgo. This discrepancy may 
be due to the use of different doses, route of administration, or testing environment. In the 
present study, social interaction was tested in a familiar arena under low light 
illumination. Unfamiliarity to the testing environment as well as bright lighting, 
conditions used by Chermat et al. (1997), have been shown to decrease social interaction 
(File, 1980). 
In sum, the results showed that chronic parenteral administration of Ginkgo 
treatment had neither anxiolytic nor anxiogenic effects in young adult male rats. Acute 
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parenteral administration of high and moderate doses of Ginkgo, however, exerted 
anxiogenic effects in some measures of anxiety. In addition, the results of the present 
study showed that cell proliferation and survival in the dentate gyrus of hippocampus 
were not affected by Ginkgo treatment in young male rats. Ginkgo may therefore exert its 
cognitive-enhancing effects in young healthy rats via mechanisms other than the 
enhancement of hippocampal neurogenesis. 
Chapter 4: Effects of Ginkgo biloba leaf extract on corticosterone-induced suppression of 
hippocampal neurogenesis in young adult male rats 
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Abstract 
The Ginkgo biloba leaf extract (Ginkgo) has been shown to decrease circulating levels of 
corticosterone (CORT) and to normalize stress-induced plasma CORT elevation. The 
involvement of CORT in stress-induced suppression of adult hippocampal neurogenesis 
has been recognized. Stress and elevated levels of CORT suppress cell proliferation, 
survival, and differentiation of newborn cells in the dentate gyrus of the hippocampus. 
The present study investigated whether CORT-induced suppression of adult hippocampal 
neurogenesis could be restored by Ginkgo co-treatment. After one week of habituation, 
32 young adult male Sprague-Dawley rats were injected i.p. with 50 mg/kg BrdU twice 
daily for three consecutive days. Starting the next day, rats were injected i.p. with vehicle 
or 25 mg/kg Ginkgo daily for 22 days. Half of the rats in the vehicle and Ginkgo groups 
were also injected immediately with 35 mg/kg CORT subcutaneously, while the other 
half in each group received the vehicle used for CORT. On days 20 and 21, one hour 
after their daily drug treatments, rats were subjected to the light/dark emergence test 
followed immediately by the elevated plus maze. On day 22, one hour after their last 
daily drug injections, rats were sacrificed. Adverse physiological effects of chronic 
CORT treatment included body weight loss as well as atrophy of the thymus and adrenal 
glands. These effects were not reversed by co-treatment with Ginkgo. Results also 
showed that CORT treatment significantly suppressed newborn cell density in the dorsal 
dentate gyrus. Ginkgo did not attenuate the suppressive effect of CORT on cell survival. 
In addition, Ginkgo by itself had no effect on survival of newborn cells in either the 
dorsal or ventral dentate gyrus. In summary, the results of the present study suggest that 
chronic CORT treatment suppressed survival of newborn cells in the dorsal dentate 
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gyrus, caused body weight loss, thymus and adrenal gland atrophy, but Ginkgo co-
treatment did not buffer these effects. 
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Standardized Ginkgo biloba leaf extracts {Ginkgo) have been shown to improve 
cognitive functioning both in humans and in rodents (Kennedy et al., 2000; Le Bars et al., 
1997; Mix & Crews, 2000, 2002; Satvat & Mallet, 2009; Stackman et al , 2003; Stoll et 
al., 1996; Stough et al., 2001; Y. Wang et al., 2006; E. Winter, 1991; J. C. Winter, 1998; 
Wirth et al., 2000). Various biological activities of Ginkgo have been suggested to 
underlie its beneficial effects on cognition. Ginkgo improves cerebral metabolism 
(Braquet & Hosford, 1991), enhances cerebral blood flow and microcirculation 
(Krieglstein et al., 1986), protects cellular membrane fluidity (Stoll et al., 1996), and 
modulates activity of the cholinergic system (Chopin & Briley, 1992; Das et al., 2002; 
Kristofikova et al., 1992; Taylor, 1986; Yamamoto et al., 2007). Since several lines of 
evidence strongly suggested that Ginkgo might enhance adult hippocampal neurogenesis 
the experiments in the preceding chapter explored its possible neurogenic-enhancing 
properties as another means to explain its nootropic effects. However, results showed that 
Ginkgo treatment affected neither cell proliferation nor survival of newborn cells in the 
dentate gyrus of the hippocampus in young adult male rats. 
Nonetheless, a recent report showed enhancing effects of Ginkgo on adult 
hippocampal cell proliferation in both young and old mice using a transgenic model of 
Alzheimer's disease (TgAPP/PSl) (Tchantchou et al., 2007). That study did not 
investigate the influence of Ginkgo on cell survival, but notably, Ginkgo treatment was 
shown to significantly enhance neuronal proliferation in aged (22 months)-matched wild 
type mice as it did in both aged and young transgenic mice. However, Ginkgo treatment 
had no effect on hippocampal cell proliferation in younger mice (6 months). Those 
findings, together with results presented earlier raise the possibility that Ginkgo may 
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exert its effect on hippocampal neurogenesis only in a brain compromised by age, stress 
or Alzheimer's disease. Thus, the aim of the present study was to investigate the effects 
of Ginkgo on hippocampal neurogenesis under conditions in which the baseline rate of 
neurogenesis is suppressed. 
Adult hippocampal neurogenesis has been shown to be sensitive to circulating 
levels of glucocorticoids (Cameron & Gould, 1994; Gould, Cameron, Daniels, Woolley, 
& McEwen, 1992). Glucocorticoids are released from the adrenal cortex in response to 
diurnal cues as well as in response to various stressors. The primary adrenal 
glucocorticoids are Cortisol and corticosterone (CORT) in humans and in rodents, 
respectively (Hibberd, Yau, & Seckl, 2000). Proliferation of progenitor cells is believed 
to be regulated, at least in part, by circulating glucocorticoids. For instance, elevated 
levels of CORT have been shown to reduce cell proliferation (Cameron & Gould, 1994). 
In addition, survival of newly born cells in the dentate gyrus (Wong & Herbert, 2004), 
and their differentiation into mature neurons (Wong & Herbert, 2006) have also been 
shown to be sensitive to circulating CORT levels. A CORT-free environment by 
adrenalectomy, on the other hand, has been shown to significantly increase proliferation 
and survival of newborn cells in the dentate gyrus (Cameron & Gould, 1994; Wong & 
Herbert, 2004). Consistent with these findings, other experimental manipulations, which 
alter levels of adrenal glucocorticoids, have been shown to modulate adult hippocampal 
neurogenesis (Tanapat et al., 2001). For example, elevated levels of CORT by aging 
decrease the rate of hippocampal neurogenesis (Kuhn, Dickinson-Anson, & Gage, 1996; 
McDonald & Wojtowicz, 2005), but this effect can be reversed by adrenalectomy 
(Cameron & McKay, 1999). In addition, stress such as predator odour in rats (Tanapat et 
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al., 2001), or psychosocial stress in tree shrews (Gould, McEwen, Tanapat, Galea, & 
Fuchs, 1997) and marmoset monkeys (Gould, Tanapat, McEwen, Flugge, & Fuchs, 
1998), causes significant suppression of cell proliferation in the dentate gyrus. Chronic 
restraint stress has also been shown to inhibit survival of newborn cells of the dentate 
gyrus (Pham, Nacher, Hof, & McEwen, 2003). Thus, the increase in the baseline CORT 
levels brought about by aging or stress is detrimental for adult hippocampal neurogenesis. 
Therefore, treatments that normalize the elevated CORT may reverse CORT-induced 
suppression of cell proliferation in the dentate gyrus. 
Repeated treatment with Ginkgo has been shown to decrease circulating levels of 
CORT by reducing levels of messenger RNA protein and drug binding of adrenocortical 
mitochondrial peripheral-type benzodiazepine receptors in rats (Amri et al., 1996). 
Ginkgo pre-treatment has also been found to normalize elevated levels of circulating 
CORT induced by restraint stress in rats (Rai et al., 2003; Shah et al., 2003). Thus, the 
ability of Ginkgo to enhance hippocampal neurogenesis in aged (Tchantchou et al., 
2007), but not young rodents (Tchantchou et al., 2007), might have been, in part, due to 
the normalizing effects of Ginkgo on aged-induced CORT elevations. Accordingly, the 
present study examined whether the reduced number of newborn cells in the dentate 
gyrus of young adult rats treated with CORT could be restored to normal levels by 
Ginkgo co-treatment. 
At the molecular level, 21 days of repeated daily CORT injections (40 mg/kg, 
i.p.) cause suppression of hippocampal neurogenesis in rats (Wong & Herbert, 2004, 
2006) and at the behavioural level, a similar regimen of CORT injections produces 
emotional changes that correspond to symptoms of clinical depression but not anxiety 
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(Gregus, Wintink, Davis, & Kalynchuk, 2005). For example, chronic CORT treatment 
(40 mg/kg i.p. for 21 days) has been shown to increase depressive like behaviour 
measured by longer immobility time and shorter swimming time in the forced swim tests 
(Gregus et al., 2005; Johnson, Fournier, & Kalynchuk, 2006). However, a similar CORT 
regimen and also implantation of a 100 mg CORT pellet for one week have been found to 
be ineffective in altering anxiety measured by the open field, elevated plus maze, and 
social interaction tests (Fernandes, McKittrick, File, & McEwen, 1997; Gregus et al., 
2005). However, CORT has been shown to induce anxiety in the light/dark emergence 
test. Female mice treated chronically with CORT (13 mg/kg for 17 or 18 days) 
significantly decreased exploratory behaviours in the light compartment of the light/dark 
emergence apparatus (Ardayfio & Kim, 2006). Because different animal tests of anxiety 
are sensitive to different 'states of anxiety' (File, 1992), the present study compared the 
chronic effects of high dose CORT treatment in two different tests of anxiety: the 
light/dark emergence and the elevated plus maze. 
It has been shown that the nature of anxiety measured in the second trial of the 
elevated plus maze is distinct from that measured in the first trial (Fernandes & File, 
1996), thus rats were tested in each of the anxiety tests twice over two consecutive days. 
In the previous chapter the acute and chronic effects of Ginkgo on anxiety were examined 
using the elevated plus maze, light/dark emergence, and social interaction tests only once. 
While an acute high dose of Ginkgo treatment appeared to be anxiogenic in some 
measures of anxiety (only in the light/dark emergence test), the chronic treatment was 
neither anxiogenic nor anxiolytic. Animals had 21 days of drug exposure before the test 
day and were tested while drug-free. In the present study, rats were tested twice in the 
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light/dark emergence and the elevated plus maze and unlike the previous study rats were 
tested under the influence of the drug treatment on both days. 
The purpose of the present investigation was two-fold. First, it investigated 
whether CORT-induced suppression of cell survival can be attenuated by Ginkgo co-
treatment. Second, it investigated any possible interactions that may exist between 
Ginkgo and CORT in anxiety-like behaviour by utilizing two behavioural tests of anxiety 
namely, the elevated plus maze and the emergence test. 
Method 
Subjects. Thirty-two male Sprague-Dawley rats (Charles River, Canada), 
weighing between 230 and 250 g upon arrival to the colony were used. Rats were pair-
housed in standard plastic shoebox cages (45 x 25 x 20 cm) maintained at 21-22°C in a 
colony room on a 12 hour reversed light-dark cycle (lights off at 0700 h). Testing was 
conducted exclusively during the dark cycle. Experimental procedures followed Canadian 
Council on Animal Care guidelines, and were approved by the Wilfrid Laurier University 
Animal Care Committee. 
Drugs. Ginkgoselect {Ginkgo, Indena S.p.A., Milan, Italy), composed of EGb 761 
complexed with soy phospholipids at a ratio of 1:2 (w/w) to increase bioavailability, was 
dissolved in 10% w/v 2-hydroxypropyl-p-cyclodextrin (2-HpC; OnBio Inc.). The dose 
(25 mg/kg) is expressed to reflect the EGb 761 content of the phospholipid complex. 5-
bromo-2'-deoxyuridine (BrdU, Sigma-Aldrich), dissolved in 10% w/v 2-HPC in a 37 ° C 
water bath, was administered at a dose of 50 mg/kg. Both Ginkgo and BrdU were 
administered intraperitoneally (i.p.) in a volume of 2 ml/kg of body weight. 
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Corticosterone (Sigma-Aldrich), dissolved in 40% w/v 2-H0C, was administered 
subcutaneously (s.c.) at a dose of 35 mg/kg in a volume of 1 ml/kg body weight. 
Apparatus. 
LIGHT/DARK EMERGENCE 
The light/dark emergence apparatus was similar to the one described in the 
previous chapter. Briefly, it consisted of a white square open field (120 x 120), and a 
black wooden hide box (40 x 24 x 15 cm) placed inside the open field. The open field 
was illuminated with red light (5 lux at floor level). The activities of the rats were tracked 
and measured by the ANY-maze video tracking system (version 4.3; Stoelting Co.). On 
test days, rats were placed inside the hide box and their behaviours were recorded for 5 
min. The percentage of time spent in the hide box (time in the hide box -f total duration of 
the test x 100), exit latency, and distance traveled were measured. The apparatus was 
cleaned between test sessions with a detergent (Coverage 256, Steris Corp) diluted 
1:1000 in water, and then thoroughly dried. 
ELEVATED PLUS MAZE 
The elevated plus-maze apparatus was similar to the one used and described in the 
preceding chapter. Briefly, it consisted of two open arms (10 x 50 cm) and two opposite 
closed arms (10 x 50 cm) with walls 40 cm in height. A central square (10 x 10 cm) 
connected the four arms. The maze was 50 cm elevated from the floor. The testing room 
was illuminated with a red light (5 lux at the maze floor). The percentage of time spent in 
the enclosed arms (time in the enclosed arms -r total duration of the test x 100) as well as 
the number of entries into each arm and locomotor activity were determined using ANY-
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maze (version 4.3; Stoelting Co.). On test days, rats were placed in the centre part of the 
maze, facing one of the open arms and were tested for 5 min. The apparatus was cleaned 
between test sessions and thoroughly dried. 
Procedure. An overview of the design of the study is shown in Figure 14. After 
one week of habituation, rats were injected with 50 mg/kg BrdU twice daily at 1100 and 
1500 h for three consecutive days. The following day, chronic administration of Ginkgo 
and CORT began. Rats first received an i.p injection of either Ginkgo (25 mg/kg) or its 
vehicle and immediately afterwards received an s.c. injection of either CORT (35 mg/kg) 
or its vehicle. Thus, four groups of rats (n=8) were formed: vehicle-vehicle (Veh-Veh), 
vehicle-CORT (Veh-CORT), GMgo-vehicle (Ginkgo-Weh), and Ginkgo-CORT (Ginkgo-
CORT). Chronic CORT treatment is typically accompanied by weight loss (e.g., see 
Kalynchuk, Gregus, Boudreau, & Perrot-Sinal, 2004) and for ethical reasons, it was 
decided that rats whose individual body weights reached less than 80% of that of the 
control group (Veh-Veh) would be removed from the study. 
On both days 20 and 21, one hour after drug treatment, rats were subjected to the 
light/dark emergence test followed immediately by the elevated plus maze. On day 22, 
one hour after the last daily drug injections, rats were anaesthetized with an overdose of 
sodium pentobarbital. Once non-reflexive, rats were perfused transcardially with 150 ml 
0.1 M phosphate buffer saline (PBS, pH =7.2) followed by 150 ml 4% paraformaldehyde 
(Mallinckrodt Baker, Inc) in 0.1 M PBS (pH= 7.2). Just prior to the perfusion blood was 
collected directly from the right atrium in EDTA coated tubes, and kept on ice until 
centrifuged at 4000 rpm for 15 minutes at 4° C. Plasma was collected and stored at -20° 
C to be assayed for CORT content. Brains, thymus and adrenal glands were removed 
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Figure 14. Timeline of the Experiment in Chapter 4. 
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immediately after the perfusion and were kept in 4% paraformaldehyde solution in PBS. 
One day after the perfusion, any fat or extra tissue attached to the thymus and adrenal 
glands was removed and the wet weight was measured immediately. 
All the procedures for the perfusion, brain sectioning, immunohistochemistry and 
BrdU-labeled cell quantification were similar to those described in the previous chapter. 
Measuring plasma CORT level. CORT levels were determined using a 
commercially available enzyme-linked immunosorbent assay (ELISA) kit (Assaypro, St. 
Charles, MO), which employs a quantitative competitive sandwich enzyme immunoassay 
technique. Plasma samples were thawed and diluted with a buffer provided with the kit at 
1:50 for the samples from Veh-Veh and Ginkgo-Veh groups and at 1:500 for the samples 
collected from Veh-CORT and Ginkgo-COKT groups. All the samples were assayed in 
duplicate in one kit along with triplicate of CORT standards ranging from 0 to 100 ng/ml. 
The absorbance (optical density at a wavelength of 450 nm) was read using a microplate 
reader (MRX Microplate Absorbance Reader and Revelation™ application program, 
DYNEX Technologies, Inc.). The standard curve was plotted as optical density against 
log concentrations of CORT using Prism (GraphPad Software, version 5.0a). Plasma 
CORT concentrations of the samples were interpolated from the standard curve using a 
non-linear regression analysis perfumed in Prism and were corrected by the dilution 
factors. 
Data analysis. Body weights were analyzed using a three-way (Ginkgo x CORT x 
day) analysis of variance with repeated measures on 'day'. When a three-way interaction 
was found data were further analyzed by two-way (Ginkgo/Veh or CORT/Veh by day) 
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ANOVAs with repeated measures on 'day'. Significant day by CORT or day by Ginkgo 
interactions were further analyzed by comparing the groups at each level of day using 
independent sample t-tests. 
Plasma CORT level presented as ng/ml was analyzed by a two-way ANOVA 
{Ginkgo x CORT). Adrenal glands and thymus weights were expressed as mg per 100 g 
body weight on the last day of the study and were analyzed using two-way ANOVAs 
(Ginkgo x CORT). Significant interactions were followed by independent sample Mests 
to compare the groups at each level of Ginkgo or CORT. 
For the light dark emergence tests, the percentage of time spent in the hide box, 
exit latency, and distance traveled were analyzed using three-way ANOVAs (CORT x 
Ginkgo x trial) with repeated measures on 'trial'. For the elevated plus maze test, the 
percentage of time spent in the enclosed arms, number of entries to the open arms, and 
distance traveled were also analyzed by separate three-way ANOVAs (CORT x Ginkgo x 
trial) with repeated measures on 'trial'. 
The number of BrdU-labeled cells, dentate gyrus volume and BrdU-labeled cell 
density in the dorsal and ventral dentate gyrus were analyzed separately using two-way 
ANOVAs (CORT x Ginkgo). 
Results 
Body weights. One rat in the Ginkgo-CORT group was excluded from the study 
because its body weight reached less than 80% of that of the control group (Veh-Veh) 14 
days into the CORT treatments. A two-way ANOVA comparing body weights of the four 
groups of rats over the three BrdU treatment days before initiation of the CORT or 
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vehicle treatments found no significant difference across groups. All rats were similarly 
gaining weights over the three days as shown in Figure 15 (A). This was supported by a 
significant main effect of day, F(2, 56)=89.61, p<0.001. There was no significant group 
by day interaction. 
The three-way ANOVA comparing body weights over the 22 days of drug 
exposure revealed significant main effects of CORT, F(l,28)=9.16 p<0.05 and day, F(21, 
588)=538.04, p<0.001. The main effect of Ginkgo was not significant. All the rats gained 
weight over 22 days. However, the two CORT-treated groups (Veh-CORT and Ginkgo-
CORT) gained significantly less weight (Figure 15, A). The ANOVA also revealed 
significant interactions of day by CORT, F(21, 588)=25.12, /?<0.001, day by Ginkgo 
F(21, 588)=2.63, p<0.001, and day by CORT by Ginkgo (21, 588)=7.35, p<0.001. To 
better understand the nature of the significant interactions separate two-way ANOVAs (at 
CORT and at Ginkgo levels) with repeated measure on 'day' factor were performed. For 
the two groups treated with CORT (i.e., comparing the Veh-CORT and Ginkgo-CORT 
groups over 22 days), the two-way ANOVA revealed only a significant effect of day, 
F(21, 294)=140.97, p<0.001. For the two no-CORT groups (i.e., comparing Veh-Veh and 
Ginkgo-Veh groups over 22 days), the two way ANOVA showed a main effect of 
Ginkgo, F(l,14)=6.01 p<0.05, a significant effect of day, F(21, 294)=487.80,p<0.001 
and a significant interactions of day by Ginkgo, F(21, 294)=10.65, p<0.001. To further 
characterize the significant day by Ginkgo interaction, the body weights of the two 
groups of rats (Veh-Veh and Ginkgo-Veti) were compared at each level of day by 
independent sample Mests. The /-tests revealed that the significant group differences 
were evident at days 4,6, 7 and 10 until the last day. These results, as evident in Figure 
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Figure 15. (A) Mean (±SEM) body weight of four groups of rats over 22 days of drug 
treatments. *p<0.05, Veh-Veh significantly different from Veh-CORT, f p<0.05 Veh-Veh 
significantly different from Ginkgo-Yeh. (B) Mean (+SEM) plasma CORT concentration 
(ng/ml) of four groups of rats. *p<0.001, significantly different from Veh-CORT and 
Ginkgo-CORT. (C) Mean (+SEM) thymus weight (mg) per 100 g body weight, and (D) 
mean (+SEM) adrenal gland weight (mg) per 100 g body weight in four groups of rats. 
*p<0.05, significantly different from Veh-Veh. 
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15 (A), indicate that Ginkgo on its own (Ginkgo-Veh) suppressed body weight over the 
22 days of the study. 
For the two groups treated with Ginkgo (i.e., comparing Ginkgo-Weh and Ginkgo-
CORT), the two-way ANOVA showed only a main effect of day, F(21, 294)=152.90, 
p<0.001. for the two no-Ginkgo groups (i.e., comparing Veh-Veh and Veh-CORT), the 
two-way ANOVA revealed a main effect of CORT, F(l,14)=11.31 p<0.0l, a significant 
effect of day, F(21, 294)=677.84, /?<0.001 and a significant interaction of day by CORT, 
F(21, 294)=65.39, /><0.001. Consequently, the significant day by CORT interaction was 
followed by independent sample ?-tests to compare the body weight of the two groups of 
rats (Veh-Veh and Veh-CORT) at each level of day. The Mests revealed that the 
significant group differences began on day 6 and continued to the last day. These results, 
as evident in Figure 15 (A), indicate that CORT significantly decreased body weight in 
Veh-treated rats; however, a similar suppression was evident in Gm&gotreated rats 
regardless of CORT treatment. 
Plasma CORT concentrations. Plasma CORT levels were expressed as ng/ml and 
were analyzed by a two-way (Ginkgo by CORT) ANOVA, which only found a 
significant main effect of CORT, F (1, 27)=41.31, ^<0.001. As shown in Figure 15 (B), 
plasma CORT levels in both CORT-treated groups (Veh-CORT and Ginkgo-CORT) were 
significantly higher than the other two groups (Veh-Veh and Ginkgo-\eh). The non-
significant main effect of Ginkgo and the non-significant interaction indicated that 
Ginkgo either by itself or in combination with CORT injection had no effects on plasma 
CORT levels. 
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Thymus and adrenal gland weights. Figure 15 (C) shows the mean (+ SEM) 
thymus gland weights in four groups of rats. The thymus weight was calculated as mg per 
100 g body weight and was analyzed by a two-way (Ginkgo by CORT) ANOVA. The 
ANOVA revealed a significant effect of CORT, F(l, 27)=151.87, p<0.001, and a 
significant CORT by Ginkgo interaction, F(l, 27)=5.78, p<0.05. The main effect of 
Ginkgo was not significant. To characterize the significant interaction effect, two 
independent sample Mests were performed to compare thymus weights between the Veh-
Veh and Ginkgo-Weh groups and between the Veh-CORT and Ginkgo-CORT groups. 
Thymus weight was significantly reduced in the Ginkgo-Weh group relative to the Veh-
Veh group, t(14)=2.46,/?<0.05. 
The adrenal gland weights were also expressed as mg per 100 g body weight and 
were analyzed by a two-way (Ginkgo by CORT) ANOVA which revealed only a 
significant main effect of CORT, F (1, 27)=42.46, /?<0.001. This indicated adrenal 
atrophy in both CORT-treated groups (Veh-CORT and Ginkgo-CORT) as shown in 
Figure 15 (D). 
Light/dark emergence test. For the percentage of time spent in the hide box the 
three-way ANOVA found only a significant effect of trial, F(l, 27)=19.29, /?<0.001. 
Neither CORT nor Ginkgo nor their interaction were significant (Figure 16, A). The 
ANOVA for exit latency also revealed a significant effect of trial, F(l, 27)=10.50, /?<0.01 
(Figure 16, B). The effect of trial, F(l, 27)=16.02, p<0.001 was also found to be 
significant for the ANOVA comparing distance traveled across groups (Figure 16, C). 
These results indicate that regardless of the treatment, rats were more anxious in the 
second trial compared to the first one. All rats spent more time in the hide box, took 
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Figure 16. Mean (+SEM) percentage of time spent in the hide box in Trials 1 and 2 (A), 
mean (+SEM) exit latency in Trials 1 and 2 (B) and mean (+SEM) distance traveled in 
the Trial 1 and 2 (C) in the light/dark emergence test. Mean (+SEM) percentage of time 
spent in the enclosed arms in Trials 1 and 2 (D), mean (+SEM) number of open arms 
entries in Trials 1 and 2 (E) and mean (+SEM) distance traveled in Trials 1 and 2 (F) in 
the elevated plus maze. Rats received chronic injections of vehicle and vehicle (Veh-
Veh), 25 mg/kg Ginkgo and vehicle (Ginkgo-Veh), vehicle and 35 mg/kg corticosterone 
(Veh-CORT) or 25 mg/kg Ginkgo and 35 mg/kg corticosterone (Ginkgo-CORT) and 
were subjected to the anxiety tests on two days (Trial 1 and Trial 2). *p<0.05, Trial 1 
significantly different from Trial 2. f p<0.05, significantly different from Veh-Veh and 
Veh-CORT groups. 
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longer to exit the hide box and traveled a shorter distance in the second trial compared to 
the first trial. 
Elevated plus maze test. For the percentage of time spent in the enclosed arms, the 
three-way ANOVA found only a significant effect of trial, F(l, 27)=7.69, p<0.05. Neither 
CORT nor Ginkgo nor their interaction was significant (Figure 16, D). The ANOVA for 
the open arms entries also revealed a significant trial effect, F(l, 27)=33.99, /?<0.001 
(Figure 16, E). The ANOVA for distance traveled revealed a significant effect of trial, 
F(l, 27)=155.70, /?<0.001, and a significant trial by Ginkgo interaction F(l, 27)=6.69, 
p<0.05. Thus, each trial was analyzed separately by two-way ANOVAs, which for 
distance traveled found a significant effect of Ginkgo F(l, 27)=4.65, p<0.05 in the first 
trial only. These results also indicate that the rats were more anxious in the second trial 
compared to the first trial and that there was no group differences either in trial 1 or in 
trial 2. All four groups of rats traveled less distance in the second elevated plus maze trial 
compared to the first one; however, Ginkgo-tveated rats (Ginkgo-Veh and Ginkgo-CORT) 
traveled less distance compared to the other groups (Veh-Veh and Veh-CORT) only in 
the first trial (Figure 16, F). 
Hippocampal neurogenesis. Data from one rat in the Ginkgo-CORT group was 
lost due to technical difficulties during the perfusion and as mentioned previously another 
rat from the same group was excluded from the study due to weight loss (final n=6 for the 
Ginkgo-CORT group). Figure 17 shows, the number of BrdU-labeled cells, volume and 
BrdU-labeled cell density for both the dorsal and the ventral dentate gyrus in the four 
groups of rats. The number of BrdU-labeled cells, dentate gyrus volume and BrdU-
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Figure 17. Mean (+SEM) number of BrdU-labeled cells (A), mean (+SEM) volume of 
dentate gyrus (B) and mean (+SEM) BrdU-labeled cell density (C) in the dorsal region 
used for quantifying BrdU-labeled cells. Mean (+SEM) number of BrdU-labeled cells 
(D), mean (+SEM) volume of the dentate gyrus (E) and mean (+SEM) BrdU-labeled cell 
density (F) in the ventral region. Rats received 50 mg/kg BrdU injections twice daily for 
3 days followed by 22 days of vehicle and vehicle (Veh-Veh), 25 mg/kg Ginkgo and 
vehicle (Ginkgo-Yeti), vehicle and 35 mg/kg corticosterone (Veh-CORT) or 25 mg/kg 
Ginkgo and 35 mg/kg corticosterone (Ginkgo-CORT) injections. Rats were perfused one 
hour after the last drug injection. 
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labeled cell density were analyzed separately for the dorsal and ventral hippocampus 
using two-way ANOVAs. There was only a significant CORT effect, F (1, 26)=4.72, 
p<0.05, for cell density in the dorsal dentate gyrus, indicating that both CORT-treated 
groups had significantly less BrdU-labeled cell density compared to the Veh-Veh and 
Ginkgo-Veh groups. These results show that Ginkgo did not reverse the suppression of 
hippocampal neurogenesis induced by CORT treatment. See Figure 18 for representative 
photomicrographs showing BrdU-labeled cells in the dentate gyrus of the four groups of 
rats. 
Discussion 
The aim of the present study was to determine whether CORT-induced 
suppression of adult hippocampal neurogenesis could be restored by Ginkgo co-
treatment. Results showed that survival of newborn cells was inhibited in the dorsal 
dentate gyrus of rats chronically treated with CORT; however, Ginkgo co-treatment 
failed to attenuate this effect. The ability of chronic CORT administration to induce 
anxiety and whether Ginkgo co-treatment could influence any observed anxiogenic 
properties of repeated CORT injection were also examined. Measures of anxiety were not 
significantly affected by repeated daily CORT treatment; however, regardless of the 
treatments, all rats appeared to be more anxious in the second trial of testing compared to 
the first trial. 
Chronic CORT treatment clearly increased plasma CORT concentrations and 
induced adverse physiological effects. The baseline level of CORT in young 
Sprague_Dawley rats is approximately 50 ng/ml (Rai et al., 2003). The mean (± SEM) 
concentration of CORT was 90.03 (±15.39) ng/ml and 221.64 (±92.13) ng/ml for the 
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Figure 18. Photomicrographs (at approximately 400x magnification) of BrdU-labeled 
cells in the dentate gyrus of rats treated with Veh-Veh (A), Ginkgo-Veh (B), Veh-CORT 
(C) and Ginkgo-CORT (D). 
Figure 18 
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Veh-Veh and Ginkgo-Veh groups, respectively. Stress induced by two daily injections in the 
Veh-Veh group may explain the increased level of circulating CORT in these animals. Repeated 
treatment with Ginkgo (50 and 100 mg/kg for 8 administered orally) has been reported to 
decrease circulating levels of CORT (Amri et al., 1996), however the dose of Ginkgo used in the 
present study administered i.p. failed to reduce circulating CORT levels in the Ginkgo-Ysh group. 
With chronic CORT treatment the plasma CORT levels reached 7468.11 (±1227.53) ng/ml in the 
Veh-CORT group, and Ginkgo co-administration failed to significantly reduce plasma CORT 
levels and was found to be 6320.75 (±1854.20) ng/ml in the Ginkgo-CORT group. Plasma CORT 
levels have been shown to increase dramatically to 450 ng/ml after a single exposure to restraint 
stress (150 min) and to approximately 300 ng/ml after chronic (150 min a day for 7 consecutive 
days) exposure to restraint stress (Rai et al., 2003). The plasma CORT concentration in the 
present study was much higher than the level of CORT reported in stressed animals and may 
explain the discrepant results. 
Consistent with previous studies (e.g., see Fernandes et al., 1997; Gregus et al., 
2005), rats chronically treated with CORT exhibited significant reductions in thymus, 
adrenal and body weights (Figure 15). Ginkgo co-treatment did not restore the effects of 
CORT on body weights or thymus and adrenal gland atrophy. In fact, the body weights of 
animals treated with Ginkgo (Ginkgo-Yeh) fell significantly lower than those of the 
control rats (Veh-Veh) on days 4, 6, 7 and 10 to the end of treatment. Surprisingly, the 
thymus weight of Ginkgo-treated rats (Ginkgo -Veh) was also found to be significantly 
lower than that of the control (Veh-Veh) group (Figure 15, B). This is in contrast with a 
report showing rejuvenating effects of Ginkgo on degenerated thymus glands in aged 
female mice (Tian, Tian, Zhang, & Dai, 2003). The reason for this discrepancy is not 
clear; however in this study, aged female mice (22-months-old) were fed a relatively low 
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dose (1.5 mg) of Ginkgo extract for 60 days. It is therefore possible that gender 
differences, age at exposure, length of treatment, route of administration, drastic 
differences in dose, or some combination of these factors, may have accounted for the 
discrepant results. Although adrenal weight was not affected by chronic Ginkgo 
administration in the present study, the fact that there was weight loss as well as thymus 
atrophy suggests that i.p. administration of this dose of the extract may have induced 
some kind of malaise. Note that this dose of Ginkgo also failed to influence baseline 
plasma CORT level in the control rats (Veh-Veh), although repeated treatment with 
Ginkgo (50 and 100 mg/kg for 8) has been reported to decrease circulating levels of 
CORT (Amri et al., 1996) and to normalize elevated levels of circulating CORT induced 
by restraint stress (Rai et al., 2003; Shah et al., 2003). 
The present study evaluated the anxiogenic effects of chronic CORT 
administration using a battery of anxiety tests, including light/dark emergence and the 
elevated plus maze. The relationship between CORT and Ginkgo co-treatment in 
measures of anxiety was also evaluated. Despite the significant elevation of plasma 
CORT levels in the CORT-treated rats, there were no significant effects on measures of 
anxiety. In the light/dark emergence test the four groups of rats spent similar amounts of 
time in the hide box (Figure 16, A), took similar amounts of time to exit the hide box 
(Figure 16, B) and traveled similar distances in the open field of the light/dark emergence 
apparatus (Figure 16, C). In the elevated plus maze test, regardless of the treatment, rats 
spent similar amounts of time in the enclosed arms (Figure 16, D) and entered into the 
open arms of the elevated plus maze similar number of times (Figure 16, E). However, 
the two groups of rats treated with Ginkgo (Ginkgo-Veh and Ginkgo-CORT) traveled less 
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distance compared to the other two groups that did not receive Ginkgo. This effect was 
only evident in the first trial (Figure 16, F). 
Previous studies have shown that elevated CORT levels due to chronic CORT 
injection (Gregus et al., 2005; Kalynchuk et al., 2004) or CORT pellet implantation 
(Fernandes et al., 1997) do not change measures of anxiety in the elevated plus maze, 
social interaction, open field and resistance-to-capture tests. In fact, it has been suggested 
that chronic CORT administration produces a double-dissociation between elevated 
corticosteroid concentration and anxiety (Fernandes et al., 1997). It seems that emotional 
changes brought about by chronic daily CORT treatment, both in male and in female rats, 
correspond to symptoms of clinical depression rather than anxiety (Gregus et al., 2005; 
Kalynchuk et al., 2004). For example, chronic CORT injection (40 mg/kg for 21 days) 
has been shown to increase depression-like behaviours in the forced swim test 
(Kalynchuk et al., 2004). The present study did not evaluate the chronic effects of CORT 
and Ginkgo co-treatment on animal models of depression, but the lack of significant 
effects in the two animal tests of anxiety employed agrees with the aforementioned 
studies. Nonetheless, one study has reported that measures of anxiety in the light/dark 
emergence test were influenced by chronic CORT treatment (13 mg/kg for 17 or 18 
days). Exit latency significantly increased in mice chronically treated with CORT 
(Ardayfio & Kim, 2006). This is in contrast with the light/dark emergence data obtained 
in the present study and may be due to the lower dose of CORT employed. 
Consistent with the results presented in the previous chapter, chronic Ginkgo 
treatment on its own was not found to influence anxiety. In our previous study, rats 
received their last daily injection of Ginkgo 1 day before behavioural tests. In the present 
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study, rats were under the influence of Ginkgo treatment during both tests and both trials 
and yet no effect was evident in the anxiety measures. Our results showing that chronic 
Ginkgo treatment had no anxiolytic effects contrast with another study which reported 
anxiolytic-like effects of Ginkgo (125 mg/kg) in the elevated plus maze after one week of 
oral administration in mice (Kuribara et al., 2003). 
The anxiety data also revealed that regardless of treatment, rats were more 
anxious in the second trial compared to the first trial (Figure 16). All rats spent more time 
in the hide box, had longer exit latencies, and traveled shorter distances in the second 
light/dark emergence trial compared to the first. Similarly, all rats spent more time in the 
enclosed arms, entered less into the open arms, and traveled shorter distances in the 
second elevated plus maze trial compared to the first. These results are consistent with 
other studies that have shown repeated exposure to the elevated plus maze reduces open 
arm exploration in the following trials even when rats are treated with diazepam (e.g., see 
Treit, Menard, & Royan, 1993). 
Finally, the present study investigated whether Ginkgo could attenuate CORT-
induced suppression of adult hippocampal neurogenesis. Survival of newborn cells was 
inhibited in the dorsal dentate gyrus of rats chronically treated with CORT (35 mg/kg for 
21 days). This was evident by the decreased density of newborn cells in the dorsal dentate 
gyrus. This finding is consistent with previous reports that suggest the rate of 
neurogenesis is regulated by levels of circulating CORT (Cameron & Gould, 1994). 
Previous studies have shown that CORT treatment suppresses proliferation (Cameron & 
Gould, 1994; Gould et al, 1992) as well as survival (Wong & Herbert, 2004) of newborn 
cells in the dentate gyrus of the hippocampus. Differentiation of newborn cells into 
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mature neurons has also been shown to be inhibited by repeated CORT treatment (Wong 
& Herbert, 2006). However, previous studies did not differentiate between the influence 
of CORT on neurogenesis in the dorsal and ventral regions of the dentate gyrus. A novel 
aspect of the present study was that chronic CORT treatment suppressed survival of 
newborn cells exclusively in the dorsal, but not ventral dentate gyrus (Figure 17). In the 
preceding chapter the influence of fluoxetine on hippocampal cell survival were also 
included as a positive control to verify the immunohistochemical and cell quantification 
methods employed. However, fluoxetine in our study failed to increase survival of 
newborn cells in the dentate gyrus. In the present study, the fact that CORT treatment 
was found to reduce cell survival confirmed the immunohistochemical methods used in 
both studies. 
Consistent with the results presented in the previous chapter, chronic Ginkgo 
treatment on its own had no effect on the survival of newborn cells in the dentate gyrus, 
confirming that the beneficial effects of Ginkgo on cognitive processing do not appear to 
be mediated by the enhancement of hippocampal neurogenesis. However, in contrast to 
the expected results, Ginkgo co-treatment did not attenuate CORT-induced suppression 
of newborn cell survival (Figure 17). Since repeated treatment with Ginkgo has been 
found to decrease circulating levels of CORT (Amri et al., 1996) and to normalize the 
elevated levels of circulating CORT induced by restraint stress (Rai et al., 2003; Shah et 
al., 2003), it was hypothesized that the reduced number of newborn cells in the dentate 
gyrus of young adult rats treated with CORT could be restored to normal levels by 
Ginkgo co-treatment. Unexpected findings may, in part, be related to the timing of the 
injections. That is, rats were treated with both Ginkgo and CORT at about the same time, 
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but it is possible that the two drugs had different bioavailability. Pharmacokinetic 
information on the dose of Ginkgo (25 mg/kg administered i.p.) and CORT (35 mg/kg 
administered s.c.) used in the present study is not available. However, the half-lives of 
ginkgolide A, B, and bilobalide (active constituents of Ginkgo), after 100 mg/kg oral 
administration have been shown to be 1.8, 2.0 and 3.0 h, respectively (Biber & Koch, 
1999). It is also possible that the dose of Ginkgo used in the present study was not high 
enough to counteract the effects of such a high dose of CORT. The present study only 
investigated the influence of chronic CORT and Ginkgo treatment on cell survival. Future 
studies might aim to examine whether chronic Ginkgo pre-treatment can protect CORT-
induced suppression of cell proliferation and survival. 
To summarize, results of the present study showed that chronic CORT treatment 
had no significant effect on measures of anxiety in adult male rats. It significantly 
reduced body weight and induced thymus and adrenal gland atrophy. Moreover, it 
suppressed survival of newborn cells in the dorsal dentate gyrus. None of these adverse 
effects were restored by Ginkgo co-treatment. 
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Foreword to Chapter 5 
The following chapter is based on a manuscript submitted to the journal 
Psychopharmacology in April 2008. The manuscript was accepted for publication in July 
2008 and is now published (Jan 2009, vol 202, pg 173-185). Dr. Paul E. Mallet is a co-
author. The author of the present dissertation collected and analyzed all data, and wrote 
the first manuscript draft. 
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Chapter 5: Chronic administration of a Ginkgo biloba leaf extract facilitates acquisition 
but not performance of a working memory task 
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Abstract 
Ginkgo biloba leaf extracts have been shown to improve learning and memory when 
administered chronically prior to the learning phase. However, the influence of Ginkgo 
on learning without prior chronic treatment and on memory per se (i.e., post-training 
administration) is less clear. Thus, Experiment 1 investigated the influence of Ginkgo on 
acquisition, and Experiment 2 examined the acute and chronic effects of Ginkgo on 
memory in young adult rats using a food-reinforced two-component double Y-maze task. 
In Experiment 1, seventeen rats were treated daily with a standardized Ginkgo biloba 
extract (13.75 mg/kg, i.p.) or vehicle 30 min prior to daily maze training for 14 days. 
Gm/fcgo-treated rats reached the training criteria slightly faster, and made fewer errors. In 
Experiment 2, twelve rats received 24 training trials daily, then received Ginkgo (0, 0.25, 
2.5, 13.75, or 25 mg/kg, i.p.) 30 min prior to each test session. Post-training Ginkgo 
administration did not enhance memory. Subsequently, the same rats received daily 
injections of either Ginkgo (13.75 mg/kg, i.p.) or its vehicle. Memory was tested after 10 
and 20 days of drug treatment, once under the influence of the drug, and once in a drug-
free state. In all cases Ginkgo produced no significant effects. Taken together, results 
demonstrate that repeated daily pre-session Ginkgo injection subtly facilitates acquisition 
of a spatial working memory task, but neither acute nor chronic post-training exposure 
enhances spatial working memory. We conclude that ongoing Ginkgo administration 
does not offer any continued beneficial effects in an already-learned working memory 
task. 
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Ginkgo biloba is an evolutionarily ancient tree native to China (Major, 1967). Its 
fruits and seeds have been used in traditional Chinese medicine to treat a wide variety of 
health disorders for thousands of years (Maclennan et al., 2002); however, the 
standardized Ginkgo biloba leaf extract EGb 761 was developed for pharmaceutical use 
only recently (Maclennan et al., 2002). Today, EGb 761, marketed under multiple trade 
names including Rokan, Tanakan, Tebonin and Ginkgold, is one of the best-selling herbal 
medicines in Europe and the United States (Chan et al., 2007). In fact, retail sales of 
Ginkgo biloba products in the United States reached $150 million in 1998, making it the 
most commonly purchased herbal supplement in the mainstream market (Blumenthal, 
1999). Ginkgo biloba extracts are commonly prescribed for the treatment of intermittent 
claudication, "cerebral insufficiency", vertigo, and tinnitus of vascular origin. However, 
it is also purchased as an over-the-counter supplement for use by healthy individuals as a 
nootropic, or cognitive enhancer (Darlington et al., 2000; Gold et al., 2002; Yoshikawa et 
al., 1999). 
EGb 761 is a water-acetone extract of dried green leaves of Ginkgo biloba, 
standardized to contain 24% flavonoid glycosides (including quercetin, kaempferol, 
isorhamnetin), 6% terpenoids (containing 3.1 % ginkgolides A, B, C, and J and 2.9% 
bilobalide), and less than 9% proanthocyanidins and organic acids (DeFeudis & Drieu, 
2000; Maclennan et al., 2002). The beneficial effects of EGb 761 are believed to be the 
result of agonistic, antagonistic and synergistic effects of its active ingredients (DeFeudis 
& Drieu, 2000). The pharmacological actions of each active constituent have been 
extensively studied. For example, flavonoid and proanthocyanidins components 
contribute to its antioxidant and free radical scavenging effects (DeFeudis & Drieu, 
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2000). Ginkgolide components are known to antagonize effects of platelet activating 
factor, to improve cerebral metabolism, and to protect neural tissues against hypoxic 
damage (Braquet & Hosford, 1991). Additionally, EGb 761 protects cellular membrane 
fluidity (Stoll et al., 1996), reverses neurotransmitter receptor density loss induced by 
aging (Taylor, 1986), and decreases circulating corticosteroid levels by reducing levels of 
messenger RNA protein and drug binding of adrenocortical mitochondrial peripheral-
type benzodiazepine receptors (Amri et al., 1996). These beneficial properties of the 
extract may underlie its apparent therapeutic effects on a wide range of disorders 
(DeFeudis & Drieu, 2000). 
Nonetheless, there are conflicting results in clinical studies regarding the putative 
beneficial effects of Ginkgo biloba extracts on cognitive function. For example, while Le 
Bars et al. (1997) reported that EGb 761 improved cognitive decline associated with 
Alzheimer's disease or multi-infarct dementia, van Dongen et al. (2000) found 
contradictory results. Mix and Crews (2000;, 2002) reported that EGb 761 enhanced 
certain aspects of cognitive performance of healthy older adults, but Solomon et al. 
(2002) found the Ginkgo biloba extract Ginkoba to be ineffective in improving cognitive 
functioning in a similar population. In young healthy individuals administration of the 
Ginkgo biloba leaf extract (GK 501) improves attention (Kennedy et al., 2000), while 
chronic administration of EGb 761 facilitates speed of processing and working memory 
(Stough et al., 2001). However, in a meta-analysis of 15 randomized clinical trials, Canter 
and Ernst (2007) reported no favourable effects of Ginkgo biloba extracts on any aspect 
of cognitive performance of young healthy adults after both acute and chronic 
administration. 
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While the clinical data are somewhat inconclusive, a few well-designed animal 
studies support the notion that Ginkgo biloba extracts enhance cognitive functioning in 
both young and old animals (Stackman et al., 2003; Stoll et al., 1996; Y. Wang et al., 
2006; E. Winter, 1991; J. C. Winter, 1998; Wirth et al., 2000). In one study, acquisition 
and retention of a learned response was enhanced in young healthy mice treated for 4 or 8 
weeks with 100 mg/kg Ginkgo prior to learning a 2-lever response sequence for food (E. 
Winter, 1991). In another study, aged mice (22 to 24 months old) treated with Ginkgo 
daily for 3 weeks prior to learning a passive avoidance task showed significant 
" improvements in short-term but not long-term memory measured by avoidance latency 
60 s and 24 h after shock, respectively. No improvement was evident in young (3 months 
old) and middle-aged (12 months old) groups (Stoll et al., 1996), perhaps due to a ceiling 
effect in the younger mice. Chronic daily pre-session treatment of Ginkgo has been 
shown to facilitate learning an eight-arm radial maze in young rats and a delayed non-
matching to position task in aged rats. Interestingly, the life span of the Gmfcgo-treated 
rats was significantly increased (J. C. Winter, 1998). 
Spatial memory deficits have been also shown to be prevented by chronic Ginkgo 
treatment in both aged rats (Y. Wang et al., 2006) and in a transgenic mouse model of 
Alzheimer's disease (Stackman et al., 2003), effects that were attributed to enhancement 
of hippocampal long-term potentiation by Ginkgo (Y. Wang et al., 2006). However, one 
study reported no effect of chronic treatment (28 and 70 days) on either acquisition or 
retention of memory in a water maze task in aged mice (Ward et al., 2002). In this latter 
experiment, there was a significant difference in baseline anxiety levels measured using 
an elevated plus maze prior to water maze training. In a subsequent experiment, to reduce 
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pre-existing differences in anxiety level, a matched-pair design was applied and the 
results indicated that Ginkgo significantly reduced stress induced by cold water exposure. 
The authors suggested that Ginkgo may act as an anti-stress buffer rather than a cognitive 
' enhancer (Ward et al., 2002). Indeed, it has been demonstrated, for example, that stress-
induced learning deficits in a discrimination task (Rapin et al., 1994) and stress-induced 
memory deficits in a passive avoidance task (Walesiuk et al., 2005) can be diminished by 
repeated pre-treatment of Ginkgo. 
Most studies that have investigated the effects of Ginkgo on cognitive functioning 
have utilized the Morris water maze, or tasks that involve inhibitory avoidance learning 
or appetitive operant conditioning. Because it is difficult to determine the relative 
contribution of non-mnemonic processes in these tasks, the present study employed a 
double Y-maze task comprising separate spatial discrimination and delayed alternation 
components. The task is unique in that it includes control procedures that guard against 
misinterpretation of possible non-mnemonic effects such as altered motor function, 
motivation, or sensory-perceptual abilities (Mallet & Beninger, 1993; Mason, Mallet, 
Jhamandas, Boegman, & Beninger, 1999; Smith, Beninger, Mallet, Jhamandas, & 
Boegman, 1994). The delayed alternation task, but not the spatial discrimination task, 
requires the use of working memory. A selective impairment in the delayed alternation 
task can therefore be confidently attributed to a deficit of working memory. 
In previous studies, Ginkgo biloba extract treatment typically began weeks or 
months prior to the first training session. Thus, it is not clear whether Ginkgo is effective 
in improving acquisition and memory of a task without prior chronic treatment. 
Accordingly, the first experiment in the present study was undertaken to elucidate the 
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effects of Ginkgo on training and memory of a double Y-maze task without prior Ginkgo 
treatment. Furthermore, the possible acute effects of Ginkgo on memory have rarely been 
investigated. In fact, only a single study has reported the facilitative effects of acute 
injection of Ginkgo (60 and 120 mg/kg, i.p.) on an olfactory short-term recognition test in 
both young and aged rats (Wirth et al., 2000). More studies are clearly needed to clarify 
the acute effects of Ginkgo on memory. Therefore, the second experiment explored the 
acute post-training effects of Ginkgo on memory of a learned double Y-maze task; that is, 
by administrating the extract after completion of training. After the acute test, rats were 
injected daily with either Ginkgo or vehicle and the chronic post-treatment effects on 
spatial working memory in a learned double Y-maze task were examined. 
Experiment 1: Effects of Ginkgo on maze task acquisition 
Method 
Subject. Eighteen male Sprague-Dawley rats (Charles River, Canada), weighing 
between 300 and 340 g at the start of the experiment were used. Rats were pair-housed in 
standard plastic shoebox cages (45 x 25 x 20 cm) maintained at 21-22°C in a colony 
room on a 12 hour reversed light-dark cycle (lights off at 0700 h): Testing was conducted 
exclusively during the dark cycle. Experimental procedures followed Canadian Council 
on Animal Care guidelines, and were approved by the Wilfrid Laurier University Animal 
Care Committee. 
Rats were acclimatized to the colony and handling procedures, then were given 3 
g of Kellogg's Froot Loops breakfast cereal in the home cage once daily for 2 days. 
Beginning the following day, food access was limited to 2 h per day. The quantity of food 
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was adjusted to maintain body weights at 90% of individual baseline free-feeding 
weights, adjusted for growth. Rats were fed in individual cages after maze training or 
testing, then were placed back into their home cages for the remainder of the day. Water 
was freely available in the home and feeding cages. 
Drug. Ginkgoselect (Indena S.p.A., Milan, Italy) was dissolved in 10% w/v 2-
hydroxypropyl-P-cyclodextrin (2-HpC; OnBio Inc., Richmond Hill, Ontario, Canada). 
Ginkgoselect is composed of EGb 761 complexed with soy phospholipids at a ratio of 1:2 
(w/w) to increase bioavailability. Ginkgoselect and vehicle control injections (10% w/v 
HPC) were injected intraperitoneally (i.p.) in a volume of 2 ml/kg. The i.p. route of 
administration was used to reduce stress associated with more traditional gavage 
procedures, and to better control doses and time course compared to more traditional 
drinking water exposure procedures. Doses are expressed to reflect the EGb 761 content 
of the phospholipid complex. 
Apparatus. The double Y-maze (see Figure 19) was similar to that used 
previously (Mallet & Beninger, 1993; O'Shea & Mallet, 2005; Smith et al., 1994), but 
with minor modifications. The walls of the maze were constructed of melamine, and the 
floor was made of black ABS plastic sheeting. The walls of the first 'Y' were white, 
while those of the second 'Y' were dark purple. Passageways measured 16.5 cm wide and 
25 cm high. There were four arms, each 35 cm long, that extended at 120° angles from a 
45-cm long central stem. Removable guillotine doors were used to control access to 
certain parts of the maze. Opaque food cups (2 cm high, 7 cm diameter) were placed at 
the ends of the arms and in the central stem. Small pieces of Froot Loops cereal 
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Figure 19. Schematic representation of a top view of the double Y-maze. Dashed lines 
represent the locations of removable guillotine doors that restricted access to different 
parts of the maze. Food cups were located in start boxes (Si and S2), the centre box (C), 
and goal boxes (Gi and G2). Arrows show possible correct paths. In the spatial 
discrimination, rats were placed quasi-randomly into either start box S| or S2. Proceeding 
to box C was correct, while entering the other start box constituted an incorrect choice. In 
the delayed alternation, the correct response was to alternate between Gi and G2 on 
successive trials. 
Figure 19 
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(approximately one-sixth of a full piece) were placed in the food cups and were used to 
reward correct responses. To mask possible food odor cues, cereal dust was scattered 
throughout the maze. The entire maze was placed on a 76-cm high table in a testing room 
illuminated with moderate white lighting (360 lux at the maze floor). Constant visual 
cues such as posters, light fixtures, and the researcher were visible from within the maze. 
Between individual tests, the walls and floor of the maze were cleaned with a detergent 
(Coverage 256, Steris Corp, Mentor, OH, USA) diluted 1:1000 in water, and then 
thoroughly dried. 
Procedure. An overview of the timeline of the phases of Experiment 1 is shown 
in Figure 20 (Top). 
HABITUATION 
Two days after initiation of food restriction, rats were habituated to the maze over 
four consecutive days. Daily i.p. injections of either 10% w/v 2-HpC (vehicle) or 13.75 
mg/kg Ginkgo began on the first day of habituation. Each day, rats received 15 min of 
free access to all maze areas 30 min after drug injection, and were permitted to collect 
cereal pieces from all food cups. Beginning on the second day of habituation, rats were 
gradually introduced to the movement of the guillotine doors. One rat from the Ginkgo 
group still displayed overt signs of fear (defecating, urinating and freezing or jumping out 
of the maze) on the last day of habituation and was therefore excluded from the study. 
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Figure 20. Timeline of the various phases of Experiment 1 (top) and Experiment 2 
(bottom) in chapter 5. 
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TRAINING 
Following habituation, rats were given one 24-trial training session per day, 30 
min after injection of either vehicle or Ginkgo. Half the rats in each group were randomly 
chosen to be initially trained in the first' Y' (i.e., the spatial discrimination task), while 
the other half were initially trained in the second ' Y' (i.e., the delayed alternation task). 
Training in each task continued until animals reached an acquisition criterion of at least 
21 out of 24 trials correct on 2 consecutive days. 
Spatial discrimination training involved placing a rat into one of the randomly 
chosen start boxes (SI or S2, see Figure 19), with the guillotine door lowered. The 
guillotine door at the distal end of box ' C was also lowered to prevent entry into the 
second 'Y' maze. A small piece of cereal reward was placed in the food cup located in 
' C . The start box guillotine door was raised and the rat was allowed to find the reward in 
box ' C \ If the animal first entered the other start box, the guillotine door was lowered 
behind it, an error was scored and the animal was immediately placed back into the start 
box to start the next trial. Entering ' C without first entering the other start box was 
scored as a correct choice. Once the rat was in ' C the guillotine door behind it was 
lowered, and the animal was permitted to consume the food. The animal was then 
immediately placed into a randomly chosen start box to begin the next trial. 
For delayed alternation training, each trial began by placing an animal in ' C (see 
Figure 19) with the guillotine doors lowered in front of and behind the animal. Box ' C 
therefore served as a start box. The task was to choose alternate arms on consecutive 
trials. That is, if the reward was placed in Gl on the first trial, it was placed in G2 on the 
second, and so on. On the first trial of each session, the initial goal box (Gl or G2) was 
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chosen randomly and was baited with a piece of cereal. On this first un-scored trial only, 
a guillotine door blocked the incorrect goal box such that an error was not possible. On 
subsequent trials, the start box door was raised and the rat was permitted to collect food 
by choosing the alternate arm on each trial. After a correct choice, the guillotine door was 
lowered behind the rat. After consuming its reward, the rat was removed immediately 
from the goal box and was placed back into ' C to begin the next trial. Incorrect choices 
were not reinforced, and the guillotine door was lowered to prevent further choices. The 
animal was immediately placed back into ' C box to start the next trial. 
Once rats had reached the acquisition criterion in the first task, training in the 
second task was undertaken. When the rats reached the training criteria for both 
individual tasks, they were tested on the whole maze task. That is, each trial consisted of 
a spatial discrimination, followed by a delayed alternation. The initial start box was 
chosen randomly on each trial, with the proviso that an equal number of each start box 
was chosen in each session, and the same box was not used consecutively more than three 
times. Each rat was placed into one of the randomly chosen start boxes. At this stage, the 
distal door of the ' C box was closed. If the rat entered the other start box, a door was 
placed behind it, and a spatial discrimination task error was noted. The rat was placed 
back into the start box to initiate the trial again. When the rat entered the correct ' C box, 
a door was placed behind it to prevent the animal's retreat back in to the first Y. After 
consuming the reward in box ' C \ the distal door of box ' C was opened and the rat was 
presented with the alternation task. The rat had to choose alternate arms on successive 
trials. Rats were tested on the full maze task for 14 days. 
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DELAY TESTING 
Delay testing was identical to full maze testing, except that the working memory 
load needed to solve the delayed alternation task was increased by the addition of inter-
trial delays. Delays were imposed by retaining the rat in the start box for 0,15, or 60 s 
before opening the door at the start of each trial. The order of delays was quasi-random, 
with an equal number of each delay (i.e., eight) used within each session. Approximately 
5 s was required between trials to remove the rat from the goal box, place it back in the 
start box, bait the appropriate food cups, and lower the guillotine doors. Thus, the inter-
trial delays should be understood as 0,15, or 60 s plus the few seconds required to 
prepare the maze for the next trial. Rats were habituated to the delay intervals for one day 
before being tested for two consecutive days. Rats were injected with vehicle or Ginkgo, 
30 min prior to testing. 
DRUG-FREE RE-TEST 
To determine whether Ginkgo had any lasting residual effects, injections were 
discontinued after the last delay test, and 8 days later rats were tested in the maze without 
any treatments or delays for 3 consecutive days. 
Data analysis. The number of trials required to reach the training criterion and the 
total number of errors committed during the individual task training phases were 
analyzed separately using two-way (group x task) ANOVAs with repeated measures on 
the 'task' factor. 
For the whole-maze (no delay) test phase, the number of correct choices was 
converted to percentage correct scores for both the spatial discrimination and delayed 
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alternation tasks for each of the 14 test sessions. Two-way ANOVAs (group x day) with 
repeated measures on the 'day' factor were performed separately for the spatial 
discrimination and delayed alternation tasks. Significant day main effects were further 
analyzed using Bonferroni-corrected pairwise comparisons to compare the first day with 
the remaining 13 days. Planned comparisons using independent sample Mests were also 
used to compare groups at each day. 
Raw scores for the number of correct responses in the two delay tests were 
converted to percentage correct responses. For each test, the spatial discrimination and 
delayed alternation tasks were analyzed separately using two-way ANOVAs (group x 
delay) with repeated measures on the 'delay' factor. Significant interactions were 
followed by tests of the simple main effects to compare groups at each level of delay. In 
addition, the mean time (s) required to complete both delay tests was compared across 
groups using independent sample Mests. 
Raw scores for the number of correct choices in drug-free retention tests were also 
converted to percentage correct choices. The correct choices for the spatial discrimination 
and delayed alternation components were analyzed separately using two-way (group x 
day) ANOVAs with repeated measures on the 'day' factor. Independent sample Mests 
were used to compare the total number of errors made by the two groups over the three 
retention tests. 
Whenever the sphericity assumption was violated, determined by a significant 
Mauchly' s test, the Huynh-Feldt epsilon correction was applied. In all cases the corrected 
F-tests agreed with the uncorrected tests; therefore for ease of interpretation of the results 
only non-adjusted degrees of freedom are reported. For the independent sample Mests, 
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Levene's test of homogeneity of variance was considered. When the homogeneity of 
variance assumption was violated, adjusted t statistics were used. 
Results 
Training in individual tasks. Regardless of treatment, animals required fewer 
trials to acquire the spatial discrimination task relative to the delayed alternation task (see 
Figure 21, A), shown by a significant main effect of task, F(l,15)=26.33,/?<0.001. 
Furthermore, Ginkgo-treated animals required fewer trials to reach the combined 
acquisition criteria, shown by a significant main effect of group, F(l,15)=5.45, p<0.05. 
The group by task interaction was not significant. 
Regardless of treatment, animals also committed significantly more errors in the 
delayed alternation relative to the spatial discrimination, as shown by a significant main 
effect of task, F(l,15)=26.02, p<0.001. However, Ginkgo had no significant effect on the 
total number of errors committed during training (see Figure 21, B), as shown by a non-
significant main effect of group, and a non-significant group by task interaction. 
Whole maze testing. Performance of the spatial discrimination task during the 14 
days of whole-maze testing was highly accurate, but was similar across groups (see 
Figure 22, A). A two-way ANOVA revealed no significant main effects of group or day, 
or group by day interaction. 
Baseline response accuracy in the delayed alternation task began lower (see 
Figure 22, B), then improved steadily across days in both groups; however, Ginkgo-
treated animals attained a high level of accuracy considerably earlier than the vehicle-
treated animals. Two-way ANOVA revealed significant main effects of group, 
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Figure 21. Mean (+SEM) number of trials required to reach the training criteria (A) and 
mean (+SEM) number of errors committed (B) in the spatial discrimination (SD) and 
delayed alternation (DA) tasks in Experiment 1. Rats were injected with a standardized 
Ginkgo biloba extract (13.75 mg/kg, i.p.) or vehicle 30 min prior to all training sessions. 
*p<0.05, significant main effect of group; tp<0.001, significant main effect of task. 
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Figure 22. Mean (±SEM) percentage of correct responses in the spatial discrimination 
(A) and delayed alternation (B) tasks over 14 days of whole-maze testing in Experiment 
1. Bar graphs on the right represent the mean (+SEM) percentage of correct responses 
over 14 days. Rats were injected with a standardized Ginkgo biloba extract (13.75 mg/kg, 
i.p.) or its vehicle 30 min prior to each test. *p<0.05, significantly different from vehicle. 
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F(l,15)=6.20, /xO.05, and day, F(13,195)=19.53, p<0.001, but the group by day 
interaction was not significant. To further characterize the significant day main effect in 
the delayed alternation, scores from the first day were compared with those from all other 
days. Response accuracy was found to be higher at days 5 through 14 relative to day 1, 
p<0.05. Furthermore, the planned pairwise comparisons of groups at each level of day 
revealed that the Gm/cgo-treated group made significantly fewer errors on training days 8 
and 10 (p<0.05). A similar trend was observed on days 9 and 11, but the group difference 
was not significant (p=0.07). 
The time (s) required to finish the whole maze test over 14 days of the experiment 
was analyzed by a two-way ANOVAs (group x day) with repeated measures on the 'day' 
factor and found only a significant main effect of day F(13,195)=15.32, p<0.001. The 
main effect of group and day by group interaction were not significant. Regardless of 
treatment, rats required significantly less time to finish the whole maze test over days. 
The mean (± SEM) time required to complete the test session on the first day was 388.88 
(±17.46) and 381.33 (±14.50) s for the Ginkgo and vehicle groups, respectively. The 
mean (± SEM) time required to complete the test session on the last day significantly 
reduced to 290 (±14.69) and 267.11 (±8.68) s for the Ginkgo and vehicle groups, 
respectively. 
Delay testing. Regardless of treatment, response accuracy in the spatial 
discrimination task decreased slightly, but significantly, as a function of delay (see Figure 
23, A), shown by a significant main effect of delay, F(2,30)=3.72, p<0.05. The main 
effect of group and the group by delay interaction were not significant. Post-hoc paired 
sample Mests comparing each delay interval to the other two revealed that the 60-s delay 
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Figure 23. Mean (±SEM) percentage of correct responses in the spatial discrimination 
(A) and delayed alternation (B) tasks across three delay intervals (0, 15 and 60 s) in 
Experiment 1. *p<0.05, significantly different from vehicle. 
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differed significantly from the 0 and 15 s delays (p<0.05). None of the other comparisons 
was significant. 
As expected, a pronounced delay-dependent decline in response accuracy was 
observed for both groups in the delayed alternation (see Figure 23, B). Furthermore, 
response accuracy was better in Gmfcgo-treated animals at the shortest and longest delay 
intervals. ANOVA revealed a significant main effect of delay, F(2,30)=52.49, p<0.001, 
and a significant group by delay interaction, F(2,30)=4.38, p<0.05. The main effect of 
group was non-significant. Post hoc paired sample Mests revealed that the 0-s delay 
differed from both the 15- and 60-s delays (p<0.05), and the 15-s delay differed 
significantly from the 60-s delay (p<0.05). To further characterize the significant 
interaction, pairwise group comparisons conducted at each level of delay revealed that 
response accuracy was significantly better in the Ginkgo-treated animals at the 0- and 60-
s delays (p<0.05). 
The mean (± SEM) time required to complete each delay test sessions was 916.2 
± 28.1 and 873.5 ± 10.1 s for the vehicle and Ginkgo groups, respectively. An 
independent samples Mest comparing these values was not significant. Taken together, 
results demonstrated that Ginkgo improved performance of the delayed alternation task at 
both the 0- and 60-s delay intervals. 
Drug-free retest. In the drug-free retest, spatial discrimination performance 
remained highly accurate across groups over three days of testing (see Figure 24, A). 
ANOVA revealed no significant effects of group, day, or group by day interaction. 
Response accuracy in the delayed alternation task improved slightly, but not significantly 
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Figure 24. Mean (±SEM) percentage of correct responses in the spatial discrimination 
(A) and delayed alternation (B) tasks during the drug-free re-test in Experiment 1. Rats 
were re-tested for 3 consecutive days 8 days after the last administration of a standardized 
Ginkgo biloba extract or its vehicle. 
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F(2,30)=3.26, p=0.052, over the three days of testing (see Figure 24, B). In addition, 
response accuracy was slightly higher in the Ginkgo-tceated group relative to the vehicle 
control group, but the difference did not reach statistical significance. The group by day 
interaction was not also significant. 
The mean (± SEM) amount of time required to complete the drug-free retest 
sessions ranged from 259.9 (± 6.9) to 307.0 (± 17.0) s. A two-way ANOVAs (group x 
day) with repeated measures on the 'day' factor revealed that the main effects of day and 
group, and the day by group interaction were not significant. 
Experiment 2: Post-training effects of Ginkgo 
Results from Experiment 1 revealed that Ginkgo not only enhanced acquisition of 
the double Y-maze task, but also improved the post-training performance of the delayed 
alternation task. However, it was not clear whether the improvement in response accuracy 
was due to improved working memory per se, or was simply the result of enhanced task 
acquisition by Ginkgo (i.e., higher baseline performance). Thus, Experiment 2 examined 
the acute post-training effects of several doses of Ginkgo in experimentally naive rats 
with no prior exposure to Ginkgo. At the completion of testing, animals also received 
sub-chronic exposure to Ginkgo or vehicle, then memory was re-assessed both under the 
influence of Ginkgo and in a drug-free state. 
Method 
Subject. Twelve male Sprague-Dawley rats (Charles River, Canada), weighing 
270-300 g at the start of the experiment were used. Animals were housed and maintained 
as described in Experiment 1. 
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Drugs. EGb 761 (Ginkgo) and vehicle solutions were prepared as described in 
Experiment 1. 
Procedures. An overview of the design of Experiment 2 is shown in Figure 20 
(Bottom). Habituation and maze training was similar to that described in Experiment 1, 
but rather than being tested for 14 days, rats were trained to an acquisition criterion of 
two or fewer errors over 2 successive days prior to drug testing. Rats were then 
habituated to the injection procedure (1 ml/kg saline, i.p.) and delay intervals for 2 days 
prior to drug tests as described in Experiment 1. 
PART 1: ACUTE EFFECTS OF GINKGO 
Thirty min prior to test sessions, rats were injected with vehicle or one dose of 
Ginkgo (0.25, 2.5,13.75, or 25 mg/kg) using a within subjects design. Rats received one 
experimental treatment every 2 days, with the order of treatments being counterbalanced 
across sessions. To ensure washout between treatments, rats received an identical drug-
free test on the days between treatments. 
PART 2: CHRONIC EFFECTS OF GINKGO 
One day after the last acute test, animals were assigned randomly to two groups of 
six animals. One group received sub-chronic exposure to Ginkgo (13.75 mg/kg, i.p.) once 
daily for 10 days, and the other half received comparable vehicle injections. Rats were 
not exposed to the maze during this period. Animals were then re-tested using delays for 
2 consecutive days as described in Experiment 1. Rats continued to receive Ginkgo or 
vehicle during the two delay tests. However, to determine whether any possible 
improvements in performance were dependent on continued exposure to Ginkgo, half the 
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animals received Ginkgo or vehicle 30 min prior to the first test session (pre-test 
exposure), while the other half received Ginkgo or vehicle 30 min after the first test 
session (post-test exposure). On the second day of testing, the timing of injections was 
reversed so that the rats previously receiving pre-test exposure were injected post-test, 
and vise versa. Daily sub-chronic treatments continued for 10 additional days, then 
animals were again tested on the maze for 2 consecutive days as described above. 
Data analysis. Raw scores were converted to percentage correct responses. Data 
for the acute administration experiment (part 1) were analyzed separately for the spatial 
discrimination and delayed alternation tasks using two-way (treatment x delay) repeated 
measures ANOVAs. Where significant interactions were found, tests of the simple main 
effects were used to compare treatments at each level of delay. The possible influence of 
Ginkgo on the time needed to complete the maze was also analyzed using a one-way 
repeated measure ANOVA. 
For the chronic administration experiment (part 2), three-way (group x delay x 
test) ANOVAs with repeated measures on the 'delay' and 'test' (10 and 20 days) factors 
were performed separately for the spatial discrimination and delayed alternation results. 
When a significant group by delay interaction was found, independent sample Mests 
were used to compare vehicle- and Ginkgo-tvcated groups at each level of delay. 
Significant main effects of delay were followed by Bonferroni-adjusted paired Mests to 
compare each delay interval to all others. Finally, the time required to complete the maze 
was analyzed using a two-way (group x test) ANOVA with repeated measures on the 
'test' factor. Independent Mests were then used to compare groups separately at pre- and 
post-session tests. 
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When the assumption of homogeneity of variance was violated, adjusted t 
statistics were reported. Whenever the Mauchly's test of sphericity was found to be 
significant, the Huynh-Feldt epsilon correction was used. For ease of interpretation, only 
the non-adjusted degrees of freedom are reported. 
Results 
Part 1: Acute effects of Ginkgo. Response accuracy was high across all three 
delay intervals in the spatial discrimination task following administration of vehicle or 
Ginkgo (see Figure 25, A). The ANOVA revealed no significant main effects of 
treatment or delay. The treatment by delay interaction was marginally significant, 
F(8,88)=2.19, p=0.04; however, tests of the simple main effects revealed no significant 
differences between treatments at any delay intervals, indicating that response accuracy 
was not influenced by any dose of Ginkgo at any single delay interval in the spatial 
discrimination task. 
As expected, response accuracy decreased in a delay-dependent manner in the 
delayed alternation task (see Figure 25, B), shown by a significant main effect of delay, 
F(2,22)=134.49, p<0.001. Pairwise comparisons revealed that response accuracy was 
significantly higher at 0-s delay relative to both the 15- and 60-s delays (p<0.05) and 
significantly higher at the 15-s delay relative to the 60-s delay (p<0.05). Ginkgo failed to 
influence response accuracy in the delayed alternation task, shown by a non-significant 
main effect of treatment, and a non-significant treatment by delay interaction. 
The mean (+SEM) amount of time needed to complete the task was increased 
significantly by Ginkgo (see Figure 25, C). A one-way repeated measures ANOVA 
revealed a significant effect of treatment, F(4,44)=7.61, p<0.001. Pairwise comparisons 
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Figure 25. Mean (±SEM) percentage of correct responses in the spatial discrimination 
(A) and delayed alternation (B) tasks across 3 delay intervals 30 min following 
administration of 0, 0.25, 2.5, 13.75 or 25 mg/kg Ginkgo in Experiment 2. Data are from 
animals receiving a standardized Ginkgo biloba extract for the first time (in a 
counterbalanced order) after acquiring both maze tasks in a drug-free state. (C) Mean 
(+SEM) amount of time (s) required to complete the test sessions for each of the five 
treatments. 
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showed that animals receiving the 25 mg/kg dose required significantly longer to 
complete the maze relative to vehicle controls, p<0.05; none of the other doses 
significantly influenced maze completion times. 
Taken together, results indicate that acute post-training administration of Ginkgo 
does not enhance response accuracy in the double Y-maze. Administration of a high 
dose of Ginkgo, however, may influence locomotor activity, as shown by increased time 
required to complete the maze. 
Part 2: Chronic effects of Ginkgo. Pre-session test. Figure 26 (A and B) shows the 
mean (+SEM) percentage of correct responses over three delay intervals following 10 and 
20 days of Ginkgo exposure when animals were also given Ginkgo or vehicle just prior to 
maze testing. For the spatial discrimination task, the three-way ANOVA revealed no 
significant main effects of group or test, but the delay effect was significant, 
F(2,20)=4.35, p=0.027. Both the delay by test and delay by group interactions were non-
significant, but the test by group and the three-way (group x delay x test) interaction 
were significant, F(l,10)=5.71, p=0.038 and F(2,20)=6.19, p<0.01, respectively. Separate 
group by delay ANOVAs with repeated measures on 'delay' were performed for each test 
(10 and 20 days). At 10 days of treatment, the ANOVA revealed no significant effects of 
group or delay, but the group by delay interaction was significant, F(2,20)=6.74, p< 0.01. 
Independent samples Mests comparing groups at each level of delay revealed that 
Gmfcgo-treated rats made fewer correct responses than vehicle-treated animals at the 15-s 
delay, t(5)=3.16, p<0.05. None of the other comparisons was significant. At 20 days of 
treatment, the two-way ANOVA revealed no significant main effects or interaction. 
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Figure 26. Mean (±SEM) percentage of correct responses in the pre-session tests for the 
spatial discrimination (A) and delayed alternation (B) tasks, respectively. (C) Mean 
(+SEM) amount of time (s) required to complete the pre-session tests after 10 or 20 days 
of daily treatment with a standardized extract of Ginkgo biloba (13.75 mg/kg, i.p.). Mean 
(±SEM) percentage of correct responses in the post-session tests for the spatial 
discrimination (D) and delayed alternation (E) tasks, respectively. (F) Mean (+SEM) 
amount of time (s) required to complete the post-session tests after 10 or 20 days of drug 
treatment. 
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For the delayed alternation task, the three-way ANOVA found only a significant 
main effect of delay F(2,20)=25.17, p<0.001 (see Figure 26, B). Pairwise comparisons 
revealed that the 0-s delay differed significantly from the 15- and 60-s delays (p<0.05) 
and that the 15-s delay differed significantly from the 60-s delay interval (p<0.05). 
For both tests there was a tendency for Gmfcgo-treated animals to complete the 
maze in less time relative to vehicle-treated animals (see Figure 26, C). A two-way 
ANOVA with repeated measures on 'test' revealed a significant main effect of group, 
F(l,10)=5.57, p<0.05, and a significant group by test interaction, F(l,10)=7.35, p<0.05. 
Pairwise group comparisons conducted separately at each test found a significant 
difference between groups at the first test only (10 days treatment), t(10)=2.66, p<0.05. 
To summarize, results showed that the spatial discrimination was selectively 
impaired at the 15-s delay interval following 10 days of Ginkgo exposure when animals 
were also given Ginkgo just prior to testing. Although this finding is surprising, the fact 
that the Gmfcgo-treated rats also required significantly less time to finish the task suggests 
that the observed impairment may have been related to impaired attention. Regardless of 
the treatment, response accuracy declined as a function of delay in the delayed alternation 
task as expected, but prior exposure to Ginkgo did not significantly influence response 
accuracy. 
Post-session test. Figure 26 (D) shows the mean (+SEM) percentage of correct 
responses over the three delay intervals after 10 and 20 days of drug treatment for the 
spatial discrimination task for animals receiving Ginkgo or vehicle just after each maze 
test. The three-way ANOVA for the spatial discrimination task found only a significant 
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main effect of delay, F(2, 20) = 4.29, p = 0.028. Pairwise comparisons revealed that none 
of the delays differed significantly from any other delays (p>0.05). 
In the delayed alternation, response accuracy declined as the delay interval was 
increased regardless of treatment (see Figure 26, E) after both 10 and 20 days of drug 
treatment. The three-way ANOVA for the delayed alternation task revealed only a 
significant main effect of delay, F(2,20) = 43.49, p <0.001. Pairwise comparisons 
revealed that response accuracy was significantly higher at the 0-s delay relative to both 
the 15- and 60-s delays (p<0.05), and was significantly higher at the 15-s delay relative to 
60 s (p<0.05). 
The two-way ANOVA for test 2 (20 days treatment) found only a significant 
effect of delay F(2, 20) = 19.56, p < 0.001. Post hoc paired sample r-tests found that the 
60-s delay was significantly different from both the 0- and 15-s delays (p<0.05) and the 
5-s delay differed significantly from the 0-s delay (p<0.05). The main effect of group and 
group by delay interaction were found to be non-significant. When comparing Figures 26 
(B) and 26 (E) at the 60-sec delay interval, there appear to be group differences, such that 
pre-session vehicle-treated rats performed better than post-session vehicle- and Ginkgo-
treated rats. Thus data were also analyzed using three-way (group x delay x pre-post) 
ANOVAs with repeated measures on the 'delay' and 'pre-post' (pre-session and post-
session) factors once after 10 days and once after 20 days of drug treatment, but no group 
effect was found (see Appendix B for details). 
Chapter 5 146 
The mean (+SEM) amount of time required to complete the tasks for both post-
session tests are shown in Figure 26 (F). Two-way ANOVA with repeated measure on 
the 'test' factor found no significant effects of group, test or group by test interaction. 
Discussion 
The present study demonstrates that repeated daily pre-session parenteral 
administration of a Ginkgo biloba leaf extract subtly, but significantly, facilitates 
acquisition and performance of a working memory task in young adult rats, as shown by 
improved response accuracy in a delayed alternation task. Results also revealed that the 
cognitive-enhancing effects of Ginkgo are specific to the learning phase, since neither 
acute nor chronic post-training Ginkgo administration improved memory. In most 
previous studies, Ginkgo treatment was shown to improve learning when treatment began 
weeks or months before initiation of training sessions (e.g., see Stoll et al., 1996; Y. 
Wang et al., 2006; Ward et al., 2002; E. Winter, 1991). The present study, however, 
shows that chronic pre-training Ginkgo treatment is not required to reveal improved 
learning in young adult animals. 
Experiment 1 examined the effects of Ginkgo on learning using a double Y-maze 
comprising two distinctive tasks: a spatial discrimination and a delayed alternation. Rats 
treated with Ginkgo shortly before each training session learned the individual tasks 
significantly faster than vehicle-treated animals (see Figure 21). Animals then received 
14 additional days of whole-maze testing during which each trial consisted of both a 
spatial discrimination and delayed alternation task. Here, Gm/cgo-treated rats made 
significantly fewer errors compared to vehicle-treated animals in the delayed alternation 
task, especially during the latter half of testing (see Figure 22). No significant group 
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differences were observed for the spatial discrimination task, suggesting that the 
improvement of learning produced by Ginkgo was due to a facilitation of working 
memory. That is, both double Y-maze tasks involved a food-motivated two-choice 
discrimination in a Y-maze, but only the delayed alternation task required working 
memory. 
The working memory load was further increased by introducing delays between 
successive trials. Results showed that response accuracy in the delayed alternation task 
declined in a delay-dependent manner (see Figure 23), confirming that in trained animals 
the delayed alternation, but not the spatial discrimination task requires working memory 
as reported previously (Mallet & Beninger, 1993; Mason et al., 1999; Smith et al., 1994). 
A comparison of groups revealed that response accuracy was higher in animals treated 
with Ginkgo, but unexpectedly the improvement was not limited to the longer delay 
intervals; rather, it was restricted to the 0- and 60-s delays (see Figure 23, B). It is not 
clear why response accuracy was not improved at the 15-s delay. Ginkgo treatment was 
then withdrawn, and animals were re-tested 8 days later. Although response accuracy 
remained slightly higher in rats previously treated with Ginkgo (see Figure 24), the 
difference was not statistically significant. It therefore appears that the beneficial effects 
of Ginkgo on task acquisition subside following a period of abstinence. 
Experiment 2 evaluated the acute post-training effects on memory by 
administering Ginkgo just prior to each test session in animals that had already been well 
trained in the double Y-maze. The finding that response accuracy declined in a delay-
dependent manner regardless of treatment in the delayed alternation task again confirmed 
that the task depends on intact working memory. However, acute post-training treatment 
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across a wide range of doses of Ginkgo failed to enhance response accuracy in either the 
spatial discrimination or delayed alternation tasks (see Figure 25). These findings are at 
odds with those of Wirth et al. (2000) who reported facilitative effects of acute Ginkgo 
administration (60 and 120 mg/kg, i.p.) in young and aged rats in a spontaneous olfactory 
recognition task. This discrepancy may be due to differences in behavioural tasks, drug 
dosages, or age and strain of the animals used. It is noteworthy that the highest doses 
tested here (25 mg/kg) significantly increased the time required to complete the maze, 
suggesting some non-mnomonic effects may occur following high dose parenteral 
Ginkgo administration. Suppression of motor activity by a single oral dose of Ginkgo 
biloba extract (500 and 1000 mg/kg but not 250 mg/kg) have also been reported 
elsewhere (Kuribara et al., 2003). 
Experiment 2 further examined the short-term (10 days) and longer-term (20 days) 
chronic post-training effects of Ginkgo on memory both while the rats were under the 
influence of the drug, and while they were in a drug-free state. Results revealed that 
Ginkgo did not improve response accuracy of either the spatial discrimination task or the 
delayed alternation task (see Figure 26). In fact, surprisingly, response accuracy for the 
spatial discrimination task was reduced at the 15-s delay at 10 days of exposure when 
Ginkgo was also administered pre-test. However, the pre-session Gm/cgo-treated rats 
required significantly less time to complete the maze (see Figure 26, C) suggesting that 
the spatial discrimination task impairment may have been caused by reduced attention. 
The finding that chronic post-training Ginkgo failed to enhance performance of spatial 
discrimination and delayed alternation tasks agrees with a recent report showing that 
repeated post-training administration of an extract of Ginkgo biloba in young adult rats 
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had no significant effects in a Morris water maze task, or in radial arm maze tasks 
designed to assess short-term working and long-term reference memory (Shif et al., 
2006). 
Taken together, results from the present study revealed that acquisition of a 
spatial working memory task was amenable to the cognitive-enhancing effects of Ginkgo. 
It is worth stressing, however, that the facilitative effects of Ginkgo on maze acquisition 
were subtle. Previous studies of the cognitive effects of Ginkgo have typically employed 
an oral route of administration (e.g., see Stackman et al., 2003; Stoll et al., 1996; Y. 
Wang et al., 2006; E. Winter, 1991; J. C. Winter, 1998;, but see Wirth et al., 2000); the 
present study therefore provides evidence that parenteral administration of an extract of 
Ginkgo biloba is equally effective in improving learning, provided that the treatment is 
administered before training sessions. Performance of a working memory task, however, 
was largely unaffected by both acute and chronic post-training Ginkgo administration. 
Results therefore support the notion that ongoing Ginkgo administration does not appear 
to offer any continued beneficial effects, at least in an already-learned working memory 
task. 
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Chapter 6: General discussion 
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The present dissertation aimed to identify neural sites involved in the cognitive 
enhancing effects of the Ginkgo biloba leaf extract, EGb 761, and to explore its possible 
neurogenic-enhancing properties on adult hippocampal neurogenesis. Additionally, this 
dissertation aimed to assess anxiolytic-or anxiogenic-like properties as well as cognitive-
enhancing effects of this widely used herbal supplement. 
Experiments described in Chapter 2 used c-Fos immunoreactivity (Fos-IR) to map 
regional activity in selected limbic and related structures in response to oral or parenteral 
Ginkgo administration. Immediate early genes and their protein products such as c-Fos 
have been extensively utilized in mapping neuronal activity (for a review, see Kaczmarek 
& Chaudhuri, 1997). After acute oral or intraperitoneal (i.p.) administration of Ginkgo, c-
Fos expression was increased in selected structures in a region-specific manner. Increased 
Fos-IR in the insular cortex and central nucleus of amygdala was observed after both oral 
and i.p. Ginkgo administration. However, while a single i.p. treatment of Ginkgo 
significantly increased Fos-IR in the paraventricular nucleus, nucleus accumbens shell, 
and dentate gyrus, a single oral treatment of the extract did not produce similar effects. 
On the other hand, oral but not i.p. administration of the extract significantly increased 
Fos-IR in the basolateral nucleus of the amygdala. As previously noted, these differential 
observations using two different routes of administration do not necessarily imply that 
each route produces unique neural (and consequently behavioural) effects. However, it is 
possible that different doses of the extract, as well as different time courses (the time 
between administration and perfusion), may have induced Fos-IR specific to each route 
of administration. Due to the different pharmacodynamics of the two routes of 
administration employed, it is difficult to compare the results. However, the i.p. route of 
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administration was employed to demonstrate that any observed changes in Fos-IR found 
with oral administration of the extract were not due to novel gustatory experience. In 
future studies plasma and brain concentrations of Ginkgo constituents following the two 
routes of administration should be quantified to facilitate the comparison of results. 
Increased neural activity in the insular cortex, central nucleus of the amygdala, 
and dentate gyrus by acute Ginkgo treatment indicates that these limbic structures may 
possibly play roles in the long-term cognitive enhancing properties of the extract. The 
central nucleus of the amygdala and the insular cortex are believed to be involved in 
learning and memory. For example, the insular cortex has been shown to play a role in 
incentive memory (Balleine & Dickinson, 2000), the consolidation of object memory 
(Bermudez-Rattoni et al., 2005), the acquisition and consolidation of inhibitory 
avoidance (Mello e Souza et al., 2001; Miranda & McGaugh, 2004), and the 
consolidation of conditioned taste aversion (Miranda & McGaugh, 2004). The central 
nucleus of the amygdala is involved in the acquisition, consolidation, and expression of 
Pavlovian fear conditioning (Wilensky et al., 2006). 
It was particularly interesting to find a significant increase in Fos-IR in the 
dentate gyrus after i.p. administration; however, it is noteworthy that a non-significant 
trend (p=0.088) in Fos-IR was also observed in the dentate gyrus after oral administration 
of Ginkgo. This hippocampal sub-region plays a pivotal role in learning and memory and 
mediates mnemonic processing of spatial information (for a review, see Kesner, 2007). In 
addition, the dentate gyrus is one of only two undisputed neurogenic regions of the adult 
mammalian brain (Ming & Song, 2005). Recent studies have taken advantage of the fact 
that synaptic activation induces expression of immediate early genes and have provided 
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convincing support for the involvement of newborn dentate gyrus neurons in cognitive 
processes and their relevance to hippocampal activity. Incredibly, newborn neurons are 
two to three times more likely to be activated during water maze learning or spatial 
exploration task than older neighboring neurons (Kee et al., 2007; Ramirez-Amaya et al., 
2006). The c-Fos immunohistochemical study presented in Chapter 2 did not investigate 
the expression of immediate early gene products in newly born dentate gyrus neurons, 
nor after animals performed a hippocampal-dependent task. Rather, it assessed cell 
responsiveness in selected limbic structures including the dentate gyrus. Given that 
newborn dentate gyrus neurons are more responsive to hippocampal-dependent tasks, it 
might be possible that they are also more responsive (in terms of immediate early genes 
and their encoding protein product expression) to nootropic agents. To the best of the 
author's knowledge this possibility has not been investigated. 
The increased Fos-IR found in the dentate gyrus, together with other lines of 
evidence suggesting the possible neurogenic-enhancing potential of Ginkgo formed the 
basis for the experiments described in Chapter 3, which investigated the effects of 
varying doses of Ginkgo on cell proliferation and cell survival. Neural stem cells reside in 
the neurogenic niche of the SGZ of the dentate gyrus and can unlimitedly self-renew 
through symmetric cell division, and can give rise through asymmetric cell division to 
neurons, astrocytes or oligodandrocytes (Gage, 2000). Adult neural stem cells appear to 
be a subset of astrocytes, expressing GFAP and nestin. (Seri, Garcia-Verdugo, McEwen, 
& Alvarez-Buylla, 2001). The niche has a special microenvironment that not only 
maintains the stem cells but also regulates their proliferation and fate determination. For 
example, the stem cells are intimately associated with resident astrocytes and 
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vasculatures. Astrocytes and blood factors released from vasculatures have been shown to 
play important roles in proliferation and fate specification of neural stem cells (Palmer et 
al 2000). The proliferating neural stem cells give rise to transient amplifying progenitor 
cells, which in turn differentiate into immature neurons (Kempermann et al., 2004; Ming 
& Song, 2005). Transient amplifying progenitors have limited potential for self-renewal. 
Some will die while some symmetrically divide and rapidly give rise to a pool of 
progenitors that in turn differentiate into immature neurons, which migrate locally and 
move into the granule cell layer (Ming & Song, 2005; van Praag et al., 2002). After 
newborn cells exit the progenitor cell cycle, neurite and axonal growth start. New 
generated axons initially interact with hilar mossy cells and interneurons located in the 
hilus (Zhao, Teng, Summers, Ming, & Gage, 2006). At this stage, immature neurons 
depolarize in response to GAB A as they have a higher intracellular concentration of 
chloride ions (Ge et al., 2006). Around 8 tolO days later, the axons of immature neurons 
reach CA3 pyramidal neurons. At around 16 days after birth, dendritic spines of 
immature neurons begin to grow (Zhao, Teng, Summers, Ming, & Gage, 2006). The 
excitatory action of GAB A on newborn neurons changes to inhibitory action at 2 to 4 
weeks after birth. Glutamatergic synapses develop, once the dendritic branches of 
newborn neurons cross the molecular cell layer of the dentate gyrus (Ambrogini et al., 
2004). The density and complexity of spines however continue to increase for the next 
several months (Zhao, Teng, Summers, Ming, & Gage, 2006). It has been estimated that 
about 9000 new cells are generated in the dentate gyrus of an adult rat every day 
(Cameron & McKay, 2001). However, half of the newborn neurons die within the first 3 
weeks after birth. If they survive this critical time window, they can survival for at least 
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11 more months after birth in the dentate gyrus of rodents (Kempermann, Gast, 
Kronenberg, Yamaguchi, & Gage, 2003) and for at least 2 more years in the human 
dentate gyrus (Eriksson et al., 1998). At 4 weeks of age, newborn neurons start 
expressing NeuN, a marker of mature neurons (Ming & Song, 2005). Finally, newborn 
granular neurons functionally integrate into existing neuronal circuits in the dentate 
gyrus, receiving inputs from the perforant path, and sending outputs to CA3 pyramidal 
cells (van Praag et al., 2002). 
Many factors have been shown to affect adult hippocampal neurogenesis. For 
example, survival of newborn granule neurons has been shown to increase considerably 
in adult mice that lived in an enriched environment (Kempermann, Kuhn, & Gage, 1997). 
Cell proliferation in the dentate gyrus of adult mice is also significantly enhanced by 
voluntary wheel running (van Praag, Kempermann, & Gage, 1999). Both enriched 
environment (Kempermann, Kuhn, & Gage, 1997) and voluntary exercise (van Praag, 
Christie, Sejnowski, & Gage, 1999) have been shown to positively influence learning and 
memory. Thus, we hypothesized that Ginkgo might also enhance learning and memory 
through enhancemnet of cell proliferation and/or cell survival in the dentate gyrus. Other 
lines of evidence described in Chapter 3 supported the hypothesis that Ginkgo might have 
pro-neurogenic potential. In two different sets of experiments this possibility was 
investigated by separately investigating the effects of the extract on cell proliferation after 
a single administration and cell survival after prolonged treatment. Results, however, 
indicated that neither cell proliferation nor cell survival was affected by Ginkgo treatment 
in neither the dorsal nor ventral dentate gyrus in young adult male rats. 
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It has been shown that Ginkgo has a positive effect on blood flow and 
microcirculation in the dentate gyrus and other brain regions (Krieglstein et al., 1986). 
The microenvironment of the neurogenic niche of the dentate gyrus has been shown to 
play a key role in neurogenesis. Newborn cells in the granule cell layers are situated in 
close proximity to fine blood vessels (Palmer et al., 2000). The negative results suggest 
that enhancement of dentate gyrus blood supply by Ginkgo is not sufficient to enhance 
neurogenesis and other factors might be required to promote this process. Consistent with 
the present findings, a recent study examining the influence of (-)-epicatechin—a plant-
derived flavanol~on adult hippocampal neurogenesis also failed to find any enhancing 
effects on cell genesis; despite the fact that (-)-epicatechin significantly improved 
memory function. However, results revealed that (-)-epicatechin selectively enhanced 
angiogenesis (generation of new blood capillaries from pre-existing blood vessels) in the 
dentate gyrus, suggesting an alternative neural mechanism for the enhancement of 
memory observed (van Praag et al., 2007). Ginkgo is similar to (-)-epicatechin in that it is 
rich in flavanol. In fact, Ginkgo contains 24% flavonoid glycosides. However, the 
experiments presented in Chapter 3 did not investigate the effects of Ginkgo on 
hippocampal angiogenesis. Nonetheless, Ginkgo treatment has been shown to increase 
proliferation of endothelial progenitor cells (Chen et al., 2004). Whether or not Ginkgo 
treatment enhances hippocampal angiogenesis remains to be investigated in the future 
studies. 
As previously described, positive modulatory effects of Ginkgo on the cholinergic 
system have been demonstrated. For example, Ginkgo treatment has been shown to 
increase hippocampal cholinergic muscarinic receptor numbers (Taylor, 1986), enhance 
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the release of acetylcholine (Kristofikova et al., 1992), and inhibit acetylcholinesterase 
activity (Chopin & Briley, 1992; Das et al., 2002; Yamamoto et al., 2007). Since the 
cholinergic system is involved in adult hippocampal neurogenesis (Cooper-Kuhn et al., 
2004; Kaneko et al., 2006; Kotani et al., 2006, 2008), it was expected that Ginkgo may 
indirectly affect adult hippocampal neurogenesis through its influence on the cholinergic 
system. However, the results did not support this hypothesis. 
Taken together, the results presented in Chapter 3 suggested that the nootropic 
effects of Ginkgo are unlikely the result of enhanced adult hippocampal neurogenesis, at 
least in young adult rats. Other forms of plasticity might explain the nootropic effects of 
the extract. Indeed, a recent study investigated whether the cognitive enhancing effect of 
the extract was related to enhanced LTP. Electrophysiological recordings of field 
excitatory postsynaptic potentials were performed from the CA1 in response to ipsilateral 
stimulation of the Schaffer collateral/commissural pathway in aged rats chronically 
treated with Ginkgo (60 mg/kg for 30 days) and found significant enhancement of in vivo 
LTP in aged but not young rats. Moreover, results of a recent study showing 
enhancement of adult hippocampal cell proliferation by Ginkgo treatment in a transgenic 
mouse model of Alzheimer's Disease (Tchantchou et al., 2007) raise the possibility that 
Ginkgo may have different effects in the dysfunctional brain where the constitutive level 
of neurogenesis is down-regulated compared to normal healthy neural systems. Thus, the 
experiments described in Chapter 4 addressed this possibility by investigating whether 
Ginkgo co-treatment could counteract the suppressive effects of corticosterone (CORT) 
treatment on cell survival (Wong & Herbert, 2004). Three weeks of CORT (35 mg/kg) 
treatment clearly increased plasma CORT concentrations, and consistent with previous 
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studies (e.g., see Fernandes et al., 1997; Gregus et al., 2005) induced adverse 
physiological effects including significant reductions in thymus, adrenal gland and body 
weights. The survival of newborn cells was also significantly suppressed in the dentate 
gyrus of rats chronically treated with CORT. However, none of the CORT-induced 
effects were significantly attenuated by Ginkgo co-treatment. In fact, the body and 
thymus weights of animals treated only with Ginkgo fell significantly below those of the 
control rats. This suggests that i.p. administration of the dose of Ginkgo chosen may have 
induced some kind of malaise. Support for this possibility comes from the finding that 
acute administration of the high dose of Ginkgo increased measures of anxiety in the 
light-dark emergence test in Chapter 3. One way to investigate whether a high dose of 
Ginkgo induces malaise is to use the conditioned taste aversion paradigm. Conditioned 
taste aversion is a form of classical conditioning by which an animal associates a novel 
taste such as a sucrose solution with a sickness-inducing agent such as lithium chloride. 
This robust association prevents subsequent consumption of the novel taste that was 
paired with the sickness-inducing agent. However, it has been shown that rewarding 
drugs such as cocaine also induce conditioned taste aversion. Thus, researchers use taste 
reactivity test to measure orofacial reactions elicited by a flavoured solution infused 
directly into the animal's mouth. Two types of reactions that are typically elicited by the 
animals are ingestive and disgust reactions. Disgust reactions are evident by infusing a 
flavoured solution that was previously paired with a sickness-inducding agent (e.g. 
lithium choloride) and ingestive reactions are observed by infusing a flavoured solution 
previously paired with an agent (e.g. cocaine) that changed the "physiological state" of 
the animal (for a review, see Parker, 2003). To the author's knowledge Ginkgo does not 
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induce any rewarding or hedonic state changes; however, the results presented in Chapter 
3 showed that acute high dose of Ginkgo increased some measures of anxiety evident by 
increased duration of time spent in the hide box and exit latency. It remains the goal of 
future research to test Ginkgo in a taste reactivity test. 
Additionally, consistent with the results presented in Chapter 3, chronic Ginkgo 
treatment on its own had no effect on the survival of newborn cells in the dentate gyrus, 
confirming that the beneficial effects of Ginkgo on cognitive processing do not appear to 
be mediated by enhanced hippocampal cell genesis. Furthermore, as expected, chronic 
CORT treatment suppressed survival of newborn cells, but contrary to the expected 
results, Ginkgo co-treatment did not attenuate this effect. 
Proliferation of progenitor cells is believed to be regulated, at least in part, by 
circulating CORT, as elevated levels of CORT suppresses proliferation (Gould et al., 
1992; Hellsten et al., 2002), and adrenalectomy stimulates this process (Cameron & 
Gould, 1994; Gould et al., 1992). Additionally, circulating CORT levels also play a role 
in the survival of newborn cells since chronic CORT treatment both before and after cell 
division has been shown to suppress survival of newborn neurons (Wong & Herbert, 
2004). CORT acts on two receptors: glucocorticoid receptors and mineralocorticoid 
receptors. Both receptor genes have been found to be expressed at high levels by granular 
cells in the dentate gyrus (Van Eekelen, Jiang, De Kloet, & Bonn, 1988). However, 
mineralocorticoid receptors have a 10-fold higher affinity to CORT relative to 
glucocorticoid receptors, which are only fully occupied when CORT levels are elevated 
(Joels, 2007). Glucocorticoid receptors are expressed by only 50% of early progenitors 
and presumably are more sensitive to the suppressive effects of CORT on cell 
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proliferation than mineralocorticoid receptors, which are expressed only by mature 
granule cells (Garcia, Steiner, Kronenberg, Bick-Sander, & Kempermann, 2004). The 
role these two receptors play in survival of newborn neurons is presently not clear, but 
the fact that both receptors are expressed in mature neurons suggests that both may be 
involved in regulating survival of newborn cells. 
One novel aspect of the results worth further discussion was the finding that 
chronic CORT treatment selectively suppressed cell survival in the dorsal dentate gyrus. 
While the dorsal hippocampus appears to be involved in spatial learning and memory 
tasks, the ventral hippocampus processes motivational and emotional information (for a 
review, see Bannerman et al., 2004). Accordingly, it has also been suggested that adult 
neurogenesis in the dorsal dentate gyrus has a distinct role from that of the ventral dentate 
gyrus (Sahay & Hen, 2007). Previous studies have not differentiated between the 
influence of CORT on neurogenesis in the dorsal and ventral regions of the dentate gyrus 
(Cameron & Gould, 1994; Wong & Herbert, 2004,2006). Additionally, to the best of the 
author's knowledge, the distribution of glucocorticoid and mineralocorticoid receptors 
along the septo-temporal axis of the dentate gyrus has not been investigated. Possible 
differential distribution of glucocorticoid and mineralocorticoid receptors along the 
dorsal and ventral dentate gyrus, assuming that cell survival is regulated by these 
receptors, may explain the selective suppression of cell survival in the dorsal dentate 
gyrus. 
Moreover, high levels of stress and high concentrations of exogenous CORT have 
been shown to impair spatial memory (de Quervain, Roozendaal, & McGaugh, 1998; 
Diamond, Fleshner, Ingersoll, & Rose, 1996). Given the preferential role for the dorsal 
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hippocampus in spatial learning and memory tasks (Bannerman et al., 2004), it may be 
assumed that CORT might induce spatial memory deficits in part by selectively impairing 
the survival of newborn cells in the dorsal dentate gyrus. Unfortunately, Chapter 4 did not 
investigate learning and memory in a spatial task. Nonetheless, there is evidence that 
chronic CORT treatment also induces 'depressive-like' behaviour (Gregus et al., 2005; 
Kalynchuk et al., 2004), which presumably should be associated with suppression of 
neurogenesis in the ventral dentate gyrus (Sahay & Hen, 2007). Future studies that aim to 
identify the roles of CORT and its receptors in adult hippocampal neurogenesis along the 
septo-temporal axis of the dentate gyrus are required. 
One limitation of the experiments described above was the lack of double 
labeling. That is, the identification of newborn neurons is often confirmed using double-
labeling techniques to detect BrdU cells that express neuronal markers such as neuron-
specific nuclear protein (NeuN). Glial cells, on the other hand, can be identified by 
detecting BrdU in cells that co-express glial cell markers such as glial fibrillary acidic 
protein (GFAP) (Ming & Song, 2005). Because Ginkgo failed to significantly alter the 
number of BrdU labeled cells, a decision was made not to carry out 
immunohistochemical procedures for double labeling because it is very unlikely that 
Ginkgo selectively increased the number of neurons while at me same time reducing the 
number of glial cells (or vise versa) such that the total number of BrdU labeled cells in 
the G/n&go-treated rats became similar to that of the vehicle-treated rats. In support of 
this argument, more than 95% of newborn cells differentiated into neurons, but less than 
1% differentiated into glial cells in the Tchantchou et al (Tchantchou et al., 2007) study 
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showing enhancement of adult hippocampal cell proliferation by chronic Ginkgo 
treatment in a transgenic mouse model of Alzheimer's Disease. 
In Chapter 3, in order to validate the immunohistochemical protocol employed, a 
group of rats were treated with fluoxetine and used as positive controls in the second 
experiment in which the survival of newborn cells were studied. Fluoxetine has been 
reported to enhance cell survival in the dentate gyrus (Nakagawa et al., 2002; J. W. Wang 
et al., 2008). The lack of fluoxetine effect on the number of BrdU labeled cells in that 
experiment raised concerns regarding the immunohistochemical methods employed. 
However, using the same immunohistochemical protocol, results presented in Chapter 4 
found suppression of cell survival in the dentate gyrus by chronic CORT treatment 
(Wong & Herbert, 2004). Anotiier recent study also failed to replicate the enhancement 
of cell survival as well as cell proliferation in either the dorsal or ventral dentate gyrus by 
chronic fluoxetine treatment (5 mg/kg for 25 days) in adolescent, adult and aged rats 
(Cowen et al., 2008). 
Since Ginkgo treatment has been shown to reduce basal and stress-induced 
anxiety, the experiments described in Chapter 3 also assessed measures of anxiety after 
single or multiple treatments with Ginkgo using a battery of behavioural tests including 
the light/dark emergence, elevated plus maze, and social interaction tests. A single high 
(25 mg/kg) or moderate (13.75 mg/kg) dose of Ginkgo appeared to induce anxiety-like 
behaviour in the light/dark emergence test as indicated by increased exit latency, and 
increased duration of time spent in the hide box. This effect was not evident after 
multiple treatments with Ginkgo. Additionally, acute and chronic administration of all 
doses of Ginkgo tested failed to alter the duration of time spent in the enclosed arms, 
Chapter 6 163 
number of entries into the open arms of the elevated plus maze, and duration of active 
social interactions. Chronic Ginkgo treatment did not alter measures of anxiety in any of 
these tests of anxiety, which contrasts with previous studies showing anxiolytic-like 
effects of the extract (Hasenohrl et al., 1996; Kuribara et al., 2003; Porsolt et al., 1990; 
Rodriguez de Turco et al., 1993; Ward et al., 2002). Reasons for these inconsistencies 
may be due to different routes of administration, dose, or the specific behavioural 
measures of anxiety employed. However, consistent with the present results, one other 
study reported that chronic Ginkgo (100 mg/kg for 21 days) treatment failed to change 
the duration of time spent in the open arms, or the number of entries into the open arms 
of the elevated plus maze (Walesiuk et al., 2005). In this latter study, rats had 21 days of 
drug exposure in a manner similar to that used in Chapter 3, but the test was conducted 
24 h after the last drug treatment such that rats were tested while drug-free. The results of 
the acute study presented in Chapter 3, however, showed that a single high or moderate 
dose of Ginkgo administered prior to the light/dark emergence test increased duration of 
time spent in the hide box and exit latency. Thus, it was decided to continue the drug 
treatment on the test day and examine anxiety-like behaviour induced by chronic Ginkgo 
treatment. In addition, it has been shown that the nature of anxiety measured in the 
second trial of the elevated plus maze is distinct from that measured in the first trial 
(Fernandes & File, 1996; File, Zangrossi, Viana, & Graeff, 1993). Thus, in Chapter 4 rats 
were tested twice in the light/dark emergence and the elevated plus maze over two 
consecutive days, and unlike the study presented in Chapter 3 rats were under the 
influence of the drug treatment on both days of testing. Additionally, the anxiogenic- or 
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anxiolytic-like effect of chronic CORT treatment alone or in combination with Ginkgo 
was assessed. 
Consistent with the results presented in Chapter 3, chronic Ginkgo treatment was 
not found to influence anxiety even when the rats were pre-treated with Ginkgo just prior 
to the testing. Thus, it appears that the seemingly anxiogenic effect of a single high dose 
of Ginkgo diminishes with repeated treatment. It is likely that rats receiving multiple 
Ginkgo treatments habituated to the active constituents of the extract that might have 
induced anxiogenic-like effects in the light/dark emergence test following a single 
treatment. Moreover, despite the significant elevation of plasma CORT levels in the 
CORT-treated rats, there were no significant effects on any of the measures of anxiety. 
Interestingly, the two groups of rats treated with Ginkgo (Ginkgo-Veh and Ginkgo-
CORT) traveled shorter distances in the elevated plus maze compared to the other two 
groups that did not receive Ginkgo. This effect was only evident in the first trial and may 
suggest a simple suppression of locomotor activity. 
The fact that CORT did not induce any anxiogenic-like effects is in agreement 
with previous studies that have shown elevated CORT levels due to chronic CORT 
injection (Gregus et al., 2005; Kalynchuk et al., 2004) or CORT pellet implantation 
(Fernandes et al., 1997) did not change measures of anxiety in the elevated plus maze, 
social interaction, open field, or resistance-to-capture tests. In fact, it has been suggested 
that chronic CORT administration produces a double-dissociation between elevated 
corticosteroid concentration and anxiety (Fernandes et al., 1997). It seems that emotional 
changes brought about by chronic daily CORT treatment, both in male and female rats, 
correspond to symptoms of clinical depression rather than anxiety (Gregus et al., 2005; 
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Kalynchuk et al., 2004). For example, chronic CORT injection (40 mg/kg for 21 days) 
has been shown to increase depression-like behaviours in the forced swim test 
(Kalynchuk et al., 2004). The present study did not evaluate the chronic effects of CORT, 
Ginkgo and their co-treatment on animal models of depression, but the lack of significant 
effects in the two animal tests of anxiety employed agrees with the aforementioned 
studies. One study, however, reported a significant increase in exit latency in female mice 
chronically treated with CORT (Ardayfio & Kim, 2006). This anxiolytic-like effect of 
CORT contrasts with results presented here, but might be related to differences in dose, 
species and/or gender employed. Indeed, it has been shown that low doses of CORT can 
produce anxiolytic-like effects (File, Vellucci, & Wendlandt, 1979). 
Consistent with other studies (e.g., see Treit et al., 1993), the data showed that 
regardless of treatment, rats appeared to be more anxious in the second trial compared to 
the first trial. All rats spent more time in the hide box, had longer exit latencies, and 
traveled shorter distances in the second light/dark emergence trial compared to the first. 
Similarly, all rats spent more time in the enclosed arms, entered less frequently into the 
open arms, and traveled shorter distances in the second elevated plus maze trial compared 
to the first. It has been argued that in the first trial of the elevated plus maze, rats acquire 
a fear of heights and thus in the second trial the response is considered a phobic response 
(File et al., 1993). It is noteworthy that in Experiment 2 in Chapter 3, regardless of the 
drug treatments, rats that were first tested in the elevated plus maze and then in the 
emergence test appeared more anxious measured by increased percentage of time in the 
hide box and by decreased distance traveled. This may suggest that experiencing the 
elevated plus maze first increased baseline levels of anxiety and thus potentiated 
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measures of anxiety in the emergence test. It has also been suggested that aversion to the 
open arms is learned during the first trial of the elevated plus maze, and thus during the 
second trial animals tend to avoid the open arms (Bertoglio & Carobrez, 2000). An 
alternate interpretation is that rats learn that the enclosed arms are safer than the open 
arms, and thus spend significantly more time in the enclosed arms during the second trial 
(Roy, Chapillon, Jeljeli, Caston, & Belzung, in press). These interpretations may also be 
applied to the second trial of the light/dark emergence test. That is, rats may have learned 
to avoid the open space in the second trial of the light/dark emergence test or conversely 
found the dark compartment safer, and thus spent significantly more time in the dark 
compartment during the second trial. In any case there were no treatment effects in either 
the first or second trials, and the results suggested that chronic treatment with Ginkgo, 
CORT or their combination induce neither anxiolytic- nor anxiogenic-like effects. 
Finally, the effects of Ginkgo on acquisition and performance of a working 
memory task were examined in two experiments described in Chapter 5. The double Y-
maze, which consists of two separate spatial discrimination and delayed alternation 
components, was employed. The double Y-maze includes control procedures that guard 
against misinterpretation of possible non-mnemonic effects such as altered motor 
function, motivation, or sensory-perceptual abilities (Mallet & Beninger, 1993; Mason et 
al., 1999; Smith et al., 1994). Experiment 1 examined the effects of pre-session treatment 
of Ginkgo on learning of the double Y-maze task. Acquisition of the individual tasks was 
found to be enhanced in rats pre-treated with Ginkgo. Animals then received 14 
additional days of whole-maze testing during which each trial consisted of both a spatial 
discrimination and delayed alternation task. Ginkgo-treated rats made significantly fewer 
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errors compared to vehicle-treated animals in the delayed alternation task. However, no 
significant group differences were observed in the spatial discrimination task, suggesting 
that the improvement of learning produced by Ginkgo was due to a facilitation of 
working memory. When the working memory load was further increased by introducing 
delays between successive trials, response accuracy declined in a delay-dependent 
manner in the delayed alternation task. This confirmed that in trained animals the delayed 
alternation, but not the spatial discrimination task, requires working memory (Mallet & 
Beninger, 1993; Mason et al., 1999; Smith et al., 1994). When Ginkgo treatment was 
withdrawn and animals were re-tested 8 days later, response accuracy was no longer 
higher in rats previously treated with Ginkgo, suggesting that Ginkgo does not have an 
ongoing beneficial effect. 
The effect of Ginkgo on memory, per se, by administrating Ginkgo in the interval 
between acquisition and testing is not clear. Thus, the acute post-training effects of 
various doses of Ginkgo on memory by administering Ginkgo just prior to each test 
session in a different group of animals that had already been well trained in the double Y-
maze was also evaluated in Chapter 5. Although response accuracy declined in a delay-
dependent manner confirming that the task depends on intact working memory, there was 
no treatment effect. Furthermore, the highest dose tested (25 mg/kg) significantly 
increased the time required to complete the maze, suggesting some non-mnemonic effects 
may occur following administration of that dose. This same dose administered acutely 
was found to induce anxiety-like behaviour in the light dark/emergence test in Chapter 3. 
Furthermore, in Chapter 4, this same dose administered chronically was found to reduce 
thymus and body weight, suggesting adverse physiological effects. 
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Short-term (10 days) and longer-term (20 days) chronic post-training effects of 
Ginkgo on memory were also assessed in Chapter 5. Ginkgo did not improve response 
accuracy of either the spatial discrimination task or the delayed alternation task. 
Consistent with these results, another study also showed that repeated post-training 
administration of an extract of Ginkgo biloba in young adult rats had no significant 
effects in a Morris water maze, or in radial arm maze tasks designed to assess working 
and reference memory (Shif et al., 2006). Thus, the cognitive-enhancing effects of 
Ginkgo were specific to the learning phase, since neither acute nor chronic post-training 
Ginkgo administration improved memory. 
Ginkgo has been shown to protect cellular membrane fluidity, to enhance cerebral 
blood flow and microcirculation, and to modulate cholinergic system functioning, 
properties that have been suggested to underlie its cognitive-enhancing effects 
(Maclennan et al., 2002). It has also been suggested that the cognitive-enhancing ability 
of Ginkgo is due to its "anti-stress" properties. That is, Ginkgo may reduce stress 
associated with behavioural learning tasks and results in better performance (Ward et al., 
2002). However, some of the results presented in this dissertation do not support this 
hypothesis. Neither acute nor chronic Ginkgo treatment reduced measures of anxiety in 
the elevated plus maze, social interaction or light/dark emergence tests. In fact, measures 
of anxiety in the light/dark emergence test were increased after a single injection of high 
or medium doses of Ginkgo extract. 
With the assumption that adult hippocampal neurogenesis is positively correlated 
with cognitive ability, the present dissertation tested the hypothesis that the cognitive-
enhancing ability of Ginkgo may be related to its neurogenic-promoting effects. A dose 
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of Ginkgo (13.75 mg/kg) that was found to improve acquisition of a working memory 
task failed to influence cell proliferation or cell survival in the dentate gyrus of young 
adult rats. Several studies suggest that the number of newborn neurons in the adult 
dentate gyrus correlates with learning abilities (e.g., see Kempermann et al., 1997b; van 
Praag, Christie et al., 1999); however, there is also evidence that this is not always the 
case. For example, learning ability in the hidden platform version of the water maze has 
been found to be a poor predictor of the number of newborn cells in the dentate gyrus of 
aged rats (Bizon & Gallagher, 2003; Bizon et al., 2004; Merrill et al., 2003). As 
mentioned earlier, (-)-epicatechin has also been shown to improve memory function 
despite its lack of effect on adult hippocampal neurogenesis (van Praag et al., 2007). 
Taken together, the experiments described in the present dissertation identified 
limbic structures that are targeted by active constituents of the Ginkgo biloba leaf extract 
EGb 761. Prominent c-Fos immunoreactivity was observed in the insular cortex, central 
nucleus of the amygdala, and dentate gyrus following a single administration of the 
extract, indicating that these limbic structures may possibly play roles in the long-term 
cognitive enhancing properties of the extract. However, Ginkgo treatment had no effect 
on cell proliferation or survival in the dentate gyrus of young adult healthy rats. Ginkgo 
also failed to restore the detrimental effects of CORT-induced suppression of cell 
survival in the dentate gyrus. Furthermore, repeated treatment with Ginkgo failed to 
produce any anxiolytic- or anxiogenic-like effects, while single high and moderate doses 
of the extract were found to increase some measures of anxiety. Lastly, while neither 
acute nor chronic post-training Ginkgo treatment improved memory of an already-learned 
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working memory task, repeated daily pre-session Ginkgo treatment facilitated acquisition 
and performance of such a task in a double Y-maze. 
It is concluded that the cognitive-enhancing effects of Ginkgo is limited to the 
enhancement of learning, rather than memory per se, and this effect is likely not related 
to a modulatory effect on adult hippocampal neurogenesis, at least in healthy young adult 
individuals. 
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Figure A Figure B 
First Second 
Vehicle C 
First Second 
|2.5 mg/kg 
Ginkgo 
113.75 mg/kg 
Ginkgo 
|25 mg/kg 
Ginkgo 
Mean (+SEM) percentage of time spent in the hide box (Figure A) and mean (+SEM) 
distance traveled (Figure B) in the light/dark emergence apparatus for rats that were 
tested in the emergence test either first or second (i.e., before or after being tested in the 
elevated plus maze). *p<0.05, second test significantly different from first. 
Half of the rats in each group were first tested in the elevated plus maze, while the other 
half began with the emergence test. The rats then were tested in the apparatus that was 
not previously tested. For this reason, two-way ANOVAs (order x treatment) were also 
performed to investigate both order and treatment effects in measures of anxiety in both 
the elevated plus maze and emergence tests. There were only significant effects of order 
for distance traveled in the emergence test, F(l, 32)=6.51, p=0.016 and in the percentage 
duration of time spent in the hide box, F(l, 32)=7.22, p=0.011. These results suggest that 
regardless of the treatment, rats appeared more anxious when they were tested in the 
emergence box after being tested in the elevated plus maze. All rats spent more time in 
the hide box and traveled a shorter distance when they were tested in the plus maze 
before emergence test. This suggests that regardless of drug treatment, experiencing the 
elevated plus maze first increased baseline level of anxiety and thus potentiated measures 
of anxiety in the emergence test. 
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Figure A 
10 Days (Delayed Alternation) 
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Figure B 
20 Days (Delayed Alternation) 
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Mean (±SEM) percentage of correct responses after 10 (Figure A) and 20 (Figure B) 
days of drug treatment in the pre- and post session tests for the delayed alternation task. 
The three-way ANOVA (group x delay x pre-post) for the first 10 days found the main 
effect of group to be non-significant. There were significant effects of pre-post, F(2, 20) 
= 4.39, p <0.05, delay F(2, 20) = 33.07, p <0.001, and the pre-post by delay interaction, 
F(l, 10) = 5.69, p <0.05. Pairwise comparisons for delay revealed that response accuracy 
was significantly higher at the 0-s delay relative to both the 15- and 60-s delays (p<0.05), 
and was significantly higher at the 15-s delay relative to 60 s (p<0.05). Pairwise 
comparisons for pre-post found that response accuracy was significantly higher at pre-test 
relative to post-test at 60-sec delay interval (p<0.05). 
The three-way ANOVA (group x delay x pre-post) for 20 days found only a significant 
effect of delay, F(2, 20) = 51.24, p O.001. Pairwise comparisons revealed that response 
accuracy was significantly higher at the 0-s delay relative to both the 15- and 60-s delays 
(p<0.05), and was significantly higher at the 15-s delay relative to 60-s (p<0.05). The 
main effect of group and the group by delay interaction were not significant. 
